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SUMMARY
The majority of cancer patients with progressive disease lose weight 
and a proportion become emaciated to the point where they appear to die 
of starvation. This complex metabolic syndrome characterised clinically by 
progressive involuntary weight loss is termed cancer cachexia. The 
importance of this cachexia has been recognised for at least 50 years and 
it has been reported that it is responsible for between 10 and 20%  of all 
cancer deaths. Furthermore, more than 50%  of cancer deaths are 
attributable to sepsis and there remains the complex relationship between 
nutritional depletion and a propensity to infection. The mechanisms which 
underlie cancer cachexia are poorly understood.
In the last decade, there have been a number of studies which have 
demonstrated a significant increase in the rate of whole body protein 
synthesis of weight-losing cancer patients. Since the energy cost of whole 
body protein synthesis is thought to be approximately 20%  of resting 
energy expenditure it has been postulated that such increased whole body 
protein synthesis, in the presence of reduced food intake, may contribute 
to a continuing negative energy balance, and thus weight loss, in these 
patients. However, it is not known which tissues in the body contribute to 
elevated protein flux in cancer patients.
The main aim of this thesis was to develop suitable methodology to 
allow investigation of the basis of the increased whole body protein 
synthesis in cancer patients. It has been estimated from work on animals 
that liver and skeletal muscle make up approximately 60%  of daily protein 
synthesis in the whole body. Therefore, following a review of literature 
methods were developed, using stable isotope-labelled amino acids, to 
measure simultaneously not only whole body protein synthetic rate but 
also protein synthetic rates in liver and skeletal muscle in man.
21
Protein synthetic rate measurements involve detection of small 
changes in isotopic enrichment requiring the use of a low resolution mass 
spectrometer. It is essential to purify samples for presentation to the mass 
spectrometer. Therefore, sample preparation protocols were developed to 
allow separation of leucine and glycine, in a pure form, from complex 
samples such as plasma, intracellular fluid and hydrolysed protein. Sample 
preparation methods were developed to enable measurement of 15N 
enrichment in urinary ammonia, plasma glycine, homogenate free glycine 
and glycine from tissue protein hydrolysate. Sample preparation methods 
were also developed to enable measurement of 13C enrichment in breath 
C 0 2, plasma leucine and leucine from tissue protein hydrolysate. 
Continuous Flow-lsotope Ratio Mass Spectrometry was used for the 
isotope enrichment measurements presented in this thesis, rather than the 
conventional approach (requiring both a Gas Chromatography-Nass 
Spectrometer and Isotope Ratio Mass Spectrometer). This permitted the 
analysis of all samples with a single mass spectrometer.
To obtain normal values for whole body and tissue protein synthetic 
rates, a group of weight-stable normal subjects (n = 6) undergoing elective 
cholecystectomy were studied. Two labelled amino acids ([13C]leucine and 
[15N]glycine) were used to assess which in the context of the present 
study would give the most reliable results. The precision and accuracy of 
the measurement of [13C]leucine enrichment was poorer than that of 
[15N]glycine. Furthermore, [15N]glycine appeared to give the most reliable 
results and therefore was used in the study of a group of (n = 6) 
weight-losing cancer patients.
In comparison with the control group the mean rate of whole body 
protein synthesis in the cancer patients was increased by 71% . However, 
when individual tissues were studied, non-export liver protein synthesis
22
was reduced by 32%  whereas skeletal muscle protein synthesis was 
increased by 86%  in the cancer patients. Therefore, much of the increase 
in whole body protein synthesis in weight-losing cancer patients appears to 
be due to an increase in skeletal muscle protein synthesis. There was no 
significant difference in resting energy expenditure between the two  
groups. Furthermore, the increase in skeletal muscle protein synthesis 
conflicts with previous reported results and other indirect measurements in 
this group of patients. These results posed two questions. Firstly, does the 
incorporation of 15N into a metabolic end-product (ammonia) reflect the 
change in whole body protein synthesis in weight-losing cancer patients? 
Secondly, what is the basis of the increased incorporation of [15N]glycine 
into the muscle of the weight-losing cancer patients? One explanation, 
discussed in detail, is that in the cancer patients increased amounts of 
glycine-rich proteins are synthesised as part of the inflammatory response 
and bring about the apparent increase in whole body protein synthesis and 
increased [15N]glycine enrichment in the skeletal muscle.
It is concluded, firstly, that the analytical approach developed in this 
thesis was satisfactory for use in [15N]glycine tracer studies. Secondly, 
that the data presented draws attention to the limitations of extrapolating 
the kinetics of a single labelled amino acid to the rate of synthesis of 
protein either in individual tissues or in the whole body. A variety of 
mechanisms and mediators are discussed which might account for the 
altered tracer kinetics observed in the weight-losing cancer patient.
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CHAPTER 1: INTRODUCTION AND AIMS
1.1 Protein metabolism in man
Proteins play a crucial role in virtually all biological processes (Stryer, 
1988). Peptides and proteins have many functions within the human body, 
notably as enzymes responsible for metabolic processes including those 
involved in making energy available, as structural proteins of the skin 
(keratin and collagen), connective tissues, tendons and bone (collagen) and 
muscle (actin and myosin), as hormones (such as insulin) and as 
antibodies. In addition proteins are used in the transport of substances in 
the blood (haemoglobin and many of the plasma proteins) and in 
transcellular and intracellular transport processes. Protein can also serve as 
a critical reserve of metabolic fuel that is depleted during progressive 
malnutrition. The fundamental units from which all proteins are constructed 
are amino acids. Many proteins have additional non-protein components as 
integral parts of their molecules. Examples of such proteins are 
haemoglobin and the cytochromes (metalloproteins), glycoproteins, and 
lipoproteins. Proteins are synthesised from a pool of 20 different amino 
acids, but some proteins contain additional amino acids which are formed 
from the modification of one of the original 20 after the protein chain has 
been synthesised. The wide variety of functions of peptides and proteins 
is matched by the wide variety of physical and chemical characteristics. 
For example their molecular weights vary from 5000 daltons to several 
million, their shapes vary from globular to linear and their surfaces are 
capable of binding a wide variety of substances.
The ordered structure of protein molecules is critical to their 
biological function. Maintenance of this function is achieved by resynthesis 
and consequently proteins have a finite lifespan and are eventually
24
degraded to their constituent amino acids, to be replaced by newly 
synthesised proteins. Therefore there is a persistent need for their 
resynthesis (Reeds, Fuller and Nicholson, 1985).
In contrast to the ability of the body to store moderate amounts of 
carbohydrate and large amounts of fat, the tissues have relatively little 
capacity for storing amino acids or protein. Therefore efficient utilisation of 
amino acids from the diet or protein breakdown is necessary to maintain 
body function. After a protein meal almost all of the absorbed amino acids 
are removed from the blood by the liver and skeletal muscle so that the 
plasma concentration of amino acid nitrogen rises only slightly  
(Jeejeebhoy, 1988). Similarly, amino acids given into the systemic 
circulation disappear rapidly from the blood. Amino acids derived from 
food and the breakdown of tissue proteins form a 'metabolic pool' in the 
blood and tissues for the synthesis of proteins and the oxidation to C 0 2 
and urea. This pool serves as a source of amino acids some of which are 
used to build nitrogenous substances such as proteins, while the rest is 
degraded and the nitrogen excreted, mostly as urea. Not only do amino 
acids from all sources form a common pool but the amino groups of one 
amino acid may be transferred to other amino acids by transamination.
The labile nature of body proteins was demonstrated in one of the 
f irs t studies of in term ediary  m etabolism  using stab le  isotopes  
(Schoenheimer, Ratner and Rittenberg, 1939). The term turnover has been 
used to describe the process of renewal or replacement of a substance. In 
this work protein turnover is considered to be a mass of protein (either a 
single protein or a mixture) which exchanges with a pool of free amino 
acids. The turnover is determined by the balance of synthesis and 
breakdown of this protein mass. In general, structural proteins have a large
25
pool size and low turnover rate whereas metabolic proteins have a small 
pool size and rapid rate of turnover.
The constant and considerable breakdown and resynthesis of most 
body proteins in the adult and even higher rates of both synthesis and 
breakdown during growth in the young are now well recognised 
(Waterlow, Garlick and Millward, 1978a). It is also well established that 
these rates of turnover vary from tissue to tissue and the pattern of 
contribution made by different organs and tissues to whole body protein 
turnover changes during development and as the organ ages (Waterlow 
Garlick and Millward, 1978b). Furthermore, synthesis and breakdown rates 
also change with alterations in diet, especially in response to altered 
protein intakes (Waterlow and Jackson, 1981).
The turnover of body proteins is accompanied by an extensive 
reutilisation of amino acids for the formation of new proteins. Protein 
synthesis is a process which requires energy and some energy may be 
used in the hydrolysis of peptide bonds when protein is broken down 
(Waterlow, Garlick and Millward, 1978c). However, this process is not 
completely efficient, so that some amino acids are lost by oxidative 
catabolism (Waterlow and Stephen, 1966). Thus a state of dynamic 
protein turnover is expensive in terms of energy and to a lesser extent, 
amino acids.
It is clear that simple nitrogen balance studies in man cannot address 
questions about protein dynamics in health and disease since alterations in 
intensity, quality and the distribution of tissue and organ protein 
metabolism are not revealed. Also these studies do not provide any insight 
into the changes in protein synthesis and/or breakdown which determine 
nitrogen balance. Therefore, protein turnover measurements can be of
26
considerable value. In order to measure protein turnover it is necessary to 
use labelled amino acids as tracers.
1.2 Turnover measurements using isotope tracers
The use of stable isotopes for tracer studies began in the 1930's at 
Columbia University, where in early studies, Schoenheimer and Rittenberg 
(1935b) used the stable isotope of hydrogen (deuterium) to study fat 
metabolism in mice. Shortly after this they used [15N]glycine to 
demonstrate the dynamic nature of body protein in man (Schoenheimer, 
Ratner and Rittenberg, 1939). When 2H, 15N, and 13C became more 
readily available, isotope labelling techniques were applied to metabolism 
studies in many laboratories. Of particular importance were the pioneer 
studies with 13C on C 0 2 fixation and various aspects of carbohydrate 
metabolism in plants and animals (Rittenberg and Waelsch, 1940; Wood et 
al., 1940; Rittenberg and Foster, 1940). From this and other work the 
concept of the metabolic pool was developed (Rittenberg, 1949).
However, the introduction of scintillation counting and the 
availability of a wide variety of radioactive tracers resulted in radioactive 
tracers (14C, 3H) being used for most metabolic pathway studies in the 
1950's and 1960's. Throughout the period 1950-1970, when radioactive 
tracer administration was most active, nutritionists remained the principal 
users of stable isotope tracers for clinical investigation. There were 
several reasons; (a) the dynamics of substrate interactions with body fuel 
stores were first revealed with stable isotope tracers (Schoenheimer and 
Rittenberg, 1935a); (b) deuterium oxide dilution had proven to be a safe 
and reliable means of estimating total body water for body composition 
analysis; (c) radio-tracer use was prohibited in populations of malnourished 
children where urgent questions of pathophysiology and therapy awaited
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quantitative data; (d) nitrogen and oxygen have no radioactive equivalents 
of sufficiently long half-life to undertake metabolic studies in man. Even so, 
limited availability of compounds labelled with stable nuclides and the more 
restric tive  analytical requirem ents compared w ith  the equivalent 
radio-tracer measurement, limited growth of stable isotope tracer 
applications in human investigations over this period.
In the last 15 years this situation has changed considerably. Stable 
nuclides separated at various national laboratories have been available in 
quantity. In addition, the coincident microelectronics 'revolution' has 
helped make available a range of computer controlled analytical systems 
capable of sensitive, precise quantitation of stable isotope tracers in 
biological materials. Also over this period, the scientific drive for mapping 
metabolic pathways decreased, as more and more pathways were 
elucidated. Much of this work was done using radioisotope-labelled 
substrates. The key question for many investigators in this field has 
changed from what were the intermediate substrates of the metabolic 
pathway to what amounts of these substrates were being consumed in the 
pathway (ie from 'what goes' to 'how much'?; Kascer and Burns, 1973). 
The need to answer such questions in man has increased demand for 
stable isotopes. Lastly, investigators have realised that stable isotope 
tracer techniques offer advantages over radio-isotopes (in addition to the 
avoidance of radiological hazard). These advantages include the ability to 
measure simultaneously substrate content and isotope enrichment 
(Bougneres and Bier, 1982); the capacity to determine the intramolecular 
location of the tracer labels (Matthews et al., 1981a); the ability to study 
the same individual repeatedly in order to assess intrasubject variability 
(Fern, Garlick and Waterlow, 1985a), natural progression, or the effects of 
therapeutic intervention (Conley et al., 1980); the ability to use several
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isotope tracers simultaneously (Kahlan et al., 1980); and the better 
sensitivity of the stable isotope technique, when the amount of tracer is 
restricted on ethical grounds and is subjected to a large dilution, e.g., 
incorporation of a label into tissue.
1.3 Measurement of stable isotopes
Protein metabolism studies using 15N or 13C-labelled amino acids as 
tracers can generate considerable numbers of samples for analysis. 
Therefore, appropriate instrumentation for the measurement of these 
isotopes is an important consideration in undertaking such studies. Until 
recently isotope analysis of samples from such studies required the use of 
two mass spectrometers, Isotope Ratio Mass Spectrometry for analysis of 
the re latively  large concentrations of low enrichm ent m etabolic  
end-product and Gas Chromatography-Mass Spectrometry for analysis of 
the labelled substrate usually present at high enrichment but low  
concentration. The recent development of Continuous Flow-lsotope Ratio 
Mass Spectrometry, combined with cation exchange High Performance 
Liquid Chromatography, developed as part of this thesis (Chapters 3 and 
4), offers an alternative to such conventional approaches (Preston and 
Owens, 1983,1985; Preston and McMillan, 1988).
1 .4  Protein turnover measurements
In the majority of tracer studies in man, it is now considered 
necessary to use stable isotopes. In protein turnover studies not only is 
there a choice of stable isotopes, (mainly 13C or 15N), but also a variety of 
amino acids to act as tracers. Alanine, glycine, leucine, lysine, 
phenylalanine, and tyrosine have all been used in such studies, however 
most measurements have been made with [15N]glycine or L-[1-13C]leucine.
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Glycine was the first amino acid used to estimate whole body protein 
turnover as it was readily purified and has no isomers. Its use has been 
extensive, but in the last 10 years, l_-[13C]leucine has been used 
increasingly. This has reflected a move away from end-product analysis to 
precursor analysis. The perceived advantages of each substrate are 
discussed in detail in Chapter 2.
1.5 Cancer cachexia
1.5.1 Weight loss in cancer
The majority of patients with progressive malignant disease lose 
weight (Nixon et al., 1980) and a proportion become emaciated to the 
point where they appear to die of starvation (Warren, 1932; Inagaki, 
Rodriguez and Bodey, 1974 ). This complex metabolic syndrome 
characterised clinically by progressive weight loss is termed cancer 
cachexia. The word cachexia is derived from two greek words, 'kakos' and 
'hexis' meaning 'poor condition' and is descriptive of any disease that 
results in host tissue wasting. The importance of cancer cachexia has long 
been recognised. Warren (1932), in a post mortem study of 500  cancer 
patients concluded that 22%  of deaths were directly attributable to 
cachexia and this was the single most common cause of death in cancer 
patients. More recent studies (Inagaki, Rodriguez and Bodey, 1974) have 
suggested that this figure is closer to 10% . However, more than 50%  of 
cancer deaths are attributable to sepsis and there remains the complex 
relationship between nutritional depletion and a propensity to infection. 
Furthermore, patients with a marked weight loss have a poor tolerance of 
vigorous antineoplastic therapy with lower response rates and an increased 
risk of suppression of cell-mediated immunity as compared with weight
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stable cancer patients. Hypoalbuminaemia associated with the cachetic 
patient is significantly correlated with the rate of post-operative  
complications (Daly and Thom, 1988). Given such nutritionally associated 
morbidity and mortality there is an urgent need to correct cachexia in 
cancer patients. The obvious treatment is to remove the tumour, but this is 
not always possible and therefore it is necessary to understand the 
mechanism of weight loss and try to plan alternative forms of treatment.
The pathogenesis of weight loss in cancer is not clearly understood. 
Weight loss does not correlate with the type of cancer or with the site or 
number of metastases (Costa and Donaldson, 1979). Moreover weight loss 
is not the result of tumour growth per se, since it is not induced by all 
tumours (Bozzetti et al., 1982). In general, loss or gain of body mass is 
due to an imbalance between energy intake and energy expenditure. A 
negative energy balance could be due to decreased food intake, an 
increased energy expenditure, or a combination of these two. Although 
anorexia is often a prominent symptom in wasted cancer patients, the 
weight lost by patients is often in excess of that expected from their 
documented reduction in food intake (Costa et al., 1981). This has led to 
suggestions that there must be a metabolic disorder contributing to the 
development of weight loss in cancer patients (Theologides, 1979). There 
are numerous reported abnormalities of intermediary metabolism in 
cancer-bearing animals and man involving glucose, protein, fat and energy 
metabolism (Kern and Norton, 1988). However, it is not clear which of 
these abnormalities contributes to weight loss. The persistent failure of 
cachetic patients to gain weight in the form of useful, metabolically active 
body cell mass despite seemingly adequate nutritional support may also be 
due to these widespread metabolic abnormalities.
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1 .5 .2  Body composition in cancer cachexia
In order to understand the mechanisms of weight loss in cancer 
cachexia it is necessary to determine the nature and extent of tissue loss. 
Several studies over the years have attempted to define the composition of 
tissue loss. A study by Cohn and coworkers (1981) of cancer patients with 
different tumour types, in which total body nitrogen, potassium and water 
were measured, suggested that weight loss reflects primarily the loss of fat 
and muscle tissue. Furthermore, they reported that there was no change in 
the amount of non-muscle tissue (including visceral tissue) w ith  
progressive weight loss in the cancer patients. Preston and coworkers 
(1987), using neutron activation analysis to measure total body minerals 
and nitrogen and whole body counting to measure total body potassium, 
derived muscle and non-muscle protein mass by compartmental analysis. 
They studied body composition in a group of cachetic lung cancer patients 
who had lost 30%  of their pre-illness weight and compared them with a 
group of control patients who were matched for the age, sex, height and 
pre-illness weight of the cancer group. The most dramatic alteration in 
body composition associated with the development of cachexia was the 
loss of greater than 80%  of body fat. They concluded that since fat is the 
principal energy store of the body, the patients had been in a prolonged, 
severe, negative energy balance. The other notable finding was a 75%  
reduction of skeletal muscle protein mass and this accounted for almost all 
of the net negative nitrogen balance. In accord with other studies they 
reported an expansion of the extracellular water space with relative 
preservation of the non-muscle protein mass. Such body composition 
analysis seems to support the finding that weight losing cancer patients 
show marked muscle wasting with little change in liver, spleen, kidney and 
heart weights (Heymsfield and McManus, 1985). This contrasts with
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simple starvation where the weight of these tissues and organs fall in 
parallel with that of the whole body (Heymsfield and McManus, 1985).
1 .5 .3  Energy metabolism in cancer cachexia
Studies of energy expenditure in cancer cachexia have shown 
conflicting results. Recent studies using indirect calorimetry have shown 
either no elevation or minimal elevation in metabolic rates in some cancer 
patients (Burke,Bryson and Kark, 1980; Macfie et al., 1982; Hansell et al., 
1986). In contrast, others have shown that specific tumour types may be 
accompanied by a hypermetabolic state. Dempsey et al (1984, 1986) have 
shown by indirect calorimetry that gastric cancer patients have elevated 
energy expenditure. Peacock et al (1987) studied a homogenous group of 
sarcoma patients with indirect calorimetry and 40K analysis of body 
composition. When compared to age and sex matched controls, sarcoma 
patients had significantly elevated resting energy expenditure, and a 
significantly decreased body cell mass. These patients did not have overt 
anorexia or weight loss. This study in humans confirms the finding of 
earlier studies with animal models of cancer cachexia that loss of host 
tissue begins early, at low tumour burdens, and precedes clinical evidence 
of weight loss.
Such contradictory findings in relation to the energy expenditure of 
patients with malignant disease may be partly due to the larger spectrum 
of energy expenditure in cancer compared to the normal population (Knox 
et al., 1983), reflecting the diverse nature of the effects of cancer on host 
energy metabolism. Furthermore, although results of energy expenditure 
studies vary, an important finding is that the metabolic rate fails to adjust 
to changes in food intake. Even small increases in metabolic rate must be 
met by equivalent increases in caloric intake, or persistent weight loss will
33
ensue. However, interpretation of such studies must be made in the light 
of the technical difficulties with measuring food intake accurately.
1 .5 .4  Whole body protein metabolism in cancer cachexia
Whole body protein turnover has been estimated to account for 
between 10%  and 20%  of resting energy expenditure in man (Reeds, 
Fuller and Nicholson, 1985). A reduction in the rate of protein turnover is 
thought to be one of the main methods of energy conservation during 
periods of reduced food intake (Waterlow and Jackson, 1981). It has been 
suggested that this adaptive mechanism might be impaired in patients with 
malignant disease (Brennan, 1981). Such adaptation is essential if the host 
is to minimise fat and protein losses in the presence of a reduced food 
intake.
In an attempt to assess specifically the effects of the tumour, Glass, 
Fern and Garlick (1983), using oral doses of [15N]glycine, measured rates 
of whole body protein turnover synthesis and breakdown in 11 patients 
with colorectal cancer before and after surgery. They did not find any 
significant changes in protein metabolism when comparing patients before 
and 12 weeks after tumour resection. They concluded that the presence of 
the primary tumour did not alter the overall rate of protein metabolism. 
However, the patients in this study had no evidence of protein calorie 
malnutrition and were at an early stage of the disease. In contrast, Eden 
and co-workers (1984) demonstrated that whole body protein turnover 
was increased in patients with cancer (as was resting energy expenditure) 
and concluded that these changes had contributed to the loss of body fat 
(energy) and protein (amino acid) reserves. Other studies have confirmed 
that whole body protein turnover is indeed elevated in patients with cancer 
(Norton, Stein and Brennan, 1981; Heber et al., 1982; Jeevanandam et al.,
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1984; Fearon et al., 1988). As with energy expenditure measurements in 
these patients there is a broader range of whole body protein turnover 
compared with controls (Fearon et al., 1988) (Figure 1.1).
In one of the few studies to measure resting energy and whole body 
protein turnover simultaneously, a corresponding increase in energy 
expenditure was not observed in weight-losing cancer patients with 
increased whole body protein turnover (Fearon et al., 1988). This 
observation has recently been confirmed in weight stable cancer patients 
who had increased whole body protein turnover but no increase in resting 
energy expenditure (Melville et al., 1990). There could be several reasons 
for this apparent contradiction. Firstly, that the measurement of energy 
expenditure by indirect calorimetry is insufficiently sensitive to detect the 
small increase in energy expenditure due to increased whole body protein 
turnover. Secondly, that since resting energy expenditure is the sum of all 
energy dependent processes in the resting, postabsorptive individual, other 
energy requiring processes are reduced to compensate for the energy cost 
of increased protein turnover. Lastly, although patients with cancer may 
have an elevated rate of tracer flux, this might represent regional changes 
in amino acid flux rather than a uniformly elevated rate in the whole body. 
If such regional changes are responsible for an increased amino acid flux 
(giving an apparent increased whole body protein turnover) then it is likely 
that the liver and muscle compartments are involved since together these 
are thought to account for approximately 60%  of whole body protein 
turnover.
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1.5 .5  Tissue protein metabolism in cancer cachexia
To obtain greater insight into the mechanism of altered protein 
metabolism in the cancer host several workers have attempted to measure 
rates of protein synthesis in skeletal muscle and liver. This work on rates 
of protein synthesis in different tissues is in its infancy, particularly in 
man. Not all tissues and organs have been studied, and the results are in 
general inaccurate since they take no account of the anatomical 
heterogeniety of tissues eg in the liver only about two thirds of the cells 
are parenchymatous cells. Moreover, in the gut, pancreas and liver an 
allowance has to be made for a substantial production of export protein if 
a complete picture of the activity of protein synthesis is to be obtained.
Skeletal muscle protein metabolism: Skeletal muscle accounts for 
approximately 40%  of body weight in man and is thought to be 
responsible for approximately 40%  of whole body protein synthesis. This 
tissue therefore has a major role in the protein metabolism of the whole 
body (Waterlow, Garlick and Millward, 1978b). In a study of human rectus 
abdominis muscle from both cancer patients and age matched controls 
Lundholm and coworkers (1976) reported decreased skeletal muscle 
protein synthesis (as measured by decreased incorporation of 14C-leucine 
into muscle protein in vitro). It must be considered however, that such in 
vitro measurements may not be physiologically meaningful. Nevertheless, 
studies of 3-methylhistidine release (a marker of muscle breakdown) from 
skeletal muscle in cancer patients have also suggested that protein is lost 
due to decreased synthesis rather increased breakdown (Lundholm et al., 
1982). These findings are in agreement with decreased skeletal muscle 
protein synthesis rates in animal studies in a variety of diseases 
characterised by malnutrition and wasting (Svaninger et al, 1983), where 
protein synthesis (rather than increased breakdown) is the main regulator
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of muscle protein turnover (Rennie et al., 1983). However, several animal 
studies suggest that protein breakdown is abnormally elevated in tumour 
bearing host muscle. Urinary 3-methylhistidine (primarily a skeletal muscle 
breakdown product) has been shown to be significantly greater in rats 
bearing a sarcoma than in control rats (Norton et al., 1981). Emery and 
coworkers, (1984b) reported an 80%  increase in the intramuscular free 
3-methylhistidine of tumour bearing mice. Thus, it appears that tumour 
bearing animals may lose skeletal muscle protein either by a decrease in 
protein synthesis or an elevation in muscle protein breakdown or a 
combination of the two.
Liver protein metabolism: The liver has a central function in energy 
and substrate metabolism and although the liver represents only 2%  of 
body weight it is thought to account for 20%  of whole body protein 
synthesis (Waterlow, Garlick and Millward, 1978b). The normal liver is 
known to have a major synthetic capacity which is divided equally 
between the production of export and non-export proteins.
Studies of the cachetic effects in the tumour-bearing state on liver 
protein synthesis have produced paradoxical results. The consistent finding 
of hypoalbuminaemia in cachetic cancer patients has been assumed by 
clinicians to be the result of decreased hepatic synthesis of albumin 
(Waldmann, Trier and Fallow, 1963). However, Karlberg, Kern and Fischer 
(1983) using sarcoma-bearing rats determined that rates of albumin 
synthesis were increased. The low serum albumin levels were a result of 
increased albumin degradation and expansion of the intravascular fluid 
space.
Synthetic rates of total protein in hepatocytes isolated from 
tumour-bearing animals have been shown to be twice that of control 
hepatocytes, with the increase proportional to the tumour burden (Warren,
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Jeevanandam and Brennan, 1987, 1985). Synthesis of both secretory and 
structural proteins was increased and because no net accrual of protein 
occurred in the livers of tumour-bearing rats, the protein degradation rate 
was assumed to be increased as well. Little work has been done 
specifically on fixed or structural liver protein synthesis either in man or 
animals and therefore their relative contribution to the apparently increased 
total liver protein synthesis in cancer cachexia is not known.
In summary, work on tumour-bearing animals suggests that 
fractional synthetic rates in liver are increased but that protein synthesis is 
decreased in skeletal muscle, the overall effect being an increase in whole 
body protein turnover. However, differences in the tumour type and the 
cachexia produced together with different methods of measuring protein 
synthesis make interpretation and comparison of results difficult. 
Observations on the rate of tissue protein synthesis in man are limited and 
the lack of in vivo data on both liver (fixed and export) and skeletal muscle 
means that the changes in tissue protein metabolism associated with 
cancer cachexia are not clearly understood.
38
1.6 Aims of thesis
1. To develop methods whereby whole body and tissue protein 
fractional synthetic rates can be measured using a single mass 
spectrometer.
2. To establish a clinical protocol to measure simultaneously resting 
energy expenditure and whole body, fixed hepatic and skeletal muscle 
protein synthesis, in man.
3. To use this protocol to compare the protein and energy metabolism 
in normal subjects with those in weight-losing cancer patients.
1.7 Plan of thesis
In Chapter 2 techniques for measuring whole body protein turnover 
and tissue protein synthesis rates in man are discussed. Methods 
developed for the enrichment measurement of precursor and end-product 
samples generated from the infusion of stable isotope labelled amino acids 
are described in Chapters 3 and 4. Methods for the measurement of other 
biochemical parameters and resting energy expenditure are described in 
Chapter 3. Validation of the study protocol is described in Chapter 4. A 
study in which resting energy expenditure and whole body, liver and 
skeletal muscle protein synthesis were simultaneously measured in a group 
of healthy subjects is described in Chapter 5. In Chapter 6 a second study 
is described in which the same parameters were measured in a group of 
weight-losing cancer patients. The results from these studies are discussed 
in Chapter 7. In Chapter 8 the aims of the thesis are discussed.
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CHAPTER 2: TECHNIQUES FOR MEASURING WHOLE BODY PROTEIN
TURNOVER AND TISSUE PROTEIN SYNTHESIS RATES IN MAN
2.1 Introduction
Estimation of whole body protein turnover requires the measurement 
of the rate of flux (or turnover) of a labelled (or tracer) amino acid. In 
order to calculate whole body protein turnover from the flux (or turnover) 
of an amino acid a metabolic model of protein metabolism is needed. A 
simple example of such a model, used extensively (Figure 2 .1 ), is one in 
which the labelled amino acid, whether given intravenously or orally, 
enters a single homogeneous free amino acid pool, from which it can be 
oxidised, giving rise to C 0 2 and urinary N, or it can be incorporated into 
protein. The protein of the whole body is considered as a single pool which 
is continually recycling amino acids back into the metabolic pool, but 
because of its large size, does not return the label during the course of the 
experiment. When the free amino acid pool is constant in size, its turnover 
(termed the flux, Q) is given by the following expression:
Q = S + E = B + I
where S is synthesis, E is excretion, B is breakdown and I is intake 
(Figure 2.1). Using this model the protocol for the estimation of amino acid 
flux is determined either by compartmental or stochastic analysis of the 
data. Between 1950-1970, there was dispute as to which type of analysis 
might give the best estimate of amino acid turnover. The compartmental 
approach involves giving the labelled amino acid as a single dose and 
measuring the label enrichment in the metabolite at different time intervals, 
either in the pool into which the labelled amino acid was given or other 
pool(s). From the decay curve of label enrichment against time, fractional 
turnover rates of protein can be calculated by compartmental analysis
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(Waterlow, Garlick and Millward, 1978d). The compartmental approach 
represents the conventional method which had been used from the start of 
stable isotope work. In theory, this approach should yield additional 
information, namely the ability to determine the pool size and the nature of 
the turnover of the pool. However, in practice, meaningful interpretation of 
such data has proven to be very difficult, very long protocols being 
necessary to estimate whole body protein turnover in man (Long et al., 
1977) because of the need to define the decay constant of protein pools 
with very slow turnover rates. In contrast, the stochastic approach 
removes the assumption about the number of pools involved in protein 
turnover that is required for the compartmental approach (Waterlow, 
Garlick and M illward, 1978d). The stochastic method involves a 
continuous infusion of labelled amino acid until the tracer enrichment 
reaches a plateau in the chosen pool. Alternatively, a single dose and 
measurement of the cumulative tracer enrichment in the chosen pool 
(Waterlow, Golden and Garlick, 1978). Using the stochastic approach, 
fewer measurements are required to define the plateau enrichment than to 
define the decay curve of the compartmental approach. Also the stochastic 
method gives a better estimate when the enrichment of the label in a 
metabolic end-product is measured since once an isotopic equilibrium has 
been achieved the exact timing of the measurement should not matter.
It is now widely considered that the compartmental approach 
requires so many analyses that in practice the benefits are not worth the 
extra effort required when compared to the stochastic method. Indeed, 
with reference to whole body protein turnover, Waterlow, Garlick and 
Millward (1978d) have suggested that the compartmental approach is in 
error as it does not properly describe the underlying processes. In clinical 
studies, to enable stochastic analysis the continuous infusion has become
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the most commonly used method of administering the labelled amino acid 
as it is convenient and gives essentially the same turnover values as single 
or multiple dose regimens (Garlick and Fern, 1985). In such studies a bolus 
dose (termed the priming dose) of the tracer is often given in conjunction 
with a continuous infusion to shorten the time taken to reach isotopic 
equilibrium in the metabolic pool. The use of a priming dose not affect the 
plateau isotopic enrichment value, only the time taken to reach it (Wolfe, 
1984a).
Attempts to measure the rate of amino acid flux in man with stable 
isotopes have followed the development of the mass spectrometer. In most 
early studies which used stable isotopes the enrichment of the amino acid 
label in a metabolic end-product was used to derive turnover rates 
(end-product methods) rather than the enrichment of the amino acid in the 
metabolic pool (precursor methods). This was due to the Isotope Ratio 
Mass Spectrometer being the only available instrument for measuring 
stable isotope enrichment and its requirement of a relatively large sample 
size for analysis. Furthermore, if one uses a precursor method with Isotope 
Ratio Mass Spectrometry, then purification of the sample from plasma or 
the relevant metabolic pool for enrichment analysis is complex and time 
consuming, and small sample sizes often necessitate isotope dilution 
analysis.
Gas Chromatography-Mass Spectrom etry together w ith new  
automated techniques for precise analysis of specific ions (selected ion 
monitoring) allowed precursor methods to be carried out more easily in 
studies of whole body protein metabolism. Gas Chromatography-Mass 
Spectrometry combines the ability of the gas chromatograph to resolve 
components of a complex mixture with the highly selective and sensitive 
detection of a mass spectrometer. Therefore, separation of the labelled
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tracer from a complex sample matrix (plasma, intracellular fluid) and 
enrichment analysis required for precursor methods became rapid and 
much simpler. In practical terms, there was now a choice to be made as to 
which approach was used for the measurement of whole body protein 
turnover in such studies.
2 .2  Precursor methods
The constant infusion of carboxyl-labelled [13C]leucine is a good 
example of this approach (Matthews et al., 1980). Using the model for 
amino acid metabolism described in the previous section, at steady state, 
gives the relationship
Q = S +  E = B + I 
Where Q is the rate of leucine flux, S is the rate of leucine incorporation 
into protein (protein synthesis), E is the rate of leucine oxidation (or 
catabolism), B is the rate of leucine release from protein (protein 
breakdown) and I is the rate of exogenous leucine intake. The [13C]leucine 
is infused intravenously until the isotopic enrichment of the amino acid in 
the plasma reaches a constant value (Ep) from which the flux can be 
calculated from the expression
Q = i / [Ej/Ep-1]
Where i is the rate of infusion of [13C]leucine, Ej is the enrichment of the 
[13C]leucine infused. The plateau can be achieved more rapidly if a priming 
dose is given (Clague et al., 1983). At the same time the excretion of the 
label in respiratory C 0 2 also reaches a plateau (e), from which the rate of 
oxidation (E) of leucine can be calculated 
E =  e /  [Ep-Ej]
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Knowledge of the dietary intake of the amino acid and body leucine 
content then enables the rates of whole body protein synthesis (S = Q-E) 
and breakdown (B = Q-I) to be estimated (Matthews et al., 1980).
There are a number of assumptions that effect the validity of this 
approach; firstly, it is assumed that the free amino acid pool is 
homogeneous and that the enrichment of leucine in a blood sample can be 
taken as representative of leucine at the sites of protein synthesis and 
leucine oxidation. However, compartmentation of the amino acid pools, 
both among and within tissues, has been demonstrated. For instance, it 
has been demonstrated that intracellular leucine enrichment is lower than 
that in plasma (Waterlow, Garlick and Millward, 1978d). It is therefore 
important to know which precursor enrichment should be used in the 
calculation of turnover. One way around this problem is to assume that 
protein synthesis and leucine oxidation take place from the same precursor 
pool. The rate of synthesis can then be calculated from the labelled C 0 2 
production (Garlick and Clugston, 1981, Golden and Waterlow, 1977). A 
modification of this method is to use the enrichment, in the plasma, of the 
transamination product of leucine, alpha ketoisocaproate (Matthews et al., 
1982). The enrichment at the site of leucine oxidation is 10-30%  lower 
than that in the plasma, and is similar to that in skeletal muscle. If one, 
therefore, uses alpha-ketoisocaproate to calculate leucine enrichment in the 
precursor pool this gives rise to higher rates of flux and oxidation than if 
plasma leucine enrichments are used.
A second potential source of error with labelled leucine infusion is 
the assessment of labelled C 0 2 production. This is usually done by 
separate measurements of the total rate of C 0 2 production and its 13C 
enrichment. Total C 0 2 production is best measured with a continuous flow  
through system (eg. a ventilated hood) as a Douglas bag and valve is
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prone to serious error, especially with collections of a short duration 
(Garlick and Clugston, 1981). The main difficulty with this measurement is 
the apparent fixation of the isotope, resulting in recoveries of injected or 
infused 13C-bicarbonate of less than 100% . This problem can largely be 
overcome if the measurement system is calibrated by infusion of labelled 
bicarbonate as part of the labelled leucine infusion study (Clague, Keir and 
Clayton, 1979; Clugston and Garlick, 1983). The other assumptions which 
are common to both precursor and end-product analysis are; (1) that the 
metabolic pool does not change in size during the period of measurement. 
(2) the isotope tracer is treated in the same way as the major isotope. (3) 
the dose of the labelled amino acid given is tracer dose and does not itself 
affect turnover. (4) The amino acid faithfully represents protein flux.
2 .3  End-product methods
The end-product methods, with few  exceptions, have used a 
15N-labelled amino acid as the tracer and urinary ammonia or, urea as an 
end-product, where it is recognised that the 15N will not remain attached 
to one single amino acid. The 15N is therefore regarded as a label for the 
total free amino nitrogen pool. Since the urinary end-products of nitrogen 
metabolism, urea and ammonia, are derived solely from the free amino 
nitrogen pool, their labelling can be taken as representative of that pool. 
An example of this approach is the continuous intravenous infusion of 
[15N]glycine until a plateau in the labelling of ammonia or urea (Smax) in 
the urine has been achieved. This plateau value can then be used to 
calculate the total nitrogen flux (Q) in a way similar to that for leucine 
Q = « / S max
Where d is the rate of infusion of [15N]glycine. The rate of amino acid 
oxidation (E) is given by the rate of total nitrogen excretion. Once again
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knowledge of the dietary intake of nitrogen and the nitrogen composition 
of body protein enables the rates of whole body protein synthesis (S = Q-E) 
and breakdown (B =  Q-I) to be estimated (Waterlow, Garlick and Millward, 
1978d). Modifications have included the administration of the 15N as a 
single dose, and the use of ammonia as the end-product rather than urea 
(Waterlow Golden and Garlick, 1978).
The most important assumption of the end-product method is that 
the fraction of the dose of isotope excreted in the chosen end-product is 
the same as that of unlabelled nitrogen. For this assumption to be 
co m p le te ly  sa tis fied , the m etabolic  pool should not undergo  
compartmentation either anatomically or metabolically. Anatomical 
compartmentation has been implied from rates of turnover derived from 
urea and ammonia after a single dose of [15N]glycine (Fern and Garlick, 
1981). In general the two end-products do not give the same values, the 
value derived from urea is higher than that from ammonia, and the 
difference is increased by feeding and by intravenous compared with oral 
adminstration of the isotope. Fern and Garlick (1981) attributed these 
differences to the localisation of urea synthesis in the liver and ammonia 
synthesis in the kidney, and have suggested a two compartment metabolic 
pool consisting of urea precursors (gut and liver) and ammonia precursors 
(peripheral tissues). Further, they suggested that the average of the two 
rates given by urea and ammonia (termed end-product average) would give 
the best estimate for whole body protein turnover. This average is 
unbiased towards either compartment, since its value is not affected by 
the route of administration of the isotope (Fern, Garlick and Waterlow, 
1985b).
Metabolic compartmentation of nitrogen metabolism can be 
demonstrated by administration of different labelled amino acids (Fern,
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Garlick and Waterlow, 1985a). Rates of protein synthesis were estimated 
by measurements of the excretion of 15N in urea and ammonia, after both 
oral and intravenous administration of a number of [15N]-labelled amino 
acids. In general, the urea and ammonia gave different values, and this 
difference varied greatly depending on the route of administration, thus 
confirming for the other amino acids the concept of anatomical 
compartmentation described above for glycine. It is also notable that with 
the other amino acids the value of the end-product average varied little 
with the route of administration. However end-product averages did vary 
greatly among the different amino acids. Metabolic compartmentation can 
be seen, therefore, to be an important consideration that must be allowed 
for when choosing a 15N labelled amino acid for this type of study. 
Glycine, which has been used in the majority of past studies, gives rates of 
synthesis that are both in the middle of the range of those given by others, 
and are close to those given by precursor methods such as labelled leucine 
infusion (Fern, Garlick and Waterlow, 1985a).
The other assumptions with end-product methods are; (1) that 
dietary total nitrogen and glycine-N are treated in the same way as 
nitrogen derived from tissue breakdown. (2) [15N]glycine, and any amino 
acid deriving 15N from glycine, equilibrate through their respective pools so 
that their enrichment is the same at all sites of protein and end-product 
synthesis. (3) Glycine-N does not give rise to quantitatively significant 
amounts of products other than protein and excretory products and the 
end-products do not derive nitrogen from non-protein sources (eg. purines, 
creatine, hippurate etc).
Discussion as to whether precursor or end-product analysis gives the 
best estimate of substrate turnover has been continuous since the 
availability of both Gas Chromatography-Mass Spectrometry and Isotope
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Ratio Mass Spectrometry instrumentation. Each type of analysis has its 
own advantages and disadvantages, but it appears that in recent years 
that there has been a move away from end-product analysis.
In summary, whether the tracer is given by a single dose or by 
constant infusion, precursor measurements have the advantage that with a 
suitable choice of tracer the duration of the experimental protocol can be 
relatively short e.g. 4 -12h with intravenous infusion of 13C-leucine. This 
minimises the effect of recycling. It also means that the method is more 
suitable for use in patients whose clinical state may be changing. 
However, if 13C is used as a label separate mass spectrometers are 
required for measuring the enrichment in plasma and breath C 0 2. There are 
two main sources of error in the precursor method. The first, is that 
estimates of turnover are likely to be low, because the enrichment of the 
tracer in the plasma is higher than that in the precursor pool. The second 
arises when the turnover of a single labelled amino acid is used to derive 
the turnover rate of body protein since it is assumed that the body protein 
has a particular amino acid composition. End-product measurements have 
the advantage in the clinical field that they are simple to carry out and the 
isotopic m easurem ents are stra ightforw ard using a single mass 
spectrometer. The disadvantage is that, like the precursor method, 
there are doubts about some of the assumptions on which the method is 
based.
Thus, measurement of whole body protein turnover by precursor and 
end-product methods is based on assumptions that are not always valid. 
However, under normal circumstances, with a normal diet and turnover 
rate, the methods give similar and reasonable results. Furthermore, there 
appears to be no reason why such errors should affect the validity of 
comparative measurements. However, at the extremes of intake or when
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unusual mixtures of proteins are made or disposed of, the results may be 
in error. It is therefore important that careful consideration is given to the 
design of experiments to minimise the errors which the investigator can 
quantify or allow for.
2 .4  Tissue Protein Synthesis Measurement
Tissue protein synthesis is estimated by measuring the enrichment 
of the tracer incorporated into tissue protein and the isotopic enrichment of 
the free amino acid at the site of protein synthesis. Therefore, it is 
fundamental to the estimation that the source of labelled amino acids for 
protein synthesis is known. The measurement of the enrichment of the 
aminoacyl-tRNA should give a true enrichment value with which protein 
fractional synthetic rates can be calculated. However, this approach may 
be complicated by there being more than one pool of aminoacyl-tRNA at 
differing enrichm ents (W aterlow , Garlick and M illw ard , 1 9 7 8 j). 
Furthermore, the isolation of aminoacyl-tRNA required to make such 
measurements is technically difficult because of the small amount of tRNA 
present in tissues and its extremely rapid turnover rate. This approach has 
only been used in a few  studies for tissue protein synthetic rate 
measurements (Waterlow, Garlick and Millward, 1978j). The approach 
which has been used extensively in such measurements is to measure the 
enrichment of the free amino acid in the pool thought to charge 
aminoacyl-tRNA. However, there has been considerable debate about 
which free amino acid pool is responsible. There have been a number of 
studies which have suggested that the source of free amino acids for 
protein synthesis is from the intracellular pool of the tissue (Waterlow, 
Garlick and Millward, 1978j). This is what would be expected since the 
site of protein synthesis (the ribosome) is intracellular. However, there is
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also evidence that the source of particular amino acids for protein 
synthesis may be extracellular and these amino acids are channelled via 
membrane transport systems into the ribosome (Waterlow, Garlick and 
Millward, 1978j). It has been proposed that the source of an amino acid 
(intracellular or extracellular) for protein synthesis may be determined 
firstly by the relative concentration of the amino acid intra- and 
extracellularly. Secondly, by the amino acid transport mechanism involved 
(Waterlow, Garlick and Millward, 1978j). Therefore, it would appear that 
when using this approach to determine tissue protein synthetic rates it is 
important that both these factors and the synthetic rates calculated from 
intra- and extracellular amino acid enrichment are considered.
The basis for these calculations are well described for animal studies 
(Zak, Martin and Blough, 1979., Garlick, 1980). In animals, most tissue 
protein synthesis measurements have been made with radioisotopes 
because the specific activities of amino acids in individual proteins are 
easier to measure than the corresponding stable isotope enrichments and 
there is no limitation on biopsy size. However, in man, because of ethical 
considerations, stable isotope methods have been developed for measuring 
tissue protein synthetic rates. Two principal methods have been used to 
determine tissue protein synthesis in man.
2.5 Tracer dose protocol
There have been very few direct measurements of tissue protein 
synthesis in man, but of these most have used a continuous infusion of a 
labelled amino acid at a tracer dose. Halliday and McKeran (1975) in the 
first study in man used this approach to measure muscle protein synthesis 
and whole body protein turnover simultaneously. They infused an essential 
amino acid, L-[15N]lysine for 20-30h. [15N]lysine was chosen as it was
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readily available and transfers only a small fraction of its 15N to other 
amino acids during metabolism. Also it gives a plasma plateau enrichment 
in a reasonable tim e period and is readily separated by liquid 
chromatography. However, they were unable to measure the intracellular 
free lysine enrichment and used the plasma lysine enrichment in the 
calculation, thereby, underestimating the actual muscle protein fractional 
synthetic rate. Furthermore, the fractional synthetic rate of the 
sarcoplasmic fraction of the muscle was calculated from the total 15N 
enrichment rather than that of [15N]lysine. This would overestimate the 
fractional synthetic rate since the long infusion of [15N]lysine would result 
in labelled glutamate and arginine being incorporated into the sarcoplasmic 
fraction. However, accepting these limitations it was reported with this 
method that total muscle protein synthesis accounted for 53%  of whole 
body protein turnover, confirming the importance of muscle protein 
synthesis in man.
Stein et al. (1978a) used a continuous infusion of [15N]glycine to 
measure protein synthesis in liver, tumour and normal gut of patients with 
gastrointestinal cancer. A criticism of the method used in this study is that 
protein synthesis rates were estimated from the 15N incorporated into 
tissue protein and the 15N enrichment of the tissue free amino acid pool 
rather than [15N]glycine. The use of the 15N enrichment to measure 
protein fractional synthetic rates will be less accurate than using the tissue 
free and bound [15N]glycine enrichment, since the relative concentration of 
tissue bound amino acids is not the same as the relative concentration of 
tissue free amino acids (Munro, 1970). Furthermore, there are significant 
differences in the alpha-amino nitrogen enrichment of free amino acids 
during continuous infusion, even when using [15N]glycine which readily 
transfers the amino nitrogen to other amino acids (Matthews et al.,
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1981b). Indeed, using the two methods, a significant difference in the 
measured liver protein fractional synthetic rate has been reported, the 
[15N]glycine derived synthesis rates were approximately double the 15N 
derived values (Stein et al., 1980). Therefore, the accuracy of the 
fractional synthetic rate obtained by this method is in doubt (Stein et al., 
1980). Nevertheless, this study was the first attempt in man to measure 
rates of fixed protein synthesis in the liver.
Reflecting the move away from [15N]glycine to [13C]leucine for 
whole body protein turnover measurements, the next tissue measurements 
in man were made in skeletal muscle using a primed continuous infusion of 
[13C]leucine for 8h (Rennie et al., 1982a). The method that was used was 
similar to that of Halliday and McKeran, (1975) and whole body and 
muscle protein synthesis were measured sim ultaneously. Plasma 
alpha-ketoisocaproate enrichment was used to calculate the leucine flux 
and the muscle fractional synthetic rate. It was assumed that the plasma 
alpha ketoisocaproate enrichment was a better estimate of the intracellular 
precursor (leucine) enrichment. This method has been the basis of muscle 
protein synthesis measurements made since. It has been used to 
investigate the effect of feeding (Rennie et al., 1982a), muscular dystrophy 
(Rennie et al., 1982b), immobilisation of the leg (Gibson et al., 1987), and 
idiopathic scoliosis (Gibson et al., 1988) on muscle protein synthesis.
2 .6  Flooding dose protocol
As already stated, calculation of the rate of protein synthesis 
requires not only measurement of the incorporation of the labelled amino 
acid into the protein but also the enrichment of the free amino acid at the 
site of protein synthesis. The latter has proven a difficult measurement to 
make using a continuous infusion of a tracer dose of labelled amino acid.
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This difficulty is due to compartmentation of the free amino acid in the 
tissue and the problems associated with measuring the enrichment of the 
actual precursor for protein synthesis, th a t is am inoacyl-tR NA . 
Alternatively, the 'flooding dose' technique, in which the labelled amino 
acid is given with a large amount of the unlabelled amino acid as a bolus 
could be used. The basis of this method is that the high concentration of 
the free amino acid results in rapid equilibration of the amino acid in the 
intra- and extracellular compartments of the tissues, including the pool that 
is used for charging tRNA, to similar isotopic enrichments. Therefore, the 
plasma free amino acid enrichment can be used to estimate the fractional 
synthetic rate with little error. This method has been used to measure 
protein synthesis in cultured cells (Ballard, 1982; McNurlan and Clemens, 
1985) perfused or incubated tissues in vitro (Mortimore, Woodside and 
Henry, 1972; Fulks, Li and Goldberg, 1975) and animal tissues in vivo 
(Henshaw et al., 1971; Scornik, 1974; McNurlan, Tomkins and Garlick, 
1979; Garlick, McNurlan and Preedy, 1980). The advantage of accuracy 
together with rapid and convenient measurements of protein fractional 
synthetic rates has resulted in this method being validated recently for the 
measurement of muscle protein synthesis in man (Garlick et al., 1989). 
However, this technique, developed initially in animals to measure tissue 
protein synthesis, does not provide an index of protein synthesis in the 
whole body unless the tracer incorporation is measured in most tissues 
and the organ protein masses are known (Attaix et al., 1988). Moreover, 
the flooding dose protocol would fail to resolve fixed from export protein 
synthesis in the liver (since in the short time course of the flooding dose 
protocol tracer incorporation into a tissue biopsy would reflect both fixed 
and export components). Therefore, the flooding dose approach was not 
consistent with the aims of this thesis.
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2.7  Summary
To satisfy the aims of the thesis (see section 1.6) it is necessary to 
measure simultaneously whole body, liver and skeletal muscle protein 
synthetic rates, to separate the contribution to total liver protein synthesis 
between fixed and export components and to make these measurements 
within a protocol such that the tissue biopsies are obtained at the start of 
an abdominal operation. From the review of the literature presented above, 
it is clear that rather than a flooding dose technique, the stochastic 
approach together with a tracer dose of labelled amino acid best allows 
these aims to be achieved. However, what is not clear is whether 
[13C]leucine (precursor method) or [15N]glycine (end-product method) 
might give the best estimate of tissue synthetic rates. Thus, in this thesis a 
comparison was undertaken in a group of healthy controls between 
[13C]leucine and [15N]glycine (Chapter 5) and the tracer which gave the 
most reliable results was used to study a group of weight-losing cancer 
patients (Chapter 6).
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Figure 2.1 Two pool model of whole body protein metabolism
CHAPTER 3: METHODS: STABLE ISOTOPE SAMPLE PREPARATION.
BIOCHEMICAL ANALYSES AND MEASUREMENT OF RESTING ENERGY 
EXPENDITURE
3.1 Introduction
A number of 13C or 15N-labelled amino acids have been used to 
make measurements of protein synthesis in man. With few exceptions 
analysis of precursors labelled with 13C or 15N has been carried out by Gas 
Chromatography-Mass Spectrometry usually in the selected ion monitoring 
mode. An attempt has been made to measure the 15N enrichment of lysine 
by Isotope Ratio Mass Spectrometry (Halliday and McKeran, 1975), though 
the method was cumbersome and required 30ml of blood for each sample. 
Such a method was unacceptable for most clinical studies. Thus the 
Isotope Ratio Mass Spectrometry method of measuring precursor 
enrichment was at a considerable disadvantage compared to Gas 
Chromatography-Mass Spectrometry techniques capable of making the 
isotope analysis in less than 1ml of plasma. However, as discussed in 
Chapter 2, to obtain the maximum information (oxidation data) from 
turnover studies it is necessary to make an end-product measurement 
w hich  requires Isotope Ratio Mass S p ec tro m etry . A lso, Gas 
Chromatography-Mass Spectrometry is not suitable for measuring 13C or 
15N enrichment of labelled substrates incorporated into biopsy samples 
(which is usually of low enrichment). There are also methodological 
problems with this approach not least the requirement that both the Gas 
Chromatography-Mass Spectrometry and Isotope Ratio Mass Spectrometry 
instrumentation are calibrated with one another and remain so throughout 
the measurements. These disadvantages together with the fact that there 
are very few laboratories in a clinical situation equipped with both types of
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mass spectrometer have resulted in few studies of this type being carried 
out. An aim of this thesis was to develop methods by which both 
precursor and end-product 13C and 15N measurements could be made on 
the same mass spectrometry system, i.e. Continuous Flow-lsotope Ratio 
M ass S p ec tro m etry . The C ontinuous F lo w -lso to p e  Ratio Mass  
Spectrometer that was used in these studies has been shown to be 
accurate, precise and have good precision for the isotope analysis of C 0 2 
and N2 after quantitative oxidative combustion (Preston and Owens, 1983, 
1985; Preston and McMillan, 1988). However, as the isotope analysis is 
carried out after combustion of the precursor or end-product sample it is 
essential that these compounds are pure since if they are not, isotopic 
enrichment measurements will be inaccurate. This is in contrast to sample 
preparation in radioisotope tracer studies since contamination of the 
sample by any source of nitrogen or carbon (eg. from organic or aqueous 
solvents) has to be removed prior to combustion and isotope analysis. 
Therefore, a key step of the sample preparation in this work was the amino 
acid separation of leucine and glycine from the complex sample matrices of 
plasma, intracellular fluid and hydrolysed protein.
3 .2  Isolation of free amino acids from biological fluids prior to amino acid 
separation
The biological fluids in man which are most commonly analysed for 
free amino acids are blood, plasma (or serum), and intracellular fluid. The 
chief feature of these sample matrices is the presence of large amounts of 
protein, and therefore degradation of these proteins could potentially 
contribute a large amount of low enrichment amino acids to the free pool. 
Also, in order that the best separation of amino acids be obtained, it is 
important that the free amino acids as a group are removed from all
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interfering compounds. Therefore, the free amino acids should be 
separated from potentially interfering compounds, rapidly, in controlled 
conditions.
3.2.1 Removal of protein and interfering compounds
The first step in preparation of a (plasma or serum) sample for free 
amino acid separation is to remove protein, including any enzymes which 
might bring about their breakdown. The simplest and longest established 
method is to precipitate all protein and isolate the supernatant, the protein 
being denatured by the precipitant. Popular acidic reagents for protein 
precipitation are trichloroacetic acid, perchloric acid, sulphosalcylic acid 
and tungstic acid. These methods using acid precipitation leave large 
molecular weight lipids in solution. To avoid interference from these 
methanol and ethanol have been used, at least two volumes of ethanol 
being required to precipitate all plasma proteins (Dell, 1967). Both acid and 
alcohol methods of protein precipitation, because their action is through 
denaturing proteins, can give variable yields of free amino acids and 
compromise recovery of proteins from the sample. To avoid these 
problems ultrafiltration methods (using commercially available filters) have 
become increasingly popular.
In the work presented in this thesis ultrafiltration was used to 
remove protein (and all compounds of molecular weight greater than
25 ,000  daltons) from plasma and homogenate samples (Figure 3 .1 , 3.2). 
The suitability of ultrafiltration was verified by analysis of the amino acid 
content before and after ultrafiltration of a plasma sample (Table 3.2). It 
would appear from the data obtained that the ultrafiltration did not 
selectively retain any of the amino acids measured and that the recovery of 
amino acids was on average 83% . These measurements were in accord
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with the recovery of [14C]glycine (Sigma Ltd, Poole, UK.) added to plasma 
samples (Table 3.1). Further purification of the amino acids was achieved 
by batch cation exchange resin (Figure 3 .1 , 3 .2). Recovery of [14C]glycine 
following this step was determined to be approximately 90%  (Table 3.1).
3 .2 .2  Protein hvdrolvsis
There are three principal methods for cleaving peptide bonds to 
prepare hydrolysates suitable for amino acid separation. Each has 
advantages and disadvantages.
(a) Acid Hydrolysis
Several acids have been used to hydrolyse peptide bonds. Each has 
some advantages with reference to individual amino acids, and none are 
without some undesirable features, such as the introduction of artifacts or 
the partial or complete destruction of some amino acids (Hill, 1965). The 
most commonly used method employs 6N HCI at 110°C for 24h or longer. 
However, higher temperatures (up to 155°C) have been employed with 
concomitant shortening of the time required to complete the hydrolysis. 
Although the destruction of some amino acids is also increased, proper 
correction can be applied. The protein or peptide in dry form is placed in a 
suitable vessel, the acid added, and the oxygen present removed by a 
nitrogen flush, evacuation or a combination of both. The removal of 
oxygen is an important step in the procedure and is often difficult because 
solutions of peptide or denatured protein tend to foam under vacuum. This 
can be reduced by freezing and thawing slowly under vacuum. Vortexing 
during the evacuation stage is equally effective and much faster. After 
hydrolysing the protein, the HCI is removed by rotary evaporation or 
vacuum distillation. This is preferable to drying overnight in a dessicator in
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terms of both efficiency and the prevention of artifacts formed under 
anhydrous conditions (Ikawa and Snell, 1961) Dry samples can be 
reconstituted in water or an appropriate buffer for subsequent separation.
(b) Alkaline hydrolysis
The greater range of amino acids destroyed in alkali has prevented 
this method from being widely adopted. Serine, threonine, arginine, and 
cystine are extensively or completely destroyed, and considerable 
racemisation, most notably of isoleucine (to form allo-isoleucine, which is 
resolved from the natural isomer of isoleucine on automatic analysers), is 
observed. The most common application of this method is for the 
determination of tryptophan.
(c) Enzymatic hydrolysis
There are several advantages in using enzymes to hydrolyse 
peptide bonds. Firstly, the enzymes are specific and readily cleave bonds 
that are resistant to non-specific catalysts . Second, they are 
non-destructive, not only to the common amino acids, but also to labile 
groups introduced either in vivo or in vitro. Finally, they act rapidly and in 
theory could complete the hydrolysis in a matter of only a few minutes. In 
practice, these advantages are largely offset by the fact that the 
enzyme-catalysed hydrolysis of peptide bonds does not proceed materially 
faster than other catalysts and, more importantly, often does not go to 
completion. The latter observation reduces the general utility of this 
method and confines its use primarily to cases in which identification of 
labile amino derivatives is the principal point of interest.
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In order to obtain maximum recovery of the neutral amino acids, 
glycine and leucine, conventional acid hydrolysis was used in this thesis. 
However, instead of the protein being hydrolysed in 6M HCI at 110°C for 
24h it was carried out at 145°C for 4h (Roach and Gehrke, 1970). This 
was done to increase the throughput of samples in line with other parts of 
the sample analysis.
3 .3  Amino acid separation
3.3.1 Introduction
The early stages of amino acid analyses date from the discovery of 
glycine by Henri Braconnot in 1820. This was the first time in which a pure 
amino acid was obtained from an acid hydrolysate of a protein, although 
asparagine and cysteine had been observed a decade earlier. The 
succeeding century saw the identification of most of the remaining 
common amino acids, although threonine was not discovered until 1935. 
The isolation of the amino acids and their subsequent determination in 
other samples were accomplished using macroscopic methods that require 
large amounts of protein as starting material. As analytical procedures they 
suffered from inaccuracy due to the large losses encountered and from the 
extensive amount of time and effort required. Despite the overall limitations 
of the procedures in producing quantitative analyses, certain amino acids 
that contain appropriate functional groups were readily determined at 
considerably more sensitive levels by the use of colorimetric methods. 
Folin and Denis (1912) introduced such an approach to the measurement 
of tyrosine and tryptophan, and procedures for the determination of 
arginine (1925), histidine (1919), and phenylalanine (1932) were reported 
subsequently. The highly reactive thiol group of cysteine has also been
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utilised for analysis of this amino acid in a number of different systems. 
Other approaches to amino acid determination included solubility product 
procedures (Moore, Stein and Bergmann, 1942), the isotope dilution 
method (Rittenberg and Foster, 1940), the isotope derivative method 
(Keston and Udenfriend, 1 9 4 9 ), and periodate oxidation for the 
determination of serine and threonine (Shinn and Nicolet, 1941; Rees, 
1946). In addition, procedures employing the specificity of enzymes and 
the nutritional requirements of microorganisms were developed, primarily in 
the 1940's that allowed the complete determination of a mixture of amino 
acids without prior fractionation.
The introduction of chromatographic techniques, which permitted 
the complete separation of all the amino acids prior to their estimation and 
which form the basis of present methods of analysis, began with the 
studies of Martin and Synge (1941), who used silica gel columns for 
separating N-acetyl amino acids. The use of paper chromatography to 
separate free amino acids followed directly afterward (Consden, Gordon 
and Martin, 1944). Partition chromatography of amino acids on starch 
columns was reported by Elsden and Synge (1948) and Stein and Moore 
(1948) and was further developed by the latter workers (Moore and Stein, 
1949; Stein and Moore, 1949a). This line of experimentation led, in turn, 
to the introduction of ion exchange resins as the separation medium of 
choice (Moore and Stein, 1951) as well as the invention of the fraction 
collector and the use of ninhydrin as a universal reagent for detecting and 
quantifying amino acids both manually and automatically (Moore and Stein, 
1948).
Although the introduction of ion-exchange resins, particularly 
sulfonated polystyrene, led directly to automated quantitative analyses, 
paper chromatography enjoyed widespread use for a number of years as
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both a qualitative and quantitative technique. Paper chromatography is no 
longer widely used for amino acid analysis as it has poor sensitivity 
compared to modern automated ion-exchange instruments.
3 .3 .2  lon-exchanae chromatography
The separation of amino acids by ion-exchange is primarily due to 
differences in pKa values and follows the general order: acidic, neutral and 
finally basic amino acids. Various interactions between structural features 
(e.g. aromatic rings or non-polar side chains) of amino acids, and the resin 
modify retention properties. The cation-exchange resin is usually made by 
sulphonation of beads of styrene, and copolymerised with di-vinyl benzene.
The complete resolution of the normal protein-bound amino acids 
was first achieved on columns of cation exchange resin (sulphonated 
polystyrene, Dowex 50x8) in 1951. Operated in the sodium form, the 
column development was accomplished with multiple buffers covering the 
range pH 3 .4 -11 .0  at temperatures from 25°C to 75°C (Moore and Stein, 
1951). Two columns were required, one for the acidic and neutral amino 
acids and one for the basic ones. Since that time, improvements in almost 
every phase of this type of analysis have been made. Continuous 
refinement, particularly with respect to the physical state of the resin 
(Benson, 1972), has allowed a steady reduction in the size of the columns 
required. These changes have led directly to the practicability of the 
separation of all the amino acids using one column, from increasingly 
smaller loaded samples.
The constant molarity single column system described by Hare 
(1972) utilises stepwise buffer solutions of increasing pH and a constant 
sodium concentration of 0.2mol/l. The latter method is advantageous 
because the minimal changes in ionic strength of the various eluents
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provide an environment in which resin swelling and shrinkage are 
minimised. Thus, low pump pressures can effect relatively high eluent 
linear flow velocities and thereby allow a reduction in total analysis time.
Constant molarity eluents were utilised, not only to reduce pump 
pressures, but also because anions are available that can be used to 
prepare solutions with high buffering capacities over a wide pH range. The 
latter consideration was extremely important in providing sufficient 
flexibility to develop eluents capable of separating the various amino acid 
derivatives.
Similar developments leading to improved elution buffers and 
detecting reagents have been important. Along with the improvements in 
the chemistry of automated ion-exchange analysis of amino acids, there 
has been considerable advancements in instrumentation. These include 
improvements in eluent delivery, monitoring devices, and computational 
aids.
In modern amino acid analysis by cation exchange chromatography 
amino acids are displaced from the column in discrete bands by varying 
buffer pH or ionic strength. The buffer systems that are used are changed 
with the sample type, protein hydrolysate or physiological fluid, and are 
determined by the counterion used (usually sodium or lithium) and by the 
method of buffer changes applied to the resin (stepwise or gradient 
elution). The buffering component commonly used is citrate which is 
suitable for solutions below pH 7 (Bates and Pinching, 1949). Citrate 
concentrations of 0 .05  to 0.067mol/l are common. Buffers are prepared 
either with citric acid or an alkali salt. Unfortunately, for high sensitivity 
work, the largest reagent contribution to amino acid contamination is citric 
acid. If consistent analyses are to be achieved it is essential that high 
purity reagents are used for buffer preparation. Finally, there is no
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theoretical limit to the lifetime of the ion exchange column, as there is with 
silica columns. Therefore, if care is taken in use of eluants and if samples 
are carefully prepared, to avoid injecting particulates onto the column, the 
columns can separate thousands of biological samples.
3 .3 .3  Separation of derivatised amino acids
The many variations of the partition, paper, and ion-exchange 
chromatographic procedures that have been used for the determination of 
free amino acids have also been em ployed in conjunction w ith  
d e riva tisa tio n  of the am ino acids. N otab le  am ong these are  
dinitrophenylation, introduced by Sanger (1945) and developed for this 
purpose by Levy (1954), and the Edman (1950) reaction as developed by 
Sjoquist (1955). Derivatisation to provide volatile products is also required 
for gas-liquid chromatographic analysis of amino acids. Although initially 
promising because of its speed and sensitivity (Zumwalt, Roach and 
Gehrke, 1970), it has not yet proved to be sufficiently reliable to replace 
ion exchange methods for routine amino acid analysis in biological fluids.
High performance liquid chromatography has undergone rapid 
development in amino acid separation (Molnar and Horvath, 1977; Kraak, 
Jonker and Huber, 1977; Hancock, Bishop and Hearn, 1979). Alternatives 
to ion exchange chromatography have appeared in the last few years to 
allow simple and straightforward occasional analysis of amino acids. These 
are pre-colum n derivatisation methods using reverse phase High 
Performance Liquid Chromatography which are rapid and sensitive. Two of 
the most widely used methods involve the formation of dansyl (Wiedmeier, 
Porterfield and Hendrich, 1982; Dejong et al., 1982) and o-phthalaldehyde 
(Lindroth and Mopper, 1979) derivatives of the amino acids prior to High 
Performance Liquid Chromatography analysis. Both methods give greater
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sensitivity and shorter analysis time when compared to post column 
derivatisation techniques. At present, the reverse phase High Performance 
Liquid Chromatography method although suitable for some applications is 
not routinely used because of some difficulty in determining certain amino 
acids. A method has recently been reported that describes quantitative 
derivatisation of amino acids with phenylisothiocyanate, followed by the 
separation and quantitation of the resulting phenylthiocarbamyl derivatives 
by reverse phase High Performance Liquid Chromatography (Heindrikson 
and Meredith , 1984). These derivatives are stable enough to eliminate any 
need for in-line derivatisation. However, the use of reverse phase high 
performance liquid chromatography for amino acid separation with need for 
derivatisation complicates the enrichment measurement by Isotope Ratio 
Mass Spectrometry (see below, Chapter 4).
3 .3 .4  Separation of amino acids using ion-exchanae with a volatile buffer: 
Development work
Introduction: Accurate isotopic enrichment measurement of amino 
acids by Isotope Ratio Mass Spectrometry (see Chapter 4.) require that the 
amino acid be pure since contaminants are most likely to alter the 
measured enrichment of 13C or 15N. In order to obtain pure amino acids 
from biological samples for isotope analysis the use of cation exchange 
chromatography in conjunction with a volatile eluant was investigated. 
Although analysis of amino acids by ion-exchange chromatography has 
been repeatedly refined since its development in the 1950's, far less work 
has been directed towards refining separation and isolation of pure amino 
acid by ion-exchange chromatography. This has been mainly because the 
only practical use for such a system has been the isolation of isotopically 
labelled amino acids from biological sources. From the literature, it would
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appear that two volatile eluants have been used, one using HCI (Hirs, 
Moore and Stein, 1954), the other based on pyridine formate (Liebster, 
Kopoldova and Dobiasova, 1961). The use of HCI as an eluant to obtain 
pure leucine and glycine was more complex than that described for 
pyridine formate, involving not only changing the concentration of the 
eluant but also the temperature during the amino acid separation. 
Furthermore, the fractions eluted from the cation exchange column contain 
brown residues from the ion exchange resin which may not be completely 
removed by a further anion exchange step (Hirs, Moore and Stein, 1954). 
The pyridine form ate eluant, in contrast, leaves no residue after 
lyophilisation and has the advantage of separating amino acids at a fixed 
temperature (37°C). Also the pyridine formate buffer system gives a stable 
pH (reducing variability in the amino acid separation) and is a less 
aggressive eluant (to the stainless steel equipment) for high performance 
liquid chromatography. Furthermore, from the report of Liebster and 
coworkers (1961) it appeared that the separation of leucine and glycine 
could be carried out using a single buffer although glycine appeared to 
coelute with alanine. The column used in the separation described by 
Liebster and coworkers (1961) was 2.0x150cm  filled with Dowex 50x4 
(200-400mesh), operated at 37°C, and loaded with 600mg of amino acids. 
This work was confirmed by Cohen and Putter (1970) who scaled up the 
amount of amino acids separated by approximately 10 fold. The column 
they used was 7.5ftx2.0in and the resin AG50x8 (400 mesh, Biorad, CA, 
U.S.A.) and operated at 37°C. However, the resolution of the amino acid 
separation became poorer (Cohen and Putter, 1970; Cohen, Horsely and 
Sternlicht, 1970).
Therefore, in order to resolve glycine and leucine from the other 
amino acids a high resolution cation exchange column (4.6 x 250mm,
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packed with a sulphonated polystyrene-divinyl-benzene copolymer, stable 
with solutions of pH 0-14, Amino Acid Analysis column A A 911, Interaction 
Chemicals Inc., California, USA.), in which the spherical particle size was 
almost uniform ( 9 . 0 _ ± 0 . 5 u m ) ,  was used. The theoretical column loading of 
amino acids is approximately 16mg (100mg/cm2 cross sectional area, 
Instruction Manual, Interaction Chemicals Inc., CA, U.S.A.). This column 
was used in conjunction with an isocratic high performance liquid 
chromatography system (see section 3 .4 .3 ). Furthermore, since resolution 
is improved by ensuring that non-amino acid components, especially 
cationic species, are removed from the biological sample, an extensive 
amino acid clean-up procedure was carried out (see section 3.4.1 and 
3 .4 .2 ).
Methods: Pyridine formate buffer was made by adding formic acid 
(BDH, U.K.) to a given molarity (0.2mol/l) of pyridine (BDH, U.K.) in 980ml 
of water until the correct pH of the solution was reached, measured by a 
calibrated pH meter (PHM62, Radiometer, Denmark). This solution was 
made up at the time of amino acid separation and used for a maximum of 
4  days from this time. The pH of the pyridine formate solution was 
checked daily and stored in a dark brown glass bottle. The protein-free 
sample is dissolved in pyridine formate, pH2.1, for application onto the 
column of cation-exchange resin. When the sample pH is 2.1 ionisation of 
the amino acid carboxyl groups is suppressed and they are retained on the 
column of cation exchange resin via their charged amino groups.
The standard solution used in the examination of the amino acid 
separation was a mixture of neutral amino acids (L-alanine, glycine, 
L-valine, L-isoleucine, L-leucine, Sigma Chemical Co. Ltd., U.K.) at the 
concentration of 20umol/ml in 0.2mol/l pyridine formate pH 2.1.
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The retention time and purity of leucine and glycine were assessed 
as follows; The retention time of the injected amino acids was measured 
by a spot test on each fraction collected by a fraction collector 
(0.4m in/160ul) of the amino acid separation. 2cm squares were ruled and 
numbered in pencil on Whatman No.1 filter paper (BDH Chemicals Ltd, 
U.K .). Aliquots (approximately 4ul) were then spotted with capillary 
micropipettes, dried and sprayed with a 0 .3%  solution of ninhydrin in 
acetone (BDH Chemicals Ltd, U.K.) and the colour was allowed to develop 
for 20min at 90°C.
The purity of leucine and glycine in the eluant fractions was 
assessed by thin layer chromatography using a butanol/acetic acid solvent 
system (Smith, 1969). 1 ul of the fraction or standard solution (see above) 
was spotted on to a thin layer chromatography plate (silica gel 60 F254 
plates, BDH Chemicals Ltd, U.K.) 1cm apart and 2cm from the bottom of 
the plate. The plate was then run for 5h using a butanol/ acetic acid/ water 
solvent system (60 /15 /25 , BDH Chemicals Ltd, U.K.) in a glass tank. The 
plate was then dried overnight and the amino acids visualised with 
ninhydrin as described above.
Using the equipement and methods described above, the conditions 
of eluant flow, molarity and temperature were considered to optimise the 
amino acid separation with particular reference to leucine and glycine.
Eluant Flow: The maximum operating pressure of the column used 
(A A 911 , Interaction Chemicals Inc., CA. U .S .A ., see 3 .4 .3 )  is 
approximately 2500 pounds per square inch (higher pressure would result 
in permanent distortion of the spherical particles). The recommended flow  
rate for the cation-exchange column was 0.5ml/min using a conventional 
citrate buffer system, which according to the manufacturers, would 
generate an eluant pump pressure of approximately 1700pounds per
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square inch. However, when 0.2mol/l pyridine formate was pumped 
through the column this pressure was reached at 0.4ml/min flow rate. 
Therefore, with regard to the safe operating pressures and since a small 
improvement in resolution accompanies reductions in flow rate (AA911, 
amino acid analysis column instruction manual, Interaction Chemicals Inc, 
CA, USA.) 0.4ml/min eluant flow rate was used.
Molaritv: Liebster and coworkers (1961) used 5 different buffers to 
carry out the separation of all the amino acids from protein hydrolysates. 
This essentially involved using different concentrations of pyridine 
(0.1-2.0mol/l) adjusted to a different pH (3.1-5.1) with either formic acid 
or acetic acid. In this work the separation of only two amino acids were of 
interest, leucine and glycine. These amino acids occur in the same region 
of the amino acid separation with the pyridine formate eluant and this 
raised the possibilty that the separation of leucine and glycine can be 
simplified. One buffer (pyridine formate pH 3.1) at different concentrations 
(0.1, 0 .15 , 0 .20 , 0.25mol/l) was used to determine whether both leucine 
and glycine could be separated with a single buffer and how long this 
would take. 50ul of the amino acid standard solution at pH2.1 was 
injected (see above) onto the high performance liquid chromatography 
column (see 3 .4 .3 ) and fractions collected (0.4min/160ul) in the region of 
the neutral amino acids.
The effect of the concentration of pyridine formate on the retention 
time and purity of the amino acids was examined (Table 3.3). There was a 
reduction of approximately 10min in retention time of the amino acids in 
the standard mixture for each 0.05mol/l increase in pyridine formate 
concentration. This resulted in the chromatogram being compressed into 
fewer fractions until at O.25mol/I pyridine formate there were no clear 
fractions between alanine/glycine and isoleucine/leucine (as assessed by
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the spot test). Furthermore, alanine/glycine and isoleucine/leucine were 
found in the same fractions. Therefore, 0.25mol/l pyridine formate was not 
used. There was complete separation of the amino acids in the standard 
mixture using 0 .1 , 0 .15  and 0.2mol/l pyridine formate at 50°C assessed by 
the procedures described above. However, using 0.2mol/l pyridine formate 
with collection of fractions every 0.5min (200ul) the whole glycine or 
leucine peak was in less than 10 fractions. Therefore, the concentration of 
pyridine formate used was 0.2mol/l.
Temperature: The effect of temperature of the amino acid separation 
on the retention time and purity of the amino acids was examined (Table 
3.3 ). There was approximately a 10%  reduction in retention time of the 
amino acids in the standard mixture, using 0.2mol/l pyridine formate, when 
the temperature of the elution was increased from 40°C to 50°C and 50°C  
to 60°C. However, the separation carried out at 60°C or above was less 
reliable due to bubble formation in high performance liquid chromatography 
system. It appeared that the bubble formation was originating at the exit of 
the column. Therefore, the operating temperature of the column was 
chosen to be 50°C.
In order to assess the amino acid separation of glycine and leucine in 
a more complex amino acid mixture L-alanine-UL-14C (UL, uniformly 
labelled, glycine-UL-14C, L-isoleucine-UL-14C and L-leucine-UL-14C were 
added to plasma samples and treated as described in section 3.4.1 and 
3 .4 .3 . The separation of the labelled amino acids was carried out on a 
different days with freshly prepared 0.2mol/l pyridine formate at 50°C and 
the eluted fractions were counted (Table 3.4). The fractions were collected 
at 2.5min intervals to check the retention time of the amino acids, 
subsequently fractions were collected at 0.5min intervals over this period 
(20-55min). These results confirm the separation of glycine and leucine
70
from alanine and isoleucine respectively and that the separation was 
consistent with different batches of buffer. Finally, using 0.2mol/l pyridine 
formate and a flow rate of 0.4ml/min, the separation of all the amino acids 
(acidic and neutral) was defined in a tissue hydrolysate. A liver biopsy 
sample was treated as described in sections 3 .4 .2  and 3 .4 .3  and the 
eluted fractions underwent amino acid analysis (Rank Hilger Chromaspek M 
aminoacid analyser). This demonstrated that the amino acid pairs of 
glycine/alanine and leucine/isoleucine were resolved from one another 
(Figure 3.3).
Detection Direct spectrophotometric detection of free amino acids, 
after cation exchange chromatography using conventional citrate buffers is 
not generally useful since many other organic molecules absorb at similar 
wavelengths (e.g. 190nm). However, pyridine formate has a large U.V. 
absorption and this raised the possibility that underivatised amino acids 
such as valine, glycine, alanine, leucine and isoleucine may be visualised 
as negative peaks. In order to confirm whether this was the case the 
optimum wavelength for the continuous monitoring of the amino acid 
separation was determined to be 278nm by scanning (190-800nm ) 
0.2mol/l pyridine formate (DU 7 spectrophotometer, Beckman Instruments, 
High Wycombe, UK.) before and after the addition of 1umol leucine and 
glycine (Sigma Chemical Co. Ltd, U.K.). Therefore, an ultraviolet detector 
(deuterium arc lamp, diffraction grating monochromator bandwith of 8nm, 
tw o vacuum photocells and 8ul flow cell, Pye Unicam, PU 4020U V  
detector, Cambridge, UK.) at 278nm, connected to a chart recorder 
(Servoscribe 1S, Smiths Industries Ltd, U.K.) was used to monitor the 
amino acid separation. On elution of each of these amino acids from the 
column there was indeed a negative peak due to the displacement of the 
U.V. absorbing pyridine (Dolan, 1988). This was confirmed by using 14C
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labelled leucine and glycine (see Table 3.4). Therefore, this method of 
detection, although not developed into a quantitative technique, does give 
a recognisable elution pattern and enables the separation of leucine and 
glycine to be monitored. A typical trace from the detector, at different 
sensitivities, is shown in Figure 3.4 . The trace is the same whether the 
injected amino acids are from plasma, intracellular fluid or tissue 
hydro lysate.
3 .3 .5  Summary
It is more than 30 years since the separation of amino acids by ion 
exchange chromatography was first reported. Although gas-liquid 
c h ro m a to g ra p h y  and reverse  phase high p e rfo rm a n ce  liquid  
chromatography have attempted to rival this system, it still remains the 
most popular and probably the most reliable method of separating amino 
acids. With the introduction of polymeric ion-exchange columns being used 
in a High Performance Liquid Chromatography system the separation of all 
the common amino acids can be carried out in under 1h (Benson and Woo,
1984). This approach has been used in this thesis for several reasons. 
Firstly, it enables fast, reproducible separation of amino acids. Secondly, 
the amino acids do not have to be derivatised except for post-column 
detection, which avoids dilution of the tracer label. Thirdly, the 
ion-exchange separation of amino acids can be carried out with volatile 
buffers enabling the chemical contribution of the solvent to the amino acid 
fraction to be kept to a minimum.
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3 .4  Sample preparation for isotope analysis
All reagents used were analytical grade and water was doubly 
distilled, deionised (18Mohm). In the recovery experiments carried out with 
radioactive tracers, [14C]leucine and [14C]glycine (Sigma Chemical Co. Ltd, 
Poole, UK.) specific activity measurements were made using a Sample 
Channels-Ratio method (scintillant, Optifluor; scintillation counter, Tri-Carb; 
Packard Instrument Co. Ltd., Illinois, USA.) Each vial was counted until
1 0 ,000  radioactivity counts had accumulated. The Channels-Ratio method 
was used since it has the advantage of giving simultaneously both the 
sample count rate and the channels-ratio. The sample is counted once and 
no additional manipulation is required. The disadvantage of the method is 
that large errors are incurred in samples which are highly quenched or have 
low count rates (Rogers and Moran, 1966). However, the samples that 
were analysed in this work were usually of a high count rate (> 1 0 0 0  
DPM) with similar composition and were not highly quenched.
3.4.1 Plasma Sample Preparation (Figure 3.1)
5ml of plasma was deproteinised by centrifugation at 1000G for 
35m in through an u ltrafiltration  cone, m olecular w eight cu to ff 
<25000daltons (Amicon Ltd, UK.). The retained material was then washed 
with 5ml water. This was repeated with 5ml 0.15mol/l potassium chloride 
(KCI). The deproteinised plasma was then acidified with 1.5ml 0.1mol/l 
hydrochloric acid (HCI) prior to purification using 4ml cation exchange resin 
(H +  form AG50W -X8, 200-400 mesh Biorad laboratories, UK.). This step, 
carried out also in the tissue sample preparation, introduces a further 
molecular weight separation since all compounds of a molecular weight 
greater than 1000daltons are excluded from binding on to the resin and 
washed off. The purified amino acids were eluted with 5 bed volumes
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7mol/l ammonium hydroxide (NH4OH) collected in a pear shaped flask and 
freeze-dried. The freeze-dried mixed free amino acids produced from the 
above sample preparation is simple and close as possible to a standard 
amino mixture to facilitate separation.
3 .4 .2  Tissue Sample Preparation (Figure 3.2)
The methods used in the preparation of tissue samples were directed 
at obtaining both the intracellular free glycine and free leucine enrichment 
and also that of incorporated amino acids in the same sample without 
significantly altering the composition of the sample (i.e. without degrading 
the sample, adding cations or altering pH). The whole procedure from 
weighing tissue to the preparation of soluble and non-soluble material was 
carried out at 4°C in a cold room, in order to minimise tissue breakdown 
(e.g. due to enzymic hydrolysis) prior to protein separation. The liver tissue 
was weighed and then homogenised with 4ml water at 4°C . Muscle tissue 
was ground with dry ice by mortar and pestle prior to homogenisation. 
Water homogenates have been used successfully for systems in which 
enzymic activity has been measured provided that the tissues are not left 
at room temperature for more than 15min (Potter, 1955). Following 
centrifugation a sample of the homogenate supernatant (representative of 
the intracellular fluid, 2x100ul) was taken for amino acid analysis (see 
section 3 .5 .3 ) and frozen at 30°C until analysis. This treatment allowed 
the protein precipitant best suited for the amino acid analysis system to be 
used (sulphosalicylic acid, Graser et al., 1985, see section 3 .5 .3 ). 1ml of 
1mol/l HCI was added and the liver and muscle re-homogenised. The 
separation of soluble and non-soluble material was carried out using HCI 
since it is a volatile acid and is compatible with the other sample 
preparation steps. This was then centrifuged at 1000G for 35min to yield
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soluble and non-soluble material. The soluble material, containing tissue 
free amino acids, was ultrafiltered and the free amino acids purified further 
by cation exchange and freeze-dried. The non-soluble material, containing 
tissue protein (intracellular and extracellular protein), from which the 
incorporated glycine and other amino acids were extracted was washed 5 
times with 10ml 0.5mol/l HCI to remove any trace of free amino acids. 
Preliminary [15N]glycine enrichment measurements on the hydrolysed 
non-soluble protein from "normal" muscle samples gave enrichment values 
significantly higher (thus apparently high protein fractional synthetic rates) 
than would be expected from previous work. The origin of this increased 
[15N]glycine enrichment in the muscle hydrolysate was considered to come 
from tw o sources. Firstly, the trapping of free [15N]glycine in the 
non-soluble fraction and secondly contamination of the non-soluble fraction 
by an enriched protein/proteins. With reference to the first possibility the 
complete removal of labelled free glycine following this procedure was 
verified by mixing the non-soluble material with unenriched glycine 
followed by isotope analysis. Considering the second possibility, the 
protein component of the non-soluble material (solids) is composed of 
protein from intracellular solids and connective tissue solids. Furthermore, 
there will also be a protein contribution from the blood in the tissue 
(principally albumin) which, although thought to be less than 5%  in normal 
muscle tissue (Rothschild et al., 1955), is potentially a source of protein 
which is at a higher [15N]glycine enrichment than the muscle protein. 
However, the muscle biopsies in the present studies, although blotted, to 
remove excess blood, were not dissected free from blood and connective 
tissue as has been carried out by other workers (Rothschild et al., 1955; 
Garlick et al., 1989; Forsberg et al., 1991) and therefore the contribution 
of blood protein may have been greater than that estimated above. In order
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to reduce the albumin contribution from blood, the muscle tissue was 
extracted by an acid/alcohol wash (Korner and Debro, 1956). This 
treatm ent reduced the [15N]glycine enrichment in the hydrolysed 
non-soluble muscle fraction. It was confirmed by electrophoresis and 
immunofixation that albumin but not fibrinogen was extracted from the 
non-soluble muscle fraction and by electrophoresis that little other protein 
was extracted (see section 3 .5 .3; Figure 3.6). The remaining non-soluble 
protein was freeze-dried and 5mg was hydrolysed in 5ml 6mol/l HCI at 
145°C  under vacuum for 4h (Roach and Gehrke, 1970). The HCI was 
removed by vacuum distillation. This was followed by an ion exchange 
purification step and the sample freeze-dried (see section 3 .4 .1 ).
3 .4 .3  Amino Acid Separation
The resultant freeze dried material from plasma, intracellular and 
hydrolysate sample preparation was dissolved in 75ul 0.2mol/l pyridine 
formate pH 2.1. Using an isocratic high performance liquid chromatography 
system (Gilson Medical Electronics, Villiers le Bel, France), a 50ul aliquot of 
this solution was injected via a loop injector (7125, Rheodyne, CA, USA.) 
onto a 4 .6  x 250mm cation exchange column (Amino Acid Analysis 
column AA911, Interaction Chemicals Inc., California, USA.). The amount 
of amino acids injected onto the column was well below the theoretical 
column loading of approximately 16mg (100mg/cm2 cross sectional area, 
Instruction Manual, Interaction Chemicals Inc., CA, U.S.A.). The cation 
exchange column was maintained at 50°C with a column heater (Jones 
Chromatography, U.K.). The amino acids were eluted with 0.2m ol/l 
pyridine formate pH 3 .1 . The flow rate was 0.4ml/min and the fractions 
were collected by time (0.5min/200ul) using an automatic fraction collector 
(7000 Ultrorac fraction collector, LKB Bromma, Sweden). This buffer
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system gave optimum separation of the neutral amino acids although only 
glycine and leucine fractions were collected (see section 3 .3 .4 ). This 
approach yields pure amino acids when eluted fractions are freeze-dried 
and on combustion there is no detectable nitrogen residue from the 
pyridine formate buffer (see sections 4 .2 .2 , 4 .2 .3 ). In addition, retention 
times, recovery and peak shape of glycine and leucine were checked using 
14C labelled glycine and leucine. Sample recovery was approximately 70%  
for the whole procedure from sample preparation to amino acid separation 
(Table 3 .1), with approximately 50%  of the original sample being used for 
isotope analysis. This procedure was not associated with significant 
fractionation of the isotope label (see section 4 .2 .5 ). Following the 
separation of the neutral amino acids, the remaining basic amino acids and 
ammonium were washed from the column with 0.2mol/l NaOH for 10min. 
Following the NaOH wash the column was re-equilibrated with 0.2mol/l 
pyridine formate. On the resumption of a steady baseline trace on the chart 
recorder (usually 50-60min after the NaOH wash) the next sample was 
injected. The time taken to separate glycine and leucine from the other 
amino acids was 32 and 52min respectively. The glycine and leucine peaks 
were collected in 10 x 200ul fractions (Figure 4 .5 , 4 .4 ). These fractions 
were pipetted into pre-frozen aluminium combustion containers (12x5mm, 
Elemental Microanalysis, Okehampton, UK.) held in a drilled aluminium 
block at approximately -70 °C with solid C 0 2 and freeze-dried for isotope 
analysis.
3 .4 .4  Urine sample preparation
Urinary ammonium was extracted using a sodium/potassium form 
cation exchange resin (AG50W -X8, 200-400 mesh Biorad laboratories, 
UK.) after Read, Harrison and Halliday (1982). 10ml of the urine sample
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was added to 4ml of resin suspension (about 1g dry resin) in a universal 
container (Bibbey Sterlin Ltd, Staffordshire, UK.) and placed on a roller 
mixer (Luckham Ltd, Sussex, U.K.), at room temperature, for a minimum of 
15min. The resin was then allowed to settle and the fluid above the resin 
was poured off. The resin, held in a universal bottle, was then washed 
with 10 ml water and the water discarded. In a modification of the method 
of Read, Harrison and Halliday (1982), 2ml 2.5mol/l potassium hydrogen 
sulphate was added to the resin and mixed as above to elute the bound 
ammonium. The resin was then allowed to settle and 50-1 OOul subsamples 
of the solution above the resin (25-1 OOug atom NH4-N) were pipetted into 
pre-frozen combustion containers and freeze-dried for analysis.
After the removal of urinary ammonium using the batch cation 
exchange method described above, urea from an aliquot of the 
ammonium-free urine was converted to ammonium by hydrolysis with 
urease, and extracted using a second batch of the same cation exchange 
resin. Urea derived ammonium was then brought into solution from the 
washed resin by treatment with potassium hydrogen sulphate and 50ul 
aliquots (25 -100u g  atom NH4-N) were freeze-dried into aluminium  
combustion containers (Preston and McMillan, 1988). Separation of urinary 
ammonium with this batch resin technique is quantitative and does not 
appear to fractionate 15N in comparison with either aeration (Read, 
Harrison and Halliday, 1982) or microdiffusion (Preston and McMillan, 
1990).
3 .4 .5  Breath C 02 sample preparation
Breath was sampled directly from a ventilated hood calorimeter 
(Kinney et al., 1964) using a 20ml disposable syringe fitted with a luer 
stopcock. It was verified that samples collected in this way can be stored
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for up to 2 weeks, but were analysed within 24h. Three replicate samples 
for C 0 2 isotopic analysis were taken at each collection point (Figure 5.1). 
The sample preparation for isotopic analysis of breath C 0 2 by Continuous 
Flow-lsotope Ratio Mass Spectrometry (Preston and McMillan, 1988) is 
simpler and less expensive than the conventional approach which relies on 
cryogenic purification (Schoeller and Klein, 1978). The on-line purification 
of breath C 0 2 is described in section 4.2 .
3 .5  Biochemical Analyses
Most of the analyses were carried out using in-house assays in 
Glasgow Royal Infirmary. The precision and accuracy of these assays were 
monitored by internal and external quality control schemes. Where 
precision values are given (coefficient of variation) the between batch 
variation represents the poorest precision with which the assay is carried 
out. The precision values obtained for these assays are comparable to that 
obtained by other laboratories participating in quality control schemes.
3.5.1 Urine analyses
Total urinary n itrogen: This was measured by a standard  
microkjeldahl method (Fleck and Munro, 1965).
Creatinine: Urinary creatinine was analysed on a Hitachi 704  discrete 
analyser based on the standard end-point Jaffe reaction.
Hvdroxvproline: This assay was carried out using a standard method 
(Hodgkinson and Thompson, 1982) and the between batch variation was 
approximately 10%.
3-methvlhistidine: concentrations were analysed on a Chromaspek M 
amino acid analyser and is based on a cation exchange resin, two buffer 
gradient elution, ninhydrin detection.
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3 .5 .2  Blood analyses
Albumin: Plasma albumin was analysed by immunoturbidometric 
methods on an EncoreR centrifugal analyser (Baker Instruments). Antisera 
for the albumin was obtained from the Scottish Antibody Production Unit 
(Carluke, Scotland). The between batch coefficients of variation across the 
working range of the assay was < 8 % .
F i b r i n o g e n : Plasma f i b r i n o g e n  ( E D T A )  w a s  e s t i m a t e d
nephelometrically by measuring the light scattering intensity in diluted 
plasma by heat aggregation, with strict control of pH and temperature 
(Desvignes and Bonnet, 1981). The between batch coefficient of variation 
was < 5 %  across the working range of the assay.
Fibrin dearadative products: Crosslinked fibrin degradative products 
in plasma, containing the D-dimer, were measured by an enzyme 
immunoassay (DIMERTEST STRIPWELL EIA, AGEN Inc., New Jersey, 
USA.). The method is based on a monoclonal antibody which binds 
specifically to the D-dimer and fragments containing the D-dimer epitope 
that result from fibrinolysis. The within batch coefficients of variation 
across the working range of the assay was < 5 % .
C-reactive protein: This was measured by Fluorescence Polarisation 
Immunoassay using an Abbott TD XR analyser and Abbott reagents. The 
between batch coefficient of variation was < 5 %  across the working range 
of the assay.
Interleukin-6: lnterleukin-6 was determined by bioassay using 7TD1 
cells (Coulie et al., 1987). The assay is based on the proliferation of a 
lymphoid cell line that has a specific dependance on the cytokine for 
growth. The limit of detection for interleukin-6 was approximately 10pg/ml.
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Cortisol: Cortisol was measured by an in-house radioimmunoassay 
(Glasgow Royal Infirmary) using antisera obtained from the Scottish 
Antibody Production Unit (Carluke, Scotland). Separation of the assay was 
performed using a solid phase technique. The detection limit of the assay 
was 40nmol/l and the between batch coefficient of variation was < 1 0 %  
across the working range of the assay.
Insulin: Insulin concentrations were analysed by a radioimmunoassay 
using sepharose covalently linked to a second antibody as the separation 
system. The between batch coefficent of variation was 10.5%  at a 
concentration of 30mU/l.
Glucose: Glucose was analysed by an enzymatic colorimetric method 
using glucose oxidase (Hitachi 737 Autoanalyser).
Amino acids: The concentrations of free amino acids in the plasma 
were determined by high performance liquid chromatography using 
o-phthaldialdehyde/3 mercaptopropionic acid as the derivatisation agent 
and employing a 3um particle size reversed-phase column (Graser et al.,
1985).
3 .5 .3  Tissue analyses
R.N .A .: R.N.A. was analysed by U.V. absorption, at 260nm, of the 
supernatant following acid extraction from tissue (dry weight 20mg) with 
correction for the peptide content of the perchloric acid extract (Fleck and 
Begg, 1965). The procedure was as follows; 20mg freeze dried tissue (liver 
or muscle) was weighed out into a glass tube. 1ml of ice-cold 0.2mol/l 
perchloric acid was then added and mixed. On standing for 10min, the 
sample was then centrifuged and the supernatant removed. The sample 
was then washed twice with 1ml 0.2mol/l perchloric acid. The excess acid 
was drained by inverting the tube over filter paper. The precipitated
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material was then incubated for 1h in 0.8ml 0.3mol/l KOH at 37°C  and 
2x20ul samples were removed for protein determination (see protein 
below). The tube was then cooled in ice and 0.6ml 1mol/l perchloric acid 
added and stood in ice for 10min. The sample was then centrifuged, 
supernatant collected and the precipitate was washed twice more with 1 ml 
0.2m ol/l perchloric acid. The supernatant and washings were mixed 
together and 6.6ml water added to give a final concentration of 0 .1M  
perchloric acid. The absorbances of the reagent blank (0.8ml 0.3mol/l 
KOH + 0.6m l 1mol/l perchloric acid +  2ml 0.2mol/l perchloric acid+ 6.6ml 
water) and samples were measured at 260nm and 232nm.
The main source of error in estimating RNA by this method is the 
presence of U.V.-absorbing peptides in the RNA extract (Munro and Fleck, 
1969). It has been demonstrated that in muscle samples there is a greater 
amount of U.V. absorbing peptides in the RNA fraction compared with liver 
samples. In liver samples the peptide content of the RNA extract, on 
average, accounts for 2%  of the total U.V. absorption at 260nm, whereas 
in muscle samples it accounts for 10%  (Munro and Gray, 1969). This is 
mainly due to the fact that the amount of RNA present in the muscle 
samples is small and in consequence absorption due to peptide content 
becomes significant (Munro and Fleck, 1969). Therefore, in order to detect 
and correct for the presence of peptides in liver and muscle RNA extracts 
(Figure 3.4) absorption measurements were taken at 232nm as well as 
260nm (DU7 spectrophotometer, Beckman Instruments, High Wycombe, 
UK.) and the following equations were applied (Fleck and Begg, 1965).
For liver, CRNA = 3 .4 0 E260-1 .4 4 E232 
For muscle, CRNA = 3 .7 9 E260-1 .5 0 E232
Where CRNA is the concentration in ugRNA phosphorus per ml, E is 
the absorbance measured at the defined wavelength. It should be noted
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that the equation for muscle was derived from work on calf thyroid (Fleck 
and Begg, 1965), however, the contribution of peptide material to the 
absorption of RNA at 260nm was similar (11%) to that reported for muscle 
(10% , Munro and Gray, 1969). Therefore, although this approach has not 
been validated specifically for muscle RNA extracts it has been used to 
measure the muscle RNA content in man (Rennie et al., 1982a; Emery et 
al., 1984a; Gibson et al., 1987; Forsberg et al., 1991).
Repeated analysis (n = 5) of a normal human liver biopsy established 
the within batch variation of the assay to be 8% .
Protein: The protein concentration in the alkali-soluble material from 
the RNA method (see above) was measured by the method of Lowry and 
coworkers (1951). The procedure was as follows; the protein sample was 
diluted 1/20 with water. Biuret reagent was made from 100ml 2% N aC 03 
in 0.1mol/l NaOH (w/v), 1ml 2%  NaK tartrate (w/v), 1ml 1% CuS04 (w/v, 
BDH, U.K.). A working standard curve in the range 0-50ug was prepared 
by taking volumes (0-50ul) of a stock solution (1 mg/ml human albumin, 
Fraction V, A 8763, Sigma Chemical Co., U.K.) and adjusting the final 
volume to 400ul with water. To 400ul standard/sample 2ml Biuret reagent 
was added, vortexed and allowed to stand for 10min. 200ul of working 
Folin-Ciocalteau reagent (water 1:1 Folin-Ciocalteau reagent, BDH, U.K.) 
was added with immediate mixing. The solution was allowed to stand for 
3 0 m in  and th e  absorbance  w as m easured at 7 5 0 n m  (D U 7  
spectrophotometer, Beckman Instruments, High Wycombe, UK.) and the 
concentrations were read from the std curve).
Tissue free amino acids: The concentrations of free amino acids in 
liver and muscle tissue were determined by high performance liquid 
chromatography using o-phthaldialdehyde/3 mercaptopropionic acid as the
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derivatisation agent and employing a 3um particle size reversed-phase 
column (Graser et al., 1985).
Protein electrophoresis: Proteins were electrophoresed on an 
agarose film (Ciba Corning Diagnostics, CA, USA.) using universal barbital 
buffer, (Ciba Corning Diagnostics, CA, USA.) immunofixed and stained 
w ith  Amido Black 10B (Ciba Corning D iagnostics, CA, U S A .). 
Electrophoresis is based on the principle that a charged ion or group will 
migrate towards one of the electrodes when placed in an electric field 
(Smith, 1968). This technique has been used extensively to separate 
proteins. Immunofixation allows specific identification of protein in the 
same position as stained in the electrophoresed material and involves using 
an immunological overlay to fix the specific protein. A serum quality 
control sample (Seronorm , Nycom ed, UK.) was run w ith  every  
electrophoresis film. 1 ul of the acid/alcohol extract (see section 3 .4 .2) 
concentrated to 150ul or control sample (plasma sample diluted 1:10) was 
applied to the sample wells of the agarose film. The film was then inserted 
into a cassette and placed in an electrophoresis chamber (Ciba Corning 
Diagnostics, CA, USA.), each cell of which contained 95ml of barbitone 
buffer. The film was run for 27min and removed from the cassette. Strips 
of cellulose acetate were placed over the area of the film containing 
samples to be immunofixed. To these samples 25ul of antiserum (to 
albumin or fibrinogen, Scottish Antibody Production Unit) was applied to 
the strips. The film was incubated in a moist chamber for 2-4h at room 
temperature and then placed in 11 normal saline overnight to remove 
non-precipitated proteins. Films with immunofixed material and the 
conventional electrophoresed material were then stained with Amido Black 
10B working solution for 10min. The films were then dried, cleared in two
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changes of 5%  acetic acid, dried and scanned in a densitometer (Model 
620  Video Densitometer, Biorad laboratories Inc, U.K.).
3 .6  Resting energy expenditure measurement
3.6.1 Introduction
The measurement of energy expenditure is referred to as calorimetry 
in which energy expended is measured as heat output. Energy can neither 
be created nor destroyed and therefore the energy content of any system 
can be increased or decreased only by the amount of energy that is added 
to or lost from the system. Measurements of heat associated with the 
metabolism of man and animals, have long been of scientific interest. Both 
measurements of heat loss (direct calorimetry) and estimates of heat 
production by measuring gas exchange (indirect calorimetry) were first 
made approximately two centuries ago (Kinney, 1988).
3 .6 .2  Direct calorimetry
Man and animals are constantly producing heat from the chemical 
reactions in the body necessary to maintain normal metabolism. As this 
energy is not stored in the body, where it would increase body 
temperature to unacceptable levels, it must be lost to the environment. 
Direct calorimetry, the measurement of this heat loss, can be carried out in 
various ways, the accuracy of which depends only on the physical 
techniques used. No assumptions about the means of production need be 
made and the subject can be treated as a 'black box' producing heat. 
Since all direct calorimeters have to totally enclose the subject to measure 
heat loss, they are generally unsuitable for subjects who need frequent 
attention (e.g. patients, children etc.).
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3 .6 .3  Indirect calorimetry
Production of heat from food or tissue fuels in the body consumes 
oxygen and produces carbon dioxide and other excretory products. 
Measurement of gas exchange and urinary nitrogen excretion provides an 
accurate method of indirect calorimetry when metabolic processes are in 
approximate equilibrium and gives the same values as measured by direct 
calorimetry (Kinney, 1988). This technique has been used, over the last 10 
years, to measure energy expenditure in hospitalised patients in the 
Department of Surgery, Glasgow Royal Infirmary (Goll, 1981; Hansell,
1986). This indirect calorimetry system was used to estimate energy 
expenditure in the patients studied in this work.
3 .6 .4  Resting energy expenditure
Energy expenditure varies according to the activity of the subject; 
being about 20%  above resting levels when a human subject is sitting and 
50%  when standing (Durnin and Passmore, 1967). Therefore, control and 
consistency in physical conditions of calorimetric measurement are 
essential. The term 'basal metabolic rate' has been used by many authors 
(Dubois, 1927; Keys et al., 1950) to describe energy expenditure 
measurement on a quiet, resting, post-absorptive subject. Even if the 
conditions are more strictly standardised to include a thermoneutral 
environmental temperature, complete mental and bodily rest and a 
measurement period just after waking, the metabolic rate is unlikely to be a 
basal value proposed by Mitchell (1962). Body temperature, previous 
nutrition and sleep patterns are at least three of the variables that can 
effect it (Buskirk et al., 1960).
Energy expenditure measured with the subject lying down at rest 
and having no recent large meals has been termed resting energy
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expenditure. Measurements made in this manner are usually close to the 
basal values described above (Durnin and Passmore, 1967), while allowing 
a wider experimental scope. The respiratory quotient (RQ) in such 
circumstances is not necessarily well defined. However, control of the 
nutritional input, particularly if it is small or constant, can allow useful 
comparisons. To decrease the variability of resting energy expenditure 
values environmental conditions should be as constant as possible. 
Psychological stress has been shown to have a large effect in man 
(Arturson, 1977). This can be difficult to detect and impossible to quantify 
but can be mostly eliminated by use of a comfortable and relatively 
isolated environment. Training of the human subject in the use of the 
calorimetry apparatus is also important (Robertson and Reid, 1952) 
particularly where a mask or mouthpiece is utilised (Kinney et al., 1964). 
Ingestion of significant quantities of food increases metabolic rate (Kleiber, 
1961 ). The rise in metabolic rate following a meal starts almost 
immediately (Passmore and Ritchie, 1957) with the peak resting energy 
expenditure usually within two hours (Rochelle and Horvath, 1969). 
Sustained increases in oxygen consumption of up to 20%  often occur 
(Tuttle et al., 1953) so that control over dietary intake is necessary if small 
changes in resting energy expenditure are to be measured.
3 .6 .5  Indirect calorimetry technique
W ith the advent, in the 1 9 5 0 's , of continuous gas flow  
measurement of oxygen and carbon dioxide concentrations continuous 
indirect calorimetry has been possible. Using a suitable mouthpiece or 
mask and one way valve, expired air can be analysed, breath by breath or 
after mixing (Wilmore, Davis and Norton, 1976). This technique has the 
advantage of relatively high (approxim ately 5% ) changes in gas
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concentrations produced by the subject allowing accurate analysis with the 
possibility of measuring other respiratory parameters. However, rapid 
sampling or effective mixing of the gas flow is required and the relatively 
low (approximately 51/min) pulsatile flow can be difficult to measure 
accurately. Furthermore the valving provides some resistance to air flow  
and patients can also find mouthpieces and facemasks unacceptable 
(Spencer et al., 1972).
The use of an open or closed canopy system (ventilated hood 
system) instead of a mouthpiece or mask requires a relatively high air flow  
(25-50l/min) to be drawn through the canopy to keep the carbon dioxide 
concentration around the patient to within acceptable physiological limits 
(i.e. less than 1%). The diluting effect of the increased air flow requires 
high accuracy of the gas analysers. However, the subject in the canopy 
notices no effect on his breathing and the constant air flow through the 
system can be measured with a simple gas meter. The indirect calorimeter 
used in the present studies was of a closed canopy type based on the 
design of Kinney and coworkers (1964). A detailed description of the 
indirect calorimeter and its validation for use in patient studies is given by 
Goll (1981). A schematic representation of the gas circuitry is shown in 
Figure 3.5.
A sensitive param agnetic oxygen analyser (Servom ex Ltd, 
Crowborough, Sussex, UK) and an infra-red carbon dioxide analyser 
(Sieger Ltd, Poole, Dorset, UK) were used to monitor oxygen and carbon 
dioxide gases respectively. The equipment was calibrated frequently using 
oxygen-free nitrogen, 0 .80%  carbon dioxide and air at a known barometric 
pressure. All the measurements were made under computer control. The 
readings were corrected for atmospheric pressure and in the case of the air 
used as a span gas for the oxygen analyser for its moisture content. The
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computer calculated correction factors, close to unity, to account for the 
long term gain drift in the analysers. Gain and zero drifts of the instruments 
w ere not corrected using the various mechanical and electronic 
adjustments available, but the correction factor was applied by the 
computer during the calculation of results. This approach improved long 
term stability of the analysers as it resulted in less interference and 
interdependent effects which make accurate setting difficult (e.g. a change 
in gain on adjustment of the zero point were avoided).
The sensitivity and accuracy of the calorimeter was checked 
periodically by burning a known weight of fuel, in the canopy, to simulate 
a subject (Caldwell et al., 1966; Kinney et al., 1968). Butane was selected 
as an appropriate fuel with a 'respiratory quotient' of 0 .615 . Commercial 
butane gas (Camping Gaz Ltd.) in a cartridge was burnt in a small luminaire 
designed for auxiliary lighting purposes (Lumogaz, Camping Gaz Ltd.). The 
apparatus was self-contained and could fit inside the head canopy. From 
analysis of the gas composition and the amount of oxygen consumed and 
carbon dioxide produced per unit weight of gas the consumption of oxygen 
and production of carbon dioxide was calculated. The oxygen consumption 
was 97 .2%  and carbon dioxide production was 97 .4%  of the calculated 
value.
Resting energy expenditure was measured using the open circuit 
ventilated hood system, described above, in a temperature controlled 
room. The subject's head was enclosed in the perspex canopy and the 
system made air tight by a flexible adhesive neck seal. The canopy was 
ventilated with air at a rate of 35-40l/m in. Total flow was measured by a 
wet gas meter (A. Wright Ltd., Tooting, London, U.K.). The gas mixing 
time constant of the head canopy and connecting piping was measured to 
be 36s, giving approximately a 95%  response to a gas concentration
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change in 1min. The whole system provides measurements of oxygen 
consumption (V 0 2) and carbon dioxide production (V C 02) for which the 
repeatability is better than _+5% (95%  confidence intervals). Estimates of 
V 0 2 and V C 0 2 were collected every 30 seconds during each patient 
study, which lasted for 40min. Recording of data did not commence until a 
steady trace of oxygen consumption and carbon dioxide production was 
obtained, usually after 5-10 min. The 80 estimates of V 0 2 and V C 02 
collected were processed on line by a programmed microcomputer (Goll, 
1981) and converted to mean energy production (watts) using the 
abbreviated formula of Weir (1949).
REE (kcal/day) = (3 .9 V 0 2 + 1.1 V C 0 2)1440  
Where kcal/day = wattsx20.65
V 0 2 = oxygen consumption (l/min)
V C 0 2 = carbon dioxide production (l/min)
Since resting energy expenditure is known to vary with the size of 
the individual (M itchell, 1962) it is necessary to express energy 
expenditure in relation to total body weight or a defined compartment of 
the body to allow comparison of results from subjects of different height 
and weight. Durnin (1959) suggested that use of weight alone was a good
enough reference standard. However, this neglects differences in build and
it has been reported that there is a better association between lean body 
mass and resting energy expenditure (Halliday et al., 1979). However, lean 
body mass was not measured in this work and therefore, resting energy 
expenditure was expressed per unit weight.
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Table 3.1 
Recoverv of olasma ri4Clalvcine after samole oreoaration
Drocedures
Ultra­ Cation- HPLC Overall
filter exchange recovery
(% recovery of procedure) (%)
Sample 1 88.1 85.4 80.9 60.9
2 90.4 88.9 91.2 73.3
3 94.1 94.6 91.2 81.2
4 89.3 88.7 89.5 70.9
5 86.0 89.1 95.4 73.1
Mean 89.6 89.3 89.6 71.9
S.D. 3.0 3.3 5.3 7.3
Ultra-filter, ultrafiltration; HPLC, high performance 
liquid chromatography of amino acids
The overall recovery for the sample preparation was 
approximately 70%.
Table 3.2
Recovery of plasma free amino acids after ultrafiltration
Plasma
(umol/1)
Ultrafiltered
plasma
(umol/1)
% RECOVERY
ASP 31 29 95
GLU 303 300 99
ASN 31 28 98
SER 161 145 90
GLN 173 149 86
GLY 230 209 91
THR 113 96 85
HIS 111 92 83
CIT 37 36 99
3-MH 5 4 80
ALA 284 239 84
ABU 22 18 80
TYR 49 37 76
VAL 203 179 88
MET 21 19 91
TRP 33 30 91
PHE 64 56 87
ILE 77 62 81
LEU 129 103 80
ORN 58 34 58
LYS 111 60 54
TOTAL AA 2349 1932 83
Table 3.3
The effect of temperature and pyridine formate concentration on amino acid separation
F.R. P.F. TEMP. -Retention time (min)- Comments
SAMPLE <mi/min) (MOL/L) (oC) GLU ALA GLY VAL ILE LEU
AAMIX 0.4 0.1 40 51.2 62 72.8 82.8 114.4 125
AAMIX 0.4 0.1 40 46.8 56.4 66.4 75.4 104 114
AAMIX 0.4 0.1 40 52.4 63.2 74.4 84.4 116.8 127.6
AAMIX 0.4 0.1 40 50.8 61.2 72 81.6 112.8 123.6
AAMIX 0.4 0.1 50 43.6 52.8 62 70.4 97.2 106.4
AAMIX 0.4 0.1 50 42 51.2 60 68 94 102.8
AAMIX 0.4 0.1 50 42 51.2 60 68 94 102.8
AAMIX 0.4 0.1 50 44.8 54.4 64 72.4 100.4 109.6
AAMIX 0.4 0.1 50 42.4 51.6 60.8 68.8 95.2 104.4
AAMIX 0.4 0.15 50 30.4 36.8 43.2 49.2 68 74.4
AAMIX 0.4 0.15 50 30 36.4 42.8 48.8 67.2 73.6
AAMIX 0.4 0.15 50 30 36.4 42.8 48.8 67.2 73.6
AAMIX 0.4 0.15 50 30 36.8 45.6 52 71.6 78.4
AAMIX 0.4 0.15 50 32 38.8 45.6 52 71.6 78.4
AAMIX 0.4 0.2 40 24.8 30 35.2 40 55.2 60.4
AAMIX 0.4 0.2 40 24.8 30 35.2 40 55.2 60.4
AAMIX 0.4 0.2 40 24.8 30 35.6 40 55.6 60.8
AAMIX 0.4 0.2 40 24.8 30 35.6 40 55.6 60.8
AAMIX 0.4 0.2 40 24.8 30 35.6 40 55.6 60.8
AAMIX 0.4 0.2 40 25.6 31.2 36.4 41.2 57.2 62.4
AAMIX 0.4 0.2 40 25.6 31.2 36.4 41.2 57.2 62.4
AAMIX 0.4 0.2 40 25.2 30.4 35.6 40.4 55.6 61.2
AAMIX 0.4 0.2 40 25.2 30.4 36 40.8 56.4 61.6
AAMIX 0.4 0.2 40 24.8 30 35.2 40 55.2 60.4
AAMIX 0.4 0.2 40 25.2 30 35.6 40.4 55.6 61.2
AAMIX 0.4 0.2 50 20.8 25.2 29.6 33.6 46.4 50.8
AAMIX 0.4 0.2 50 20.4 24.8 29.2 33.2 45.6 50
AAMIX 0.4 0.2 50 20.8 25.2 29.6 33.6 46.4 50.8
AAMIX 0.4 0.2 50 20.4 24.8 29.2 33.2 45.6 50
AAMIX 0.4 0.2 50 20.8 25.2 29.6 33.6 46.4 50.8
AAMIX 0.4 0.2 50 20.4 24.8 29.2 33.2 45.6 50
AAMIX 0.4 0.2 50 20.4 24.8 29.2 33.2 45.6 50
AAMIX 0.4 0.2 50 17 20.8 24.4 27.6 38 41.6
AAMIX 0.4 0.2 50 17.2 21.2 24.4 28 38.8 42.4
AAMIX 0.4 0.2 50 19.2 22.8 27.2 30.8 42.4 46.4
AAMIX 0.4 0.2 50 21.6 26 30.8 34.8 48.4 52.8
AAMIX 0.4 0.2 50 21.6 26 30.8 34.8 48.4 52.8
AAMIX 0.4 0.2 50 21.6 26 30.8 34.8 48.4 52.8
AAMIX 0.4 0.2 50 21.6 26.4 30.8 35.2 48.4 53.2
AAMIX 0.4 0.2 50 22.4 26.8 31.6 36 49.6 54.4
AAMIX 0.4 0.2 50 19.2 23.2 27.6 31.2 43.2 47.2
AAMIX 0.4 0.2 50 19.6 23.6 28 31.6 43.6 48
AAMIX 0.4 0.2 50 19.6 23.6 28 31.6 43.6 48
AAMIX 0.4 0.2 60 19.2 23.2 27.2 30.8 42.4 46.4
AAMIX 0.4 0.2 60 19.2 23.2 27.2 30.8 42.4 46.4
AAMIX 0.4 0.2 60 18.8 22.8 26.8 30.4 41.6 45.6
AAMIX 0.4 0.2 60 18.4 22 26 29.6 40.8 44.4
AAMIX 0.4 0.2 60 18.4 22.4 26.4 29.6 41.2 45.2
AAMIX 0.4 0.2 60 19.2 23.2 27.2 30.8 42.4 46.4
AAMIX 0.4 0.2 60 19.2 23.6 27.6 31.2 43.2 47.2
AAMIX 0.4 0.2 60 19.2 23.6 27.6 31.2 43.2 47.2
AAMIX 0.4 0.2 60 19.2 23.6 27.6 31.2 43.2 47.2
AAMIX 0.4 0.2 60 19.2 23.6 27.2 31.2 43.2 47.2
AAMIX 0.4 0.2 60 19.2 23.2 26.8 30.8 42.4 46.4
AAMIX 0.4 0.2 60 18.8 22.8 26.8 30.4 42 46
AAMIX 0.4 0.2 60 19.2 23.2 27.2 30.8 42.4 46.4
AAMIX 0.4 0.2 60 18.8 22.8 26.8 30.4 41.6 45.6
AAMIX 0.4 0.25 50 13.2 16 19.2 21.6 30 32.8
AAMIX 0.4 0.25 50 14 16.8 19.6 22.4 31.2 34
AAMIX 0.4 0.25 50 14 16.8 19.6 22.4 31.2 34
AAMIX 0.4 0.25 50 14 16.8 19.6 22.4 31.2 34
AAMIX 0.4 0.25 50 14 16.8 19.6 22.4 31.2 34
AAMIX 0.4 0.25 50 15.6 18.8 22 25.2 34.8 38.4
AAMIX 0.4 0.25 50 15.2 18.4 22 24.8 34.4 37.6
The effect of different concentrations of pyridine formate on retention tin
of the amino acids was determined as described in section 3.3.4. F.R. flow
Complete separation of 
glycine and leucine from 
otner amino acids
glycine and leucine from 
otner amino acids
P.F. pyridine formate, TEMP, temperature, GLU glutamic acid, GLY glycine, Val valine, 
ILE isoleucine. Leu leucine.
Table 3.4
Amino acid separation of plasma using pyridine formate
time (min) DPM DPM time (min) DPM DPM DPM DPM
0-2.5 26 30 20.0-20.5 9 15 8 16
20.5-21.0 11 11 13 14
2.5-5.0 27 44 21.0-21.5 10 10 10 11
21.5-22.0 13 12 9 10
5.0-7.5 22 71 22.0-22.5 4 11 12 15
22.5-23.0 14 12 18 17
7.5-10 37 63 23.0-23.5 19 18 19 24
23.5-24.0 43 26 31 51
10.0-12.5 10 48 24.0-24.5 519 671 490 820
24.5-25.0 2485 7700 14173 9111
12.5-15.0 55 23 25.0-25.5 4410 11954 26635 17251
25.5-26.0 4089 8278 7303 16227
15.0-17.5 18 38 26.0-26.5 1960 5347 289 9329
26.5-27.0 205 143 11 1520
17.5-20.0 28 30 27.0-27.5 63 28 7 462
27.5-28.0 30 424 28 30
20.0-22.5 106 78 28.0-28.5 637 3129 472 31
28.5-29.0 2580 9403 13887 1520
22.5-25.0 4625 7903 29.0-29.5 6183 13942 26688 6742
29.5-30.0 5234 10556 7527 18900
25.0-27.5 15006 19599 alanine 30.0-30.5 2453 6567 233 9012
30.5-31.0 268 1121 7 1314
27.5-30 3992 4625 31.0-31.5 79 127 7 209
31.5-32.0 27 20 11 19
30.0-32.5 10270 11498 glycine 32.0-32.5 19 17 12 16
32.5-33.0 18 15 15 15
32.5-35 11 30
42.0-42.5 2 10 17 6
35.0-37.5 20 26 42.5-43.0 8 7 5 1
43.0-43.5 13 5 19 26
37.5-40 33 38 43.5-44.0 7 7 18 7
44.0-44.5 169 21 99 62
40.0-42.5 129 966 44.5-45.0 1815 1401 1659 957
45.5-46.0 8613 15285 48087 28204
42.5-45 34061 26423 46.0-46.5 14874 24901 90774 53003
46.5-47.0 14401 17500 24881 14325
45.0-47.5 41565 35072 isoleucine 47.0-47.5 6702 11159 985 557
47.5-48.0 691 298 32 21
47.5-50 3927 4670 48.0-48.5 31 18 19 13
48.5-49.0 12 44 95 55
50.0-52.5 15429 13971 leucine 49.0-49.5 1914 6436 1601 993
49.5-50.0 8702 19042 47212 27536
52.5-55.0 1208 391 50.5-51.0 21481 29124 90929 51309
51.0-51.5 17655 22012 25619 14798
55.0-57.5 7 10 51.5-52.0 8362 13718 10793 466
52.0-52.5 971 2941 213 13
52.5-53.0 35 265 23 14
53.0-53.5 26 5 15 21
53.5-54.0 11 17 19 22
54.0-54.5 11 11 9 19
54.5-55.0 12 9 13 12
Separation of [14C]label led amino acids (alanine, gl\rcine, isoleucine and leucine) from
plasma (see section 3.4.3, 3.4.5). Fractions were collected by time, 2.5min or 0.5min
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Figure 3.1 Plasma sample preparation
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Figure 3.2 Tissue sample preparation
i
C
o
n
c
e
n
tr
a
ti
o
n
 
(u
m
o
l/
l)
4000
GIu
3000
2000
Ser
n a G,y
1000 Val Leu
MetThr
Cys
0
20 8040 12060 100 140
Fraction number (0.4min/160ul)
i
i
i
1 Figure 3.3. Amino acid separation of liver hydrolysate using 0.2 mol/l pyridine formate.
Individual fractions were analysed on a Chromaspek M amino acid analyser. 
□  The expansion of the region of the fractions 60-140 to illustrate the 
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Figure 3.4 U.V. detector trace of amino acid separation.
Traces A and B show plasma amino acid separation using 0.2mol/l pyridine 
formate at 50°C at different detector sensitivities, trace A (0.08 Absorbance 
Units Full Scale) and trace B (0.01 Absorbance Units Full Scale). U.V. 
detector at 278nm and chart speed 120mm/min. Retention times of glycine and 
leucine are shown.
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Figure 3.6 Electrophoresis and immunofixation of the acid/alcohol extract 
from skeletal muscle biopsy (see section 3.5.3). Scan A and B, 
electrophoresis and immunofixation of plasma (diluted 1:10) using antiserum 
to fibrinogen (Scan A) and albumin (Scan B) . Scan C and D, electrophoresis 
and immunofixation of acid/alcohol extract using antiserum to fibrinogen 
(Scan C) and albumin (Scan D) . Scan E, electrophoresis of acid/alcohol 
extract. 1= sample well, 2= fibrinogen, 3= albumin, X= distance in mm.
CHAPTER 4: METHODS: STABLE ISOTOPE MEASUREMENT AND STUDY
PROTOCOL VALIDATION
4.1 introduction
The stable isotopes of carbon (13C), nitrogen (15N), oxygen (180) 
and hydrogen (2H) were all discovered in the period 1929-1932 and soon 
assumed an important role in biochemical studies. In the absence of 
radioactive isotopes a wealth of published material appeared on the 
separation and detection of stable isotopes, the synthesis of labelled 
compounds, their use in biochemistry, and especially for the study of the 
metabolism of proteins, carbohydrates and lipids. The subsequent 
widespread use of radioactive isotopes in the same fields, after the second 
world war, reduced the use of their stable equivalents which were 
disadvantaged in terms of isotope cost and the availability and expense of 
instrumentation. However, since the early 1970's there has been a return 
to the use of stable isotopes in certain fields for reasons that were 
discussed in Chapter 2.
The enrichment of stable isotopes can be measured by a number of 
techniques. However, the precision of isotope analysis required and the 
sample size available in substrate turnover and incorporation studies means 
that many of the techniques capable of isotope analysis are not suitable for 
such studies. In the measurement of whole body and tissue protein 
synthesis using a tracer dose of labelled amino acid, the analytical 
technique must be capable of measuring samples which vary in enrichment 
between natural abundance and approximately 3 .0a to m %  excess. 
Furthermore, a precision of at least 0 .3%  (relative to the enrichment) 15N 
or 13C on samples as small as 1umol of amino acid is required. For
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example _+ 0.001 atom% 15N at natural abundance, and _+ 0.01 at 
3atom% 15N.
4.1.1 Nuclear Magnetic Resonance
The phenomenon of Nuclear Magnetic Resonance was discovered in 
1946 by Bloch and Purcell. Nuclear Magnetic Resonance spectroscopy 
rapidly became an important technique in organic chemistry for elucidating 
molecular structures, complementing other techniques such as infrared 
spectroscopy and mass spectrometry. Certain stable isotopes have a 
non-zero spin and therefore can be detected by Nuclear Magnetic 
Resonance spectroscopy. 13C and 15N have nuclear spins of 1/2 and 170  
of 5/2. Of these isotopes, the majority of reported work has concerned 
13C. 13C nuclei are present in extremely small amounts in most biological 
systems, and therefore are suitable for use in labelling experiments. For 
example, the metabolism of 13C-labelled alanine and pyruvate has been 
followed in a perfused liver system (Cohen, 1983, 1987). There are, 
however, several disadvantages with this type of application. Firstly, 
because of the poor sensitivity, of detection of 13C, large concentrations 
(ie. non-tracer) of labelled precursors must be used, which may distort the 
metabolic kinetics. Secondly, most 13C compounds are expensive. Thirdly, 
there is the risk of heating the patient. This is because of the intensive 
radio frequencies needed to irradiate protons coupled to 13C in order to 
simplify the spectrum for analysis.
It is clear that Nuclear Magnetic Resonance spectroscopy does not 
fulfil the criteria stated in the introduction and therefore, is not suitable for 
the proposed protein synthesis studies.
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4 .1 .2  Emission Spectroscopy
Optical emission spectroscopy is routinely used for the determination 
of nitrogen-15. The method depends upon the wavelength separation of 
the isotopic species of nitrogen gas (14N2, 14N15N, and 15N2) due to the 
isotopic shift. Prior to assay, it is necessary to convert the nitrogen to 
nitrogen gas. For exam ple, amino compounds are treated  w ith  
hypobromite. Although compared to the isotope ratio mass spectrometer, 
more tracer is required for results of comparable accuracy, it has been 
used to determine urinary 15N-urea, 15N-ammonia and 15N-labelled amino 
acid on infusion of 15N-glycine into human subjects (Stein et al., 1975). 
Automated instruments based on this concept have been described (Klein 
and Klein, 1975). Such optical emission spectrometers have been used in 
whole body protein turnover studies using [15N]glycine (Stein et al., 1983). 
However, the analytical precision is not good enough to measure the 
incorporation of a labelled amino acid into protein pools with a slow 
turnover (eg. muscle). Furthermore, since carbon isotope ratios cannot be 
measured by this technique it was not suitable for the studies proposed in 
this thesis.
4 .1 .3  Infrared spectroscopy
This technique has limited applications in the detection and assay of 
labelled compounds. Absorption peaks at 2193 cm"1 for 12CO (carbon 
monoxide) and at 2144  cm"1 for 13CO are sufficiently separated to 
determine the isotope ratio (McDowell, 1970).
A recent development in this field has been the use of an instrument 
employing the technique called nondispersive infrared heterodyne 
ratiometry (Irving, et al, 1986). This method can be used to quantitate the 
C 0 2 of a gas mixture. Such a spectrometer measures the intensity of a
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h e te ro d y n e  s ignal g en era ted  from  th e  p a rtia l a b so rp tio n  of 
amplitude-modulated infrared radiation by a pressure-modulated gas 
sample. This method does not require monochromatic infrared radiation but 
does require that the intensity of the radiation transmitted through the 
sample be selectively modulated at the absorption wavelengths of the gas 
of interest. This process is accomplished by transmitting radiation through 
a sample of the gas while the density of the gas is modulated in a 
sinusoidal manner. As yet instruments of this type are still at the prototype 
stage and could not be used in the proposed studies.
4 .1 .4  Other techniques
Although not as widely used, the possibility of using Raman 
scattering for measuring isotope ratios has been investigated. It has been 
demonstrated that isotopic analyses of nitrogen (14N 15N) and oxygen 
(160 180 ) can be made using an argon laser (Bloom, Harney and 
Milanovich, 1976).
Activation analysis is another technique that has found some 
applications. In these methods the desired stable isotope is made to 
undergo a suitable nuclear transition. The parent isotope is determined by 
measurement of the resulting radioactive nuclide. For example, the 180  
content of water samples as small as 1.5 ul has been determined by 
charge particle activation (Wood et al., 1975).
Methods for the direct analysis of the deuterium content of aqueous 
fluids or of organic molecules (via oxidative combustion) include 
gravimetric analysis and the falling drop method (Schloerb et al., 1951).
None of these other rechniques satisfy the criteria described in the 
introduction and therefore were not used.
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4 .1 .5  Mass spectrometry
The use of stable isotope tracers in man has not been as widespread 
as predicted by pioneers in the field. The reluctance to use stable isotopes 
or to change from radioisotope methodology (brought about by ethical 
considerations) is due to the laborious sample preparation techniques, 
unavailability of suitably labelled compounds, high cost of conventional 
instrumentation and limitations in terms of sample size and precision of 
such apparatus. This is compounded in the clinical field, where stable 
isotopes are used to study protein, carbohydrate and fat metabolism, as 
13C and 15N studies typically generate large numbers of samples. At 
present it is necessary to have access to both Isotope Ratio Mass 
Spectrometry and Gas Chromatography-Mass Spectrometry to carry out 
precursor and end-product tracer analysis. The reason for needing both 
types of instrumentation lies in the sample size and precision of isotope 
ratio analysis required by protein synthesis studies (Preston and McMillan, 
1988; Figure 4.3).
The earliest mass spectrometers were developed by Nier and others 
in the late 1930's and throughout the 1940's (Nier, 1946). They were 
designed to measure isotopes of the main elements of organic matter, 
namely, hydrogen, carbon, nitrogen and oxygen. The result of such work 
was a dual-inlet (for comparison of sample and reference gases), low 
resolution (analysis of simple gases), double-collector magnetic sector 
(simultaneous measurement of major and minor isotope) instrument 
designed for precise heavy isotope measurement of low molecular weight 
permanent gases (e.g. C 0 2 and N2) which retain their molecular identity 
under electron bombardment. An Isotope Ratio Mass Spectrometer is 
capable of detecting 1 labelled molecule of the minor isotope in the 
presence of 100,000 unlabelled molecules, in its original form, requires
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3-30umole of gas for accurate isotope assay, and thus is ideal where 
sample size is not limiting but high precision isotopic measurements are 
essential.
In contrast, the Gas Chromatograph-Mass Spectrometer is a high 
resolution, high sensitivity instrument. It was during the 1960's that the 
technique of interfacing a gas chromatograph with a mass spectrometer 
was perfected. The mass spectrometer could be either a quadrupole or 
magnetic sector analyser. However, as the quadrupole is capable of 
switching masses more rapidly and is more amenable to computer control 
than the magnetic analysers in the same price range, it has been more 
usual to couple this type of mass analyser with a gas chromatograph. Gas 
Chromatography-Mass Spectrometry for metabolic studies has been further 
improved by operation in the Selected Ion Monitoring mode (Klein, 
Haumann and Eisler, 1972; Watson et al., 1973; Gruenke, Craig and Bier, 
1980). Gas Chromatography-Mass Spectrometry combines the ability of 
the gas chromatograph to resolve individual components in a complex 
mixture and the ability of the mass spectrometer to generate and quantify 
ions unique to the compound being measured.
Isotope ratios of carbon and nitrogen can be determined with very 
good precision (better than 0 .1%  relative standard deviation) by differential 
isotopic analysis of pure simple gases using the dual inlet dual collector 
Isotope Ratio Mass Spectrometer developed by McKinney et al (1950), and 
with adequate precision (10-0.5% , depending on conditions) by Selected 
Ion Monitoring-Gas Chromatography-Mass Spectrometry (Sweeley et al., 
1966). Isotope Ratio Mass Spectrometry and Selected Ion Monitoring-Gas 
Chrom atography-M ass Spectrom etry can be thought of as being 
complementary, the former providing high precision but requiring relatively 
large samples, the latter handling smaller samples but with reduced
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precision. The Gas Chromatography-Mass Spectrometry technique directly 
incorporates a process of sample purification and is capable of resolving 
m ixtures of com pounds, w hile conventional Isotope Ratio Mass 
S pectrom etry instrum entation dictates th a t sam ple preparation is 
performed off-line. In practical terms, the integral separation process gives 
Gas Chromatography-Mass Spectrometry a great advantage in the rate of 
sample throughput and in the confidence of the results that are supposed 
to relate to individual pure compounds.
There have been over the last 10-15 years several attempts to 
modify Gas Chromatography-Mass Spectrometry to improve isotope 
precision of this technique and concurrent developments have sought to 
simplify and automate the sample preparation and handling for Isotope 
Ratio Mass Spectrometry.
One approach reported by Sano et al (1976) was a modification of 
Gas Chrom atography-M ass Spectrom etry w hich allowed precise 
measurement of the 13C:12C ratio in 13C-labelled metabolites of drugs. 
This new technique enabled 13C-labelled drugs to be used in preference to 
deuterated drugs whose metabolites frequently showed a kinetic isotope 
effect of the deuterium label. Other advantages were: simplified 
identification of peaks and the number of metabolites by combining gas 
chromatograph and mass spectrometry traces of the separation. Briefly, a 
m ixture of 13C-labelled m etabolites was injected into the gas 
chromatograph and the effluent converted into C 0 2 during the passage 
through a catalytic combustion unit, the resulting C 02 was subsequently 
lead into a single collector mass spectrometer. Ions with m/e 45 (13C 0 2) 
and m/e 4 4  (12C 0 2) were detected alternately at intervals of 0 .5  s under 
computer control of the accelerating voltage. They were able to make 
isotopic ratio measurements on 5ng of labelled metabolite although the
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precision of this measurement was not given. However, the combination of 
gas chromatograph and with a combustion oven was not new. In 1960, in 
order to normalise the detector response with regard to carbon number, 
the effluent from a gas chromatograph was passed through a combustion 
oven before entering a thermal conductivity detector (Franc and Wurst, 
1960). Also in the same year, the effluent from a gas chromatograph was 
com busted in order to allow  on-line elem ental analysis of gas 
chromatograph peaks, the carbon /  hydrogen ratio being determined from 
the C 0 2 : H2 ratio after water combustion product had been reduced to 
hydrogen (Cacace, Cippollini and Perez, 1960). In another use, the same 
arrangement followed by a proportional counter was reported for the 
measurement of 14C and 3H abundances (James and Piper, 1961; 
Winkleman and Karmen, 1962; Cacace, Cippollini and Perez, 1963).
Matthews and Hayes (1978) reported on work carried out on carbon 
and nitrogen isotope ratios using essentially the same scheme as Sano and 
coworkers but with improved instrumentation and selective traps to 
remove combustion products other than those of interest. These 
investigators emphasised the capabilities of the new technique (termed 
Isotope Ratio Monitoring-Gas Chromatography- Mass Spectrometry) 
namely, the ability to separate a single compound from a complex mixture, 
the speed of Simultaneous Ion Monitoring-Gas Chromatography-Mass 
Spectrometry and the improved isotope ratio measurement of their Gas 
Chromatography-Mass Spectrometry instrumentation. They claimed that 
this technique could measure nitrogen and carbon isotope ratios down to 
natural abundance levels for any organic component (or components) that 
could be resolved gas chromatographically.
Another approach, to introduce rapid automatic sample preparation 
for Isotope Ratio Mass Spectrometry was described by Preston and Owens
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(1983) who interfaced an automatic elemental analyser on-line to a low 
resolution, multiple collector Isotope Ratio Mass Spectrometer (termed 
Continuous Flow-lsotope Ratio Mass Spectrometry). In this technique the 
combustion furnace is placed before the Gas Chromatograph which is 
designed to separate simple gases. In addition the rapid semiautomatic 
analysis of total nitrogen and nitrogen isotope ratio measurements using 
the single step Dumas combustion of the biological sample is used rather 
than the more routinely used Kjeldahl digestion to ammonium for total 
nitrogen analysis and the oxidation of ammonium to nitrogen gas by the 
Rittenberg technique (Springson and Rittenberg, 1949b) for isotope 
analysis (San Pietro, 1957). A similar scheme was described by Marshall 
and W hitew ay (1 9 85 ). The Continuous Flow-lsotope Ratio Mass 
Spectrometer is not only able to carry out more rapid analysis but because 
of the much simpler sample preparation in comparison to that of 
Kjeldahl-Rittenberg, the technique is able to provide a more sensitive, 
reliable isotope ratio. These workers also suggest that the Isotope Ratio 
Mass Spectrometer could provide more precise isotope ratio detection for 
the scheme described above by Matthews and Hayes. Although mass 
spectrometry had been used before as a detector for combustion analysis 
(Van Meter, Bailey and Brodie, 1951; Barsdate and Dugdale, 1965) and 
laboratory built Dumas combustion apparatus had been developed for 
nitrogen isotope analysis (Fiedler and Proksch, 1972; Wada et al., 1977) 
the implications for automatic rapid precise carbon and nitrogen isotope 
analysis in the continuous flow mode had not previously been described. 
Preston and Owens (1985) reported rapid automatic carbon isotope 
analysis and total carbon content with the same technique as described 
above. Continuous Flow-lsotope Ratio Mass Spectrometry has since
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undergone further refinement to become a fully automated technique 
(Barrie et al., 1989).
In summary, it is clear from the discussion above that mass 
spectrometry is the most suitable technique for the stable isotope analysis 
of samples from protein synthesis studies in man since it fulfills the criteria 
described in the introduction. However, it is also clear that, for such 
studies, Continuous Flow-lsotope Ratio Mass Spectrometry offers an 
alternative to the conventional methodology which involves both Isotope 
Ratio Mass Spectrometry and Gas Chromatography-Mass Spectrometry. 
Therefore, Continuous Flow-lsotope Ratio Mass Spectrometry was the 
technique used for stable isotope analysis in this work.
4 .2  Continuous Flow-lsotope Ratio Mass Spectrometer (Figure 4.1)
The Continuous Flow-lsotope Ratio Mass Spectrometer used in this 
study was made of two basic modules; (A) A biological sample converter 
(ROBOPREP-CN, Europa Scientific Ltd., Crewe, UK.) which was interfaced 
directly to (B) a dual collector Isotope Ratio Mass Spectrometer (MM 602, 
VG Isogas, Winsford, UK.) by a simple variable leak valve and both 
modules were controlled by a single computer (C).
(A) The biological sample converter is a software controlled sample 
preparation system employing the Dumas principle and is specifically 
designed to use a mass spectrometer as a detector. Samples are 
introduced by automatic gravity fed autosampler into an oxidation tube in 
the presence of a pulse of oxygen. The C 0 2 and N2 are purified and 
separated before being transferred to the mass spectrometer by helium 
carrier gas. The timing and size of the 0 2 pulse are software controlled 
enabling the 0 2 pulse to be optimised to suit the size and type of sample.
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For nitrogen only measurements, C 0 2 is chemically trapped but when 
carbon only measurements are made, the software switches the C 0 2 trap 
out of the gas flow. The instrument was fitted with a septum inlet after the 
oxidation furnace (Figure 4.1) for injecting breath C 0 2 samples. The helium 
gas flow rate was maintained at 60 ml/min. The sample preparation system 
can be further subdivided into its functional units; (1) Autosampler (2) 
Oxidation furnace (3) Reduction furnace (4) Gas scrubber tubes (5) GC 
column.
(1) This is a pneumatically operated sample delivery device with a 
removable 64 position sample carousel. The sample sits in a well where it 
is purged with helium at approximately 40  ml/min. When the carousel is 
activated the sample moves forward in a shaft and drops into the oxidation 
furnace following a pulse of 0 2. The next sample drops into the purge well 
ready for the next cycle. A window situated on top of the sampler allows 
visible confirmation of the correct flash combustion conditions.
(2) Many different combustion catalysts have been tested for use in 
quantitative elemental analysis, and have been reviewed extensively by Ma 
and Gutterson (1974, 1976, 1978). The catalyst suitable for Continuous 
Flow-lsotope Ratio Mass Spectrometry must (a) produce quantitative 
combustion (b) not devitrify silica (c) not decompose under reaction 
conditions and (d) not retain sample combustion products and thus 
produce memory effects. The first of these restrictions is imposed because 
incomplete combustion could be accompanied by isotopic fractionation and 
more directly because fragment ions arising from residual materials such as 
hydrocarbons might appear at masses 28, 29, 44, or 45 thus causing 
serious errors in isotope ratio measurements. The oxidation stage of the 
preparation system (Figure 4.2) was filled with granular chromium (III) 
oxide (Elemental Microanalysis Ltd., Okehampton, U.K.) and held at 980°C .
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The oxidation stage also contains a layer of silver wool, which removes 
any halogens.
(3) The products of the oxidation stage are passed to the reduction 
furnace (Figure 4.3) which contains copper granules at 550  °C where 
excess oxygen is absorbed and nitrogen oxides are reduced to elemental 
nitrogen. Specifically for samples (containing ammonium sulphate) used in 
this work, the reduction stage has a large capacity to trap sulphur dioxide.
(4) There are two gas scrubbing tubes, one of which removes water 
and the other removes C 0 2- The water scrubbing tube (Figure 8) contains 
granular anhydrous magnesium perchlorate and trapping of C 0 2 in the 
other tube (Figure 4.2) is achieved by filling the tube with 'carbosorb' 
followed by a layer of magnesium perchlorate (BDH Ltd., Poole, UK.). The 
C 0 2 trap can be switched out of the gas stream if C 0 2 is the gas of 
interest.
(5) The gas stream passes into the gas chromatograph where the 
gases of interest are separated and then bled into the mass spectrometer 
via a variable leak valve. The gas chromatograph column was kept at a 
temperature of 135°C for nitrogen, carbon and breath C 0 2 analysis.
(B) The classical dual inlet dual collector Isotope Ratio Mass 
Spectrometer is ideally suited for measuring very low enrichments in the 
easily purified end-products of metabolism, urea and C 0 2. The instrument 
derives its sensitivity for determining very small differences in isotopic 
enrichment (approximately 0.0001 atom% excess) by (a) by measuring 
only small pure gas molecules, (b) simultaneously measuring both the 
major and minor isotope-derived ions with a set of Faraday cup collectors 
for ion current measurement, optimised for each ion beam (c) always 
measuring the isotope ratio of the sample gas against the isotope ratio of
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an equal pressure of reference gas of known isotopic content via periodic 
switching with a dual gas inlet system. Although Isotope Ratio Mass 
Spectrometry has been under continuous evolution since the 1930's, the 
instrument has been tedious to use. With the recent application of the 
microcomputer to instrument control systems such instruments can now 
operate automatically.
At present, the limitation of the Isotope Ratio Mass Spectrometer 
technique is not the instrument, but the sample preparation. Because 
Isotope Ratio Mass Spectrometer measures small gas molecules placed in 
an inlet system of finite volume, determination of isotopic enrichment 
involves converting umole amounts of compound in pure form to the 
proper gas. The end-products of metabolism, typically with low levels of 
enrichment have therefore been the main sample type for isotopic 
measurement by Isotope Ratio Mass Spectrometer: C 0 2 can be readily 
trapped from expired air in mmole amounts (Schoeller et al., 1977): urea 
and ammonia can be isolated from urine and converted to N2 usually via 
reaction of ammonium salt with lithium hypobromite (Ross and Martin, 
1970). In contrast, few circulating metabolic substrates can be routinely 
isolated in pure form in suitable amounts for Isotope Ratio Mass 
Spectrometry. For example, the leucine in approximately 30ml of plasma 
must be isolated from all other carbon containing compounds to yield 
sufficient C 0 2 for isotope analysis by Isotope Ratio Mass Spectrometry.
In this work the Isotope Ratio Mass Spectrometer interfaced to the 
biological sample converter consists of a converted Nier type analyser that 
contains an ion source, 90° flight tube and ion collectors all within a 
vacuum envelope. For convenience and to reduce the volume, the vacuum 
envelope is crescent-shaped with the source and dual faraday bucket 
collectors housed at opposite ends. Ionisation is caused by the electron
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bombardment of the gas sample in the source region and the required ions 
so generated are then extracted from the source region by an electrostatic 
field. The Isotope Ratio Mass Spectrometer source filament material was 
thoriated iridium, the electron energy 70eV and the trap current 260uA. 
The ions are subjected to an accelerating voltage and ejected into a fixed 
magnetic field which separates different masses. The ion current charge 
(major or minor) imparted to its respective collector bucket, resulting from 
the ion beam impact, is converted by an electrometer amplifier into a 
measurable voltage.
(C) Computer control of Continuous Flow-lsotope Ratio Mass 
Spectrometry was performed by a custom software package (Europa 
Scientific Ltd.) residing in a IBM-PC compatible computer. The software 
acts via an interface card which has high precision voltage to frequency 
converters to quantify simultaneously each ion beam current, that is, 
integrating and computing the isotope ratio, then adding the isotope peaks 
to give the total elemental content of the simple gas. The interface card 
also contains a programmable 10volt direct current output to control the 
mass spectrometer accelerating voltage and switches and sensors which in 
turn control and monitor the following functions of the sample preparation 
system; (1) the timing and operation of the autosampler (2) the timing and 
size of the oxygen pulse (3) the switching in or out of the C 0 2 trap from 
the gas circuit. The software package also carries out data storage and 
analysis following a run of samples, calculating drift and background 
values (Barrie et al., 1989).
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4.2.1 Sample combustion
The sample combustion containers were aluminium and heated to 
450°C  for 4h to reduce the carbon and nitrogen blank to a minimum, 
accepting that the flash combustion process may be less efficient than 
with tin containers. The analytical sample time was varied according to the 
samples under analysis. The oxygen pulse size selected for each batch of 
samples was calculated by adding 2ml to the volume required by the 
maximum sample size plus that required to oxidise the combustion 
container. The oxygen pulse was 99 .998%  pure and the helium 9 9 .9998%  
pure (Air Products Ltd.). Very pure grades of these gases are needed for 
the analysis of small nitrogenous samples as this minimises carrier baseline 
and oxygen blank. The samples analysed in this work produced little ash 
on combustion compared to the usual sample type that is subjected to 
combustion analysis. Sample ash build-up in the vertical oxidation stage of 
the preparation system is undesirable as it can raise the combustion region 
from the hottest part of the furnace. Also as the ash may contain alkaline 
and alkaline earth oxides it will cause devitrification if it comes in contact 
with the quartz combustion tube. To avoid such problems an alumina tube 
with a plug of silica wool and a layer of chromic oxide was inserted into 
the quartz combustion tube. The removal of sample ash was accomplished 
by removing the alumina liner while the furnace was at the 800°C  standby 
setting and replacing it with another (for subsequent deashing). The 
sample ash was removed after approximately 2 00  samples when  
end-products were be analysed and after 70 samples when precursors 
(submicromolar samples) were analysed. The reason was that the 
elemental content of the precursor samples was much lower and therefore 
required minimal peak tailing and lower background levels of carbon and 
nitrogen. The oxidation stage was replaced after approximately 2000
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sample analyses. The reduction stage was also replaced at this time, and 
regenerated in situ with pure hydrogen after approximately 700 analyses. 
The scrubbers for water and C 0 2 were replaced after approximately 1000  
samples.
4 .2 .2  Carbon isotope analysis bv Continuous Flow-lsotope Ratio Mass 
Spectrometry
The estimation of carbon isotopic enrichment in Continuous 
Flow-lsotope Ratio Mass Spectrometry is carried out after combustion of 
organic material to C 0 2 when the aluminium boat containing the purified 
amino acid (in this case leucine) drops into the oxidation stage. The C 0 2 is 
then carried by helium through the copper reduction stage to remove 
oxygen and through a water scrubber. The C 0 2 trap was isolated 
automatically during the entire analytical cycle. The sample is finally carried 
through a gas chromatographic column (Carbosieve S, (60-80 mesh, 50cm  
x 1/4", Phase Separations, UK.) to resolve C 0 2 from nitrogen and any 
trace hydrocarbons. The 13C isotope ratio was calculated from the ratio of 
integrated peak signals of mass/charge (m/z) 44  (12C160 2) and m/z 45  
(13C160 2) from the collector buckets of the mass spectrometer (see 
4.2(B)). The m/z 45 also contains a small contribution from 12C 160 170  
which was corrected for (Craig, 1953) in the mass spectrometry software. 
Atom% 13C was calculated using the formula;
100/(R + 1)
where R is the ratio m/z 44 /45  corrected for 170  contribution and 
scaled to a working 13C standard (L-alanine, Sigma Chemical Co. Ltd, 
Dorset, UK.). The working standard was calibrated against sucrose of 
known 13C enrichment. The typical amount of carbon generated from
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plasma and intracellular leucine was of the order of 20ug split as a peak 
over 10 fractions (Figure 4 .4 ). The analytical cycle time was 7 .6  min.
In the case of breath C 0 2 a needle was fitted to the luer stopcock of 
the syringe and this was flushed by discarding 10ml of the sample. The 
remaining 10ml was then injected through a septum inlet of the 
Continuous Flow-lsotope Ratio Mass Spectrometry preparation system 
(Figure 4.1) into the helium carrier stream. The breath sample was carried 
by the helium through the copper reduction stage, removing oxygen, 
through the water scrubber and through the gas chromatograph column to 
resolve C 0 2 from N2 and any trace hydrocarbons. It is desirable to resolve 
N2 from C 0 2 (although there is no isobaric interference) to avoid any 
baseline disturbance, principally due to the great excess of nitrogen ions 
generated in the Isotope Ratio Mass Spectrometer ion source. In the mass 
spectrometer the ion beams are quantified and 13C isotope ratio calculated 
as described above. The septum inlet was positioned after the oxidation 
stage to avoid oxidising any trace hydrocarbons to C 0 2 and thus not 
compromise the isotope ratio analysis. Both oxidation and reduction tubes 
were kept at the standby temperatures (800°C and 400°C  respectively) 
during the breath C 0 2 analysis (Figure 4.1). The working standard for the 
breath C 0 2 analysis was a calibrated gas mixture (10%  C 0 2, 90%  N2, 
Corning Medical, Essex, UK.). The time from injecting the breath sample to 
the measurement of both total C 0 2 and 13C isotope ratio (analytical cycle 
time) was 4min.
4 .2 .3  Nitrogen isotope analysis bv Continuous Flow-lsotooe Ratio Mass 
Spectrometry
The estimation of nitrogen isotopic enrichment in Continuous 
Flow-lsotope Ratio Mass Spectrometry is carried out after combustion to
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N2 when the aluminium boat containing the purified amino acid (in this 
case glycine) or ammonium drops into the oxidation stage. The N2 is then 
carried by helium through the copper reduction stage which reduces 
nitrogen oxides to N2. The nitrogen is carried through a water scrubber 
and a C 0 2 trap and finally passes through a gas chromatographic column 
which resolves nitrogen from any trace hydrocarbons. The 15N isotope 
ratio was calculated from the ratio of integrated peak signals of m/z 28 
(14N2) and m/z 29 (14N15N). Atom% 15N was calculated using the 
formula;
100/(2R -h 1)
where R is the ratio m/z 28 /29 , and scaled to a working 15N 
standard (L-alanine, Sigma Chemical Co. Ltd, Dorset, UK.). The working 
standard was calibrated against ammonium sulphate of known 15N 
enrichment. The typical amount of nitrogen generated from plasma and 
intracellular glycine was in the order of 12ug split as a peak over 10 
fractions (Figure 4 .5). The typical amount of nitrogen generated from 
urinary ammonium was 25-1 OOug. The analytical cycle time was 6.3min.
4 .2 .4  Calculation of carbon and nitrogen isotope enrichment of leucine and 
alvcine following amino acid separation
The leucine and glycine peaks were collected in 10 fractions which 
were individually analysed for their isotopic enrichment. On analysis of the 
leucine fractions, there was increasing carbon rising to a peak in fraction 5 
or 6 and then falling to low levels (Figure 4 .4 ). Similarly, isotopic 
enrichment rose to a peak and then fell. However, the peak isotopic 
enrichment did not coincide with that of the peak elemental content, but 
appeared in the subsequent fraction. This finding indicates isotope 
frac tio n a tio n  by the cation exchange high perform ance liquid
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chromatography separation and has been reported by other workers 
(Laragh, Sealey and Klein, 1965; Garlick et al., 1989).
To correct for isotope fractionation two approaches can be used. 
Firstly, all the fractions containing the label can be pooled and then 
analysed or secondly, to avoid impurities in the sample collection, the 
sample is collected in several fractions symmetrically about the peak, 
analysed and a weighted average of the enrichment/specific activity of 
fractions carried out (Laragh, Sealey and Klein, 1965). With the amino acid 
separation techniques used in this thesis (see section 3 .4 .3) it is not 
possible, for an individual sample, to rule out some contamination of the 
glycine or leucine peak with an adjacent peak, because operation of the 
fraction collector was not synchronised with the eluting peak, due to small 
retention time variations. Therefore, to avoid this problem and to ensure an 
accurate isotope ratio measurement was obtained, all fractions before, 
during and following the eluting peak were analysed and a weighted 
average was taken to calculate the isotope ratio from the 6 fractions which 
contained greater than 97%  (in the case of nitrogen) and 93%  (in the case 
of carbon) of the tracer (Table 4 .4 ). These 6 fractions used for isotope 
analysis invariably contained at least 80%  of the total elemental content of 
the 10 fractions analysed. Fractions containing less than 0.7ugN would 
normally be excluded from the final isotope enrichment calculation (see 
below). This approach is unlikely to introduce a serious error into the 
measurement of the isotope ratio (Laragh, Sealey and Klein, 1965; Table 
4.4; see section 4 .2 .5 ).
In the case of 13C enrichment measurement account had to be taken 
of the contribution of the aluminium combustion container and mobile 
phase (see section 3 .4 .3 ) residue to the carbon content of each fraction, 
which together were of the order of 2ug_+0.2ug. In practice, this was
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achieved by subtracting the carbon content of the last fraction from all the
other fractions before a weighted average of the isotope ratio was
calculated. The carbon blank of the pulse of oxygen used as an aid to
combustion (see section 4 .2 .1 ) was negligible. Finally, since only 1 of the
6 carbon atoms in leucine is labelled the isotope ratio was multiplied by 6 
to give the true enrichment. It was assumed that there was no variation in 
the natural abundance of the 5 unlabelled carbon atoms.
The nitrogen blank from the aluminium combustion container and 
mobile phase residue was of the order of 0.1 _+ 0.04ugN, being much less 
than that from the oxygen pulse (typically 1.41 _±_ 0.04ugN). Samples of 
below 0.7ugN (i.e., those with a signal-to-background ratio less than 
0.5:1) gave poor isotope ratio analysis precision and were excluded from 
analysis. The typical sample signal-to-background ratio was between 0.5:1 
and 5:1, which accounts for the Gaussian shape of the isotope ratio versus 
fraction number plot (Figure 4.5; see also Matthews and Hayes, 1978).
4 .2 .5  Sample recovery: precision and accuracy of isotope analysis
As detailed in Chapter 3, sample recovery was approximately 70%  
for the whole procedure from sample preparation to amino acid separation, 
with approximately 50%  of the original sample being used for isotope 
analysis.
Precision of isotope ratio analysis improves with increasing sample 
size. In this work, urinary ammonium analysis was performed at a 
signal-to-background ratio of approximately 50:1 (25-1 OOug atom NH4-N, 
see section 3 .4 .4 ) and breath C 0 2 at greater than 100:1 (approximately 
4umol C 0 2, see section 4 .2 .2 ). Analytical precision (coefficient of 
variation) for these large sample quantities was 0 .16%  and 0 .2 2% , in 
natural abundance and low enrichment 15N samples and 0 .0 9%  at natural
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abundance and 0.11 % in low enrichment breath C 0 2 samples (Preston and 
McMillan, 1988).
Analytical precision for amino acids was determined in the free 
amino acid samples and protein hydrolysates. Repeated analysis was 
performed on plasma of known glycine concentration which had a known 
amount of [15N]glycine added. The precision was determined, for the 
whole procedure, to be 2 .77%  (see Table 4 .1 ). Similarly, for [13C]leucine 
the precision of the procedure was determined to be 4 .12%  (see Table 
4.1). The precision of the whole procedure for isotope ratio measurement 
of low enrichment [15N]glycine (approximately 0.01atom %  excess) and 
[13C]leucine (approximately 0.02atom %  excess) of duplicate hydrolysate 
samples (see section 3 .4 .2) was calculated. The relative standard deviation 
as a percentage (coefficient of variation) was 3 .97%  (n = 6) and 5 .26%  
(n =  5) for glycine and leucine respectively. The coefficient of variation was 
calculated from the formula:
Coefficient of Variation = 100xSQRT((SUM(2x(a-b)/(a +  b))2)/2n)
where a and b are the two samples from the same treated tissue, n 
is the number of duplicates, SQRT is square root and SUM is the sum of 
the terms (Forsberg et al., 1991).
The accuracy of the whole procedure (sample preparation to amino 
acid separation) was determined by repeated analysis of plasma which had 
a known amount of [15N]glycine added to plasma of known glycine 
concentration. The target value for free [15N]glycine enrichment was 
1.00atom % . The accuracy was determined, for the whole procedure, to be 
1 0 0 .3 4%  (see Table 4 .1 ). Similarly, for [13C]leucine (target value 
2.59ato m % ), the accuracy of the procedure was determined to be 
103.61%  (see Table 4.1).
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The accuracy of the Continuous Flow -lsotope Ratio Mass 
Spectrometry instrumentation used in this thesis has been verified in a 
International Atomic Energy Authority intercalibration study (Parr and 
Clements, 1991). Five standards, in a variety of chemical forms, were 
analysed as described in section 4 .2 .3 . The mean (standard deviation) 15N 
enrichment of each standard (analysed 6 times) was 0 .38125 (0 .00088 ), 
0 .3 8 4 7 1 (0 .0 0 0 2 7 ) ,  0 .4 5 6 1 5 (0 .0 0 1 1 0 ) ,  0 .5 0 2 2 3 (0 .0 0 0 7 3 )  and 
2 .0 4 6 6 5 (0 .0 1 33 5 )a to m %  w hich compared w ith  the mean values  
determined by 28 laboratories worldwide of 0 .3 8088 , 0 .3 8 3 63 , 0 .45586 , 
0 .5 0 3 7 3  and 2.0500atom %  respectively. Therefore, analytical precision 
was better than 0.001 atom% 15N at natural abundance and all results 
agreed to within 0 .005  atom% of the study mean.
As calculations reported in this study are based on the change of 
enrichment with time, that is, after subtraction of a baseline enrichment 
from a measured enrichment, accuracy could potentially be compromised 
by uncertainty in the baseline enrichment of the compound of interest. 
End-product (urinary ammonium and breath C 0 2) and plasma precursor 
enrichment calculation used the measured (pre-tracer) natural abundance 
to overcome this problem, however, this was not possible for biopsy 
samples. Baseline enrichments for tissue protein-bound and free amino 
acids were assumed to be the same as pre-tracer plasma amino acid 
enrichment. Uncertainty can be minimised be ensuring sufficient tracer 
incorporation into the product (optimising tracer dose and protocol 
duration).
The change in 15N enrichment in liver glycine (approximately 
0.02atom %  15N, (see Table 5.12) and muscle glycine (approximately 
0.009atom %  15N, see Table 5.12) were above these levels (possibly 
0.0005atom %  15N). Similarly, natural abundance variations in 13C (of the
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order of 0 .0008atom %  13C; Schoeller et al., 1977) are below the 
measured change in liver protein-bound leucine enrichment (approximately 
0.02atom %  13C, see Table 5.13). In practice, the error that natural 
abundance variations could introduce into measured rates of protein 
synthesis is likely to be less significant than other uncertainties in the 
system, such as accurate estimate of tracer enrichment at the site of 
protein synthesis (see section 2.4, 7.4)
4 .3  Study protocol validation
As discussed in Chapter 2 the simultaneous measurement of whole 
body and tissue protein synthesis can be achieved using a continuous 
infusion of a labelled amino acid. Furthermore, from the discussion of the 
relative merits of the two approaches (precursor and end-product methods) 
it was concluded that a comparison between [13C]leucine and [15N]glycine 
was required to assess which approach would be best suited for such 
simultaneous measurements in this work.
To date, [15N]lysine and [13C]leucine have been used to make these
measurements in man (Halliday and McKeran, 1975; Rennie et al., 1982a).
In contrast to [15N]lysine there are a number of studies which have used a
primed continuous intravenous infusion of [13C]leucine to make such
simultaneous protein synthesis measurements in man (Matthews et al.,
1980; Rennie et al., 1982a; Nair, Halliday and Griggs, 1988). Therefore, it
would appear that the precursor approach using [13C]leucine is suitable for
simultaneous whole body and tissue protein synthesis measurements.
However, with this approach it is necessary to determine the recovery of 
1 ^C 0 2, using the C 0 2 collection apparatus and isotope analysis methods 
of the particular laboratory, to correct expired 13C 0 2 enrichment data to 
give the oxidation rate of [13C]leucine (see section 2 .2). This was carried
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out in a single subject (fasted overnight for 12h) using a continuous 
infusion of NaH13C 0 2 (started at 09:30am) and the percentage recovery of 
13C 0 2 calculated for the closed canopy and isotope analysis systems used 
in this work (see Table 4 .5 , section 3.6 and 4.2). The recovery of labelled 
C 0 2 was shown to be, on average, 80 .6%  which is in accord with other 
reports (Wolfe, 1984b).
From the literature there appears to be no reports, in man, of 
simultaneous measurement of whole body and tissue protein synthesis 
using [15N]glycine. This may be due, in the case of [15N]glycine, to the 
further complication that the metabolic end-product (urea or ammonia) 
must also be at plateau in order to calculate the whole body protein 
turnover value.
The use of urinary urea as the end-product of [15N]glycine 
metabolism (urea being quantitatively the most important end-product of 
nitrogen metabolism) has resulted in very long infusion protocols (40-60h, 
due to the large size and relatively slow turnover of the body urea pool) 
being required before [15N]urea reaches plateau enrichment (Steffee et al., 
1976; Winterer et al., 1980). These protocols have been shortened to 
18-24h by the use of a priming dose of the tracer in conjunction with the 
constant infusion (Sim et al., 1980; Jeevanandam et al., 1985). In 
describing the tracer priming dose relative to the infusion dose rate, 
Jeevanandam and coworkers (1985) have termed this the 'prime to 
infusion ratio', although strictly speaking this is not a ratio since it has 
units of time. However, the term is used in this thesis for convenience. It 
has been demonstrated using a continuous intravenous infusion of 
[15N]glycine that a large prime to infusion ratio (prime (mg/kg)/infusion 
(mg/kg/min)) of approximately 1500min is required to achieve plateau 
isotopic enrichment in urinary urea within 24h (Jeevanandam et al., 1985).
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Such a large prime to infusion ratio would compromise the plateau isotopic 
enrichment in the plasma and tissue precursor pool and therefore the linear 
incorporation of labelled amino acid into the tissue required for accurate 
calculation of the protein fractional synthetic rate. However, the ammonia 
pool in man is of the order of 150 times smaller than that of urea and 
therefore will reach an isotopic enrichment plateau more rapidly than urea 
at the lower prime to infusion ratio required for tissue synthetic rate 
measurements. Furthermore, it is clear from the literature and work carried 
out in this laboratory that the isotopic enrichment of urinary ammonia gives 
similar relative values in both in normal subjects and cancer patients 
(Fearon et al., 1988) and therefore can be used as the metabolic 
end-product in the calculation of whole body protein turnover (Garlick and 
Fern, 1985).
The measurement of protein synthesis in tissues, without the use of 
complicated formulae and assumptions about the kinetics of [15N]glycine 
(Stein et al., 1976), requires that the plateau isotopic enrichment in the 
free amino acid precursor pool is attained rapidly and maintained 
throughout the duration of the infusion. Stein and coworkers (1976) used 
a continuous infusion (w ithout a prime dose) of [15N]glycine and 
demonstrated that plateau isotopic enrichment was reached in the plasma 
amino nitrogen in approximately 6h, urinary hippurate (reflecting hepatic 
intracellular [15N]glycine enrichment) in approximately 3h, and urinary 
ammonia in approximately 4h. Therefore, in order to calculate protein 
fractional synthetic rates they used formulae (involving a further 
assumption about the rate of isotopic equilibration in the body's free amino 
acid pool) based on the work of Garlick and coworkers (1973). In order to 
shorten the time to plateau isotopic enrichment in the plasma glycine pool 
it has been calculated that the prime to infusion ratio should be 80min
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(Jeevanandam et al., 1985). Recent studies using [15N]glycine to measure 
protein fractional synthetic rates of hepatic export proteins have used 
prime to infusion ratio of approximately 30min (Cryer et al., 1986 ; 
Thompson et al., 1989). These studies have confirmed that prime to 
infusion ratio of approximately 30min does result in a more rapid 
attainment of plateau [15N] enrichment in free plasma glycine and urinary 
hippurate (95%  of plateau isotopic enrichment within approximately 30min 
and 2h of the start of the infusion respectively). Indeed, this is what would 
be expected from the continuous infusion experiments on rats (using 
[14C]glycine) which demonstrated a rapid equilibrium between free plasma 
and liver glycine pools (Fern and Garlick, 1974). Therefore, it is likely that 
with the prime to infusion dose of approximately 30min that the plateau 
enrichment of [15N]glycine in the true precursor pool for protein synthesis 
(probably glycyl-tRNA) is achieved within 3h and is maintained for the 
duration of the infusion.
From the above discussion it is clear that what is not known is the 
time to plateau isotopic enrichment in urinary ammonia at the lower prime 
to infusion ratio of approximately 30min. Therefore, a preliminary study 
was carried out in 4  normal subjects to establish the time to plateau 
isotopic enrichment in urinary ammonia and confirm that of free plasma 
[15N]glycine following a primed continuous infusion of [15]glycine (prime to 
infusion ratio 30min).
Following a 12h fast a spot urine sample was collected for baseline 
measurement of urinary ammonia and a venous blood sample was taken 
for free plasma [15]glycine enrichment. A primed (0.014mg/kg) constant 
24h intravenous infusion (0.029mg/kg/h), prime to infusion ratio 30min, of 
[15N]glycine (99atom%, Tracer Technologies Inc., MA, USA.) was then 
commenced. All voided urine was collected over the next 24h with timed
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collections of 0-3h, 3-6h, 6-12h and 12-24h. The 15N enrichment in 
urinary ammonia was measured in all urine samples as described in 
Chapters 3 and 4. The results (Table 4.2) demonstrate that the plateau 
isotopic enrichment of [15N]ammonia is attained rapidly (probably within 
3h) and maintained for the duration of the infusion. There was no 
significant difference in the [15N]ammonia enrichment over the collection 
periods 3-6h, 6 -12h and 12-24h (analysis of variance, see 4 .4 ). In two  
subjects the rise to plateau enrichment of free plasma [15N]glycine was 
followed (Table 4 .3). The time to 90%  plateau enrichment was within 3h 
and was maintained for 24h, which is in accord with other published work 
(Cryer et al., 1986 ; Thompson et al., 1989).
These normal subjects did not undergo surgery and therefore 
sequential tissue samples were not taken to validate the plateau 
enrichment of intracellular free glycine. However, at this prime to infusion 
ratio the plateau 15N enrichment in urinary hippurate (reflecting liver 
intracellular [15]glycine enrichment) has been reported to be reached in 
approximately 2h (Cryer et al.,1986; Thompson et al., 1989). Therefore, it 
is probable that isotopic equilibrium in the liver occurs before this since 
there will be a delay in the excretion of hippurate into the urine. With 
reference to the continuous infusion of glycine in man there appears to be 
no information in the literature which allows us to determine the time taken 
to reach isotopic equilibrium in muscle. From work carried out in animals 
the time taken to reach a plateau of free [15N]glycine enrichment in muscle 
is considerably longer, due to its slow turnover rate and large pool size 
(Waterlow, Garlick and Millward, 1978i). However, even a 4 fold increase 
in the time taken to isotopic equilibrium in the muscle compared with liver 
(from the above discussion, approximately 2h for liver) would probably 
introduce no more than a 20%  overestimation (using a 20h continuous
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infusion) in the muscle protein fractional synthetic rate, calculated simply, 
as described above. The duration of the continuous infusion of 
[15N]glycine was determined not only by the aim to make protein synthetic 
measurements in the whole body, liver and muscle, but also the 
practicability of carrying out a continuous overnight infusion in hospitalised 
subjects. In previous work from this laboratory an 18h continuous infusion 
of [15Njglycine, using ammonia as an end-product, has been shown to be 
of sim ilar discrim inatory pow er as the urea end-product in the  
measurement of whole body protein turnover in normal and weight-losing 
cancer patients (Fearon, 1986; Fearon et al., 1988). Therefore, a primed 
continuous infusion of [15N]glycine of approximately 20h duration was 
used.
In summary, given that the protocol in the clinical studies (Chapters 
5 and 6) was to last 20 hours and that intrahepatic glycine would achieve 
isotopic equilibrium before urinary hippurate and urinary ammonia, any 
uncertainty in estimating the integrated precursor pool enrichment in the 
liver and presumably the muscle would introduce only a small error into 
the calculated fractional synthetic rate. From the above study, and the 
w ork of Jeevanandam  and coworkers (1 9 8 5 ), the sim ultaneous  
measurement of whole body and tissue protein synthetic rates in man 
using an intravenous infusion of [15N]glycine requires that the prime to 
infusion ratio should be between 30  and 80min and that ammonia should 
be used as the metabolic end-product. Therefore, the prime to infusion 
ratio of [15N]glycine chosen for the studies described in Chapters 5 and 6 
was 60min.
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4 .4  Statistical Methods
The statistical software used to carry out all comparisons of data 
was Minitab, release 7 (Minitab Inc., PA, USA.). All data is presented as 
individual values (except where the volume of data precluded such 
treatment) with the mean and standard deviation of the values to facilitate 
comparison with other work. Repeat measurements over time were 
assessed for statistical significance using the Kruskal Wallis test (analysis 
of variance). Paired and unpaired data from the studies presented in this 
thesis were tested for statistical significance using the Wilcoxon signed 
rank test and the Mann-whitney test respectively (Wallenstein, Zucker and 
Fleiss, 1980). Correlations between paired values was tested using simple 
regression statistics.
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Table 4.1.
Precision and accuracy of 13C and 15N isotope ratio 
analysis of plasma free leucine and alvcine
The precision and accuracy of the method was determined by 
repeated separation and analysis of plasma in which the 
free [15N]glycine enrichment was brought to 1.00 atom% by 
precise volumetric additions.
Mean isotope ratio analysis (n=4) 1.0034 atom% 15N
Standard deviation from the mean 0.0277 atom% 15N
Precision (CV) 2.77 %
Accuracy* 100.34 %
The precision and accuracy of the method was determined by 
repeated separation and analysis of plasma in which the 
free [13C]leucine enrichment was brought to 2.50 atom% by 
precise volumetric additions.
Mean isotope ratio analysis (n=4) 2.5902 atom% 13C
Standard deviation from the mean 0.1068 atom% 13C
Precision (CV) 4.12 %
Accuracy* 103.61 %
Accuracy was calculated according to the formula:
(1+(M measured isotope ratio-T isotope ratio)/T isotope
ratio))xlOO
CV, coefficient of variation = (Standard deviation/M)XlOO 
Where M is mean and T is true
Table 4.2
Urinary r15N1ammonia kinetics during a primed constant 
infusion of riSNIalvcine
0-3h
Urinary
3-6h 
[15N] ammonia
6-12h 
(atom%
12-24h
excess)
Subject A 0.0307 0.0385 0.0401 0.0412
B 0.0304 0.0401 0.0390 0.0412
C 0.0385 0.0427 0.0423 0.0449
D 0.0375 0.0415 0.0414 0.0423
Mean 0.0343 0.0407 0.0407 0.0424
S.D. 0.0043 0.0018 0.0014 0.0017
Measurement of urinary [15N]ammonia (atom% excess) during a 
primed (0.014mg/kg) constant 24h intravenous infusion 
(0.029mg/kg/h) of [^Njglycine in timed urine collections.
Table 4.3
Plasma alvcine kinetics during a primed constant infusion 
of ri5Nlglvcine
Time (h) Subject E Subject A
(% mean plateau enrichment)
0.33 59
0.66 58
1.5 74
2.0 72 58
3.0 106 88
4.0 90 113
5.0 124
6.0 121
8.0 110 90
10.0 85
12.0 114
16.0 117
24.0 78
Measurement of plasma glycine kinetics during a primed 
(0.014mg/kg) constant 24h intravenous infusion 
(0.029mg/kg/h) of [15N]glycine in two normal subjects. 
Values expressed as a percentage of the mean plateau 
enrichment.
title 4.4
f ilia tio n  o f [15N]glycine and [13C1leucine isotope enrichment. 
jlycine analysis
^ le
tion N, ugN 
I II 2
I 3
I 4
I 6
i 7
0.447 
0.693 
1.981 
2.444 
3.304 
2.366 
1.691 
1.113 
0.803 
0.531 
15.373 
12.899 
83.90685
, 9
10
jttal 
fract. 
lotal 
U e  3 
'faction N, ugN1I 2
i 3
I 4
i 5I 6
i 7
8I 9
10
ital
f r a c t .
lotal
0.417 
0.761 
1.89 
2.32 
2.989 
2.138 
1.532 
0.658 
0.452 
0.294 
13.451 
11.527 
85.69623
APE
0.0081
0.0412
0.0234
0.3497
0.5656
0.6569
0.5954
0.2641
0.0534
0.0194
0.436061
APE
0.0042
0.0121
0.0253
0.3188
0.5482
0.6368
0.5871
0.2634
0.0502
0.0111
0.421639
Sample 2
ngNl5 E C- 14(d|3m)ngN15 E C-14(dpm)
272
Fraction N, ugN APE
0.036207 1 0.821 0.0094 0.077174
0.285516 340 2 1.147 0.0478 0.548266 792
0.463554 833 3 1.745 0.2364 4.12518 2436
8.546668 2397 4 2.442 0.4337 10.59095 3668
18.68742 4437 5 3.411 0.592 20.19312 5530
15.54225 5151 6 2.523 0.6277 15.83687 5852
10.06821 3774 7 2.045 0.5689 11.63401 3696
2.939433 2057 8 1.153 0.1182 1.362846 1917
0.428802 1156 9 0.742 0.0239 0.177338 874
0.103014 527 10 0.478 0.0086 0.041108 328
57.10109 20944 Total 16.507 64.58686 25344
56.24755 18649 6 fract. 13.319 0.478587 63.74298 23099
98.50521 89.04221 % Total 
Sample 4
80.68698 98.69341 91 .14189
ngN15 E C-14(dpm)
226
Fraction N, ugN APE ngN!5 E C-14(dpm)
0.017514 1 0.656 0.0325 0.2132 204
0.092081 370 2 1.875 0.0734 1.37625 561
0.47817 913 3 2.311 0.2859 6.607149 1717
7.39616 2627 4 2.419 0.5706 13.80281 4403
16.3857 4859 5 3.431 0.7001 24.02043 5508
13.61478 5628 6 1.717 0.6469 11.10727 3621
8.994372 4131 7 1.815 0.3739 6.786285 1819
1.733172 2262 8 0.861 0.0777 0.668997 1037
0.226904 1273 9 0.37 0.0233 0.08621 323
0.032634 352 10 0.232 0.0193 0.044776 217
48.97149 22641 Total 15.687 64.71339 19410
48.60236 20420 6 fract. 12.554 0.501776 62.99295 18105
99.24623 90.19036 % Total 80.02805 97.34145 931.27666
aicine ana lysis
C, ugC 
0.878 
1.847 
2.704 
3.501 
4.29 
3.892 
3.751 
3.172 
2.132 
1.105 
27.272 
21.31 
78.13875
C, ugC 
0.914 
1.533 
2.399 
3.107 
3.685 
3.466 
3.23 
2.756 
1.852 
0.97 
23.912 
18.643 
77.96504
pie 5 
jract i on
I 2
I 3
I 4
56
7
8
9
10
fatal
1 fract. 
jlotal 
wple 7 
fraction
I 1
I 2
I 3
I \
I t
I 10
total 
i fract. 
\ Total
APE
0.0085
0.0126
0.0413
0.1701
0.1905
0.2823
0.2443
0.0901
0.0249
0.0185
0.179508
APE
0.0078
0.0117
0.0373
0.1521
0.1704
0.257
0.2422
0.0986
0.0282
0.0111
0.168148
ngC13 E 
0.07463 
0.232722 
1.116752 
5.955201 
8.17245 
10.98712 
9.163693 
2.857972 
0.530868 
0.204425 
39.29583 
38.25318 
97.34668
ngC13 E 
0.071292 
0.179361 
0.894827 
4.725747 
6.27924 
8.90762 
7.82306 
2.717416 
0.522264 
0.10767 
32.2285 
31.34791 
97.26768
C-14(dpm)
178
645
950
1275
2618
2996
2532
1773
1195
220
14382
12144
84.43888
C-14(dpm)
184
698
1266
2622
3084
2606
1924
1287
736
193
14600
12789
87.59589
Sample 6
Fraction C, ugC APE ngCl3 E C-14(dpm)
1931 0.821 0.0091 0.074711
2 1.732 0.0134 0.232088 682
3 2.521 0.0405 1.021005 990
4 3.228 0.1673 5.400444 1321
5 3.989 0.1871 7.463419 2703
6 3.386 0.2452 8.302472 2499
7 3.264 0.2122 6.926208 2112
8 2.76 0.0783 2.16108 1479
9 1.855 0.0231 0.428505 1003
10 1.009 0.0194 0.195746 229
Total 24.565 32.20568 13211
6 fract. 19.148 0.163331 31.27463 11104
% Total 77.9483 97.10905 84.05117
Sample 8
Fraction C, ugC APE ngCl3 E C-14(dpm)
2281 0.863 0.0077 0.066451
2 1.822 0.0114 0.207708 913
3 2.682 0.0349 0.305748 1353
4 3.432 0.1446 1.197768 1942
5 4.732 0.1625 6.842472 3996
6 3.051 0.2676 4.957875 3691
7 2.841 0.2316 7.602516 3115
8 2.402 0.0856 5.563032 2031
9 1.614 0.0254 1.381584 1171
10 0.774 0.0191 0.196596 268
Total 24.213 28.32175 18708
6 fract. 19.14 0.138294 26.46941 16128
% Total 79.04845 93.45966 86.20911
ibialysis of individual plasma samples for glycine enrichment (15N) and leucine enrichment (13C) as described 
jinsection 4.2.4. ugN ug nitrogen, APE atoiit% excess. ngNl5 E ngNlS excess, C-14(dpm) C-14(disintegrations 
tier minute), 6 fract. total for 6 fractions, % Total percentage of Total value.
Table 4.5
The recovery of expired 13CO2
Time Total C02 Total C02 13CO?
(APT
13co2
(apeT
H13C02 Infused h 13co2
(min) (ml/min) (mmol/min) (APE.mmo1/min) recovered
(%)
71.0
0
79 9.732
1.11327
1.14567 0.0324 0.4444
88 218 9.732 1.14993 0.03666 0.4444 80.3
96 218 9.732 1.14983 0.03656 0.4444 80.1
220 214 9.554 1.15426 0.04099 0.4444 88.1
231 214 9.554 1.15215 0.03888 0.4444 83.6
The recovery of expired 13C02 in a single subject (fasted for 12h) using 
a primed (0.38mmol) continuous infusion (4.54umol/min) of NaH13C03 
(99atom%, Tracer Technologies Inc. MA, USA).
An average of 80.6% of the labelled bicarbonate was recovered as expired
It was calculated as follows;
((Total C02 (mmol/min)x 13C02 (APE))/ H13C02 Infused (APE.mmol/min))xlOO 
AP atom%, APE atom% excess
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Figure 4.4 Analysis of the leucine peak eluted from cation-exchange high performance 
liquid chromatography separation of amino acids. The shaded area represents the 
fractions taken for the weighted average calculation of the isotopic enrichment of 
[l3C]leucine (carbon blank subtracted from each fraction), that is, the weighted average 
isotopic enrichment from the 6 fractions (multiplied by 6, to account for only 1 of the 6 
carbon atoms in [13C]leucine being labelled). The area under the peak used in the 
calculation was more than 80% of the total carbon measured (confirmed by [14C]leucine).
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Figure 4.5 Analysis of the glycine peak eluted from cation-exchange high performance 
liquid chromatography separation of amino acids.The shaded area represents the 
fractions taken for the weighted average calculation of the isotopic enrichment of 
[15N]glycine, that is , the weighted average isotopic enrichment from the 6 fractions.
The area under the peak used in the calculation was more than 80% of the total nitrogen 
measured in the peak (confirmed by [14C]glycine).
CHAPTER 5: THE SIMULTANEOUS MEASUREMENT OF WHOLE BODY. 
FIXED LIVER AND MUSCLE PROTEIN SYNTHETIC RATES IN NORMAL 
SUBJECTS USING f15N1GLYCINE AND ri3Cll_EUCINE
5.1 Introduction
As discussed in Chapter 2, in order to measure simultaneously 
whole body, liver and muscle protein synthetic rates a primed constant 
infusion protocol can be used. However, there is still the question as to 
which amino acid would be the most representative tracer in the clinical 
situation? Most recently [15N]glycine or [13C]leucine have been used in 
human studies. Leucine has been used more frequently in fractional 
synthesis measurements in man, particularly with reference to muscle. This 
has followed the move away from the use of [15N]glycine to measure 
whole body protein synthesis due to the uncertainty over which  
end-product to measure and the many metabolic routes that the nitrogen 
label can take. Nevertheless, both amino acids appear to have similar 
discriminatory power when applied various disease states and starvation 
(Garlick and Fern, 1985).
One of the major differences between glycine and leucine based 
methodologies is that the latter is a branched chain essential amino and an 
isotope of carbon is used to label the amino acid. Whereas, glycine is a 
non-essential amino acid and a nitrogen label is used. Therefore, with 
reference to liver, where the branched chain amino acids (in contrast to 
glycine and the other amino acids) pass through the liver without their 
blood concentration being altered significantly, the protein synthetic rates 
measured by these amino acids could be different. Finally, the use of these 
amino acids to measure whole body protein turnover requires different 
protocols: leucine has a small metabolic pool and rapid turnover whereas
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glycine has a large metabolic pool and slower turnover rate. The result of 
this is that to measure whole body protein synthesis, depending on the 
size of the priming dose, a leucine protocol takes 4 -12h and the glycine 
protocol 12-24h.
In deciding which tracer to use for the present study the following 
criteria were considered to be important.
(a) that the tracer give valid fractional synthetic rates using the analytical 
approach described in Chapters 3 and 4.
(b) that the tracer give valid fractional synthetic rates when the tissue 
samples are taken during an operative procedure.
With reference to (a) an important consideration in our analytical 
approach is the amount of sample required for mass spectrometric 
analysis. Although the Continuous Flow-lsotope Ratio Mass Spectrometer 
was optimised for small sample analysis approximately lumole of the 
amino acid was required for reliable analysis. The concentration of free 
amino acids is generally higher in the intracellular compartment and the 
ratio of tissue to plasma concentration varies considerably for each amino 
acid. In the rat the tissue to plasma ratio for leucine is 2.1 in liver and 0 .6  
in muscle whereas, for glycine it is 10.1 in liver and 13.6 in muscle (Lunn, 
Whitehead and Baker, 1976). In man there appears to be no published 
values for liver but, in muscle the ratio for leucine is 1.2 and for glycine is 
6.5 (Bergstrom et al., 1974). Therefore, depending on the size of the 
biopsy the amount of free leucine in both liver and skeletal muscle will be 
much less than glycine and may be below the amount required for isotopic 
analysis by Continuous Flow-lsotope Ratio Mass Spectrometry.
With reference to criteria (b), when biopsies are removed in an 
operative protocol, consideration must be given to the effect of 
anaesthesia on the measurement of fractional synthetic rates. There is
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evidence that anaesthesia alters protein synthesis in different tissues (Heys 
et a l.,1989; Ferguson et al., 1989). Furthermore, it has been suggested 
that pre-medication alters the concentration and enrichment of plasma 
leucine (and presumably intracellular leucine) (Rennie and MacLennan, 
1985). Therefore, as the fractional synthetic rate is calculated from the 
precursor amino acid enrichment and the enrichment of the amino acid 
incorporated into tissue protein then alteration of either of these 
parameters by anaesthetic work-up will result in an inaccurate estimate of 
the fractional synthetic rate.
The aim of the study reported in this Chapter was to establish, in 
otherwise healthy individuals, which amino acid would best estimate whole 
body, liver and muscle protein synthetic rates with biopsies taken at the 
time of elective surgery. The more reliable method would then be used to 
examine the basis of increased whole body protein turnover in cancer 
cachexia.
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5.2  Materials and methods
5.2.1 Subjects
Six patients with cholelithiasis whose last attack of cholecystitis had 
been at least three months prior to surgery, who had normal biochemical 
liver function tests and no history of jaundice were studied. The patients 
had been admitted for elective cholecystectomy and were weight stable. 
They were weighed (by myself and another investigator) wearing light 
night attire on beam balance standing scales in the morning of the day that 
the [15N]glycine infusion was commenced (Weylux 424, UK.). The balance 
used was accurate to 0.1kg and therefore when the weight of the 
individual was expressed to the nearest kg no error in the measurement 
was apparent.
These subjects were selected since they were healthy individuals in 
all respects except that they had gallstones and required a laparotomy at 
which incidental muscle and liver biopsies could be obtained. They had no 
evidence of an acute phase response and were judged clinically to be free 
of other metabolic or endocrine disorders. None were pyrexial, had clinical 
or radiological evidence of infection, were receiving steroids, or severely 
anaemic. All patients had a normal serum urea and creatinine. The study 
was approved by the local ethical committee. All patients were informed of 
the purpose and procedure of the study and all gave written consent.
5 .2 .2  Experimental design (Figure 5.1)
Following a twelve hour fast, a urine sample was collected for 
baseline enrichment measurement of urinary ammonia. A catheter was 
inserted into an antecubital vein of each arm. One catheter was used for 
the infusion of [15N]glycine and the other for sampling blood. Prior to the
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start of the infusion, 10ml of blood (heparinised) was taken for basal 15N 
enrichment of free glycine and 13C enrichment of free leucine and blood 
analyses. A further 10ml of blood was taken and divided between EDTA 
and plain glass containers (see analyses Chapter 3). The infusate and drip 
set were connected to the subject via a volume infusion pump (IVAC 
Corp., CA., U.S.A.) which had been calibrated over two 24h periods. A 
primed (4.2m g) constant 20h intravenous infusion (100m g/24h) of 
[15N]glycine (99atom%, Tracer Technologies Inc. MA, USA.) was then 
commenced at 18:00 on the day before the operation. All voided urine was 
collected for the next 18h, providing estimates of nitrogen, creatinine and 
3-methylhistidine excretion. In the present study the urinary nitrogen 
collection was over the last 18h of a 30h fasting period. Therefore, the 
effect of the lag in reduced urinary nitrogen excretion, postabsorptively, 
would be unlikely to cause a serious error in the nitrogen excretion 
estimate (Munro, 1964) and so correction, for changes in the plasma urea 
concentration over this period, of this estimate was not applied (Fern et 
al., 1981). A spot urine sample was taken at 18h to determine 15N 
enrichment of ammonia at plateau. After 15h of the glycine infusion the 
leucine protocol was started. This consisted of a bolus of NaH13C 03 
(57mg) and [13C]leucine (65mg) followed by a constant intravenous 
infusion of [13C]leucine (65mg/h) over approximately 6h. Further plasma 
samples were taken just before the start of the leucine infusion, at 120 
and 60min prior to surgery and at the time of surgery after induction of 
anaesthesia. These samples were used to establish the plateau enrichment 
of free [15N]glycine and [13C]leucine and their concentration in plasma 
before and during anaesthetic work up. The plasma was separated by 
centrifugation at 1500g for 10min at 4°C and promptly frozen at -30°C. 
Within 10min of the start of the operation (14:00) a wedge liver biopsy
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was taken together with a biopsy of rectus abdominus muscle (wet weight 
215-859m g, Table 5.3a) and rapidly frozen at -80°C . From these biopsies 
isotopic enrichment of the labelled amino acids in the free amino acids and 
protein hydrolysate was measured. In addition, the total RNA and free 
amino acid concentrations of the liver and muscle biopsies was measured.
5 .2 .3  Analytical Methods
Reagents; All reagents used were analytical grade and water was 
doubly distilled and deionised (18Mohm).
Isotopic m easurem ents: The study protocol involved the 
measurement of 15N and 13C in three different sample matrices: urine 
(ammonia) or breath (C 02), plasma and liver or muscle tissue. Sample 
preparation and tracer analysis was as described in sections 3 .4  and 4.2.
Resting energy expenditure: Resting energy expenditure and 
respiratory quotient were measured using an indirect calorimeter with a 
rigid canopy (Kinney et al., 1964) as described in section 3 .6 .5 . Each 
resting energy expenditure study began at 09:30h on the day of the 
operation. Prior to each study, patients remained in bed from the time of 
wakening.
Tissue R.N.A. analysis: R.N.A. was analysed by U.V. absorption of 
the supernatant following extraction from tissue (dry weight 20mg) with 
perchloric acid (Chapter 3).
A nalysis  of plasma album in and in trace llu la r am ino acid 
c o n cen tra tio n s , to g e th er w ith  urinary n itro gen , c rea tin in e  and 
3-methylhistine concentration were carried out as described in Chapter 3.
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5.2 .4 Calculations
As discussed in Chapter 2 (2.2, 2.3) whole body protein turnover 
can be derived from the whole body amino acid flux measurements by 
using a simplified model of protein metabolism (Figure 2.1). In this model, 
the labelled amino acid enters a single free amino acid pool from which it 
can either be oxidised, giving rise to labelled C 0 2 or urinary nitrogen (e) or 
it can be incorporated into protein. In this study whole body amino acid 
flux has been measured by a continuous infusion of [13C]leucine and 
[15N]glycine under assumed steady state conditions. Whole body protein 
turnover from such measurements involves different calculations for each 
labelled amino acid.
From section 2.2, using [13C]leucine, amino acid flux can be 
calculated from the expression
Q = i [Ej/Ep-1 ]
Where i is the infusion rate (umol/kg/h), Ej is the enrichment of the 
[13C]leucine infused (atom% excess) and Ep is the [13C]leucine enrichment 
in plasma at isotopic equilibrium (atom% excess). The rate of 13C 0 2 
released by leucine oxidation (umol 13C/kg/h),
e = [FC02x EC0 2/W ] x [60x41.6 /100x0.81]
Where F C 02 is the C 0 2 production (ml/min), EC 02 is the 13C 0 2 
enrichment in expired air at isotopic steady state (atom% excess) and W , 
the subject's weight (kg). The constants 60min/h and 41.6umol/ml (at 
standard temperature and pressure) convert FC02 to umol/h, the factor 
100 changes atom% excess from a percent to a fraction and the factor 
0.81 accounts for the fraction of 13C 0 2 released by [13C]leucine oxidation 
but not released from the body bicarbonate pool into expired air (see 
section 4 .3 , Table 4 .5 , Wolfe, 1984b). The rate of leucine oxidation is 
given by
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E = e/[Ep-Ej] x 100 
from which the rate of leucine incorporation into protein can be calculated 
S = Q -  E
Both estimate of rates of leucine flux (Q) and rates of leucine incorporation 
into protein (S) are expressed as umol/lg/h. The values can be converted 
to give estimates of whole body protein turnover and whole body protein 
synthesis in gProtein/kg/d by multiplying the leucine values by the constant 
[Y/241/590 where the term Y /24  normalises the infusion time Yh to 1 day 
and the term 590 converts umol leucine to gram protein. The 590umol 
leucine/g protein factor is from Matthews and coworkers (1980) who 
derived it by averaging values for leucine content of protein in human flesh 
and other mammalian muscles. Clearly, the leucine content of whole-body 
protein (a heterogenous group of proteins with different turnover rates) can 
only be an estimate and therefore values for whole body protein turnover 
calculated from values for leucine turnover must also be estimates.
From section 2.3 using [15N]glycine, the total nitrogen turnover 
(flux) can be calculated from the expression 
Q = d /  Smax
Where d is the infusion rate (mg15N/kg/h), Smax is the 15N enrichment in 
urinary ammonia at isotopic equilibrium (atom% excess) and Q is 
mgN/kg/h. Total nitrogen synthesis can be calculated 
S = Q - E
Where E is the nitrogen excretion (gN) over the period of the infusion. The 
values can be converted to give estimates of whole body protein turnover 
and whole body protein synthesis in gProtein/kg/d by multiplying the 
nitrogen values by the constant [Y /24 ]x6 .25  where the term Y /24  
normalises the infusion time Yh to 1 day and the term 6.25 converts gram 
nitrogen to gram protein (Picou and Taylor-Roberts, 1969). Faecal and
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insensible nitrogen losses were not measured or corrected for since the 
error likely to be introduced into the calculation of whole body protein 
synthesis, in a fasting protocol, would be less than 5%  (Cheng et al., 
1978; Calloway, Odell and Margen, 1971), and is less than the variability 
of the method (Preston, 1987).
In order to calculate tissue protein synthesis the uptake of the tracer 
from the plasma or intracellular fluid into liver and muscle protein is 
measured. The rate of tissue protein synthesis was calculated from the 
simple formula;
Ks = P(t)x100/A
Where Ks is the fractional rate of protein synthesis (%/day), P(t) is the 
enrichment of labelled amino acid in liver or muscle protein (corrected for 
the natural background enrichment in the plasma free amino acid) at the 
end of the incorporation period (atom% excess) and A is the area under 
the curve for precursor enrichment (atom% excess x infusion time of the 
labelled amino acid). As stated earlier (see 4.3) the measurement of protein 
fractional synthetic rates using the above formula assumes that the plateau 
isotopic enrichment in the free amino acid precursor pool is attained rapidly 
and maintained throughout the duration of the infusion of the labelled 
amino acid. It would appear from the literature and work presented in this 
thesis (see 4.3) that this approach is not in serious error.
The liver fractional synthetic rate was calculated using either the 
15N enrichment of plasma free glycine to represent the precursor pool or 
the 15N enrichment of free glycine from the liver homogenate. The liver 
fractional synthetic rate was calculated using the 13C enrichment of 
plasma free leucine to represent the precursor pool as there was 
insufficient sample to measure the isotopic enrichment of free leucine from 
the homogenate. The rate of hepatic protein synthesis in grams per day
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was calculated assuming that liver mass is 2%  of body weight and that 
146g/kg of liver is protein (Geigy Scientific Tables). The muscle fractional 
synthetic rate was calculated using either the 15N enrichment of plasma 
free glycine to represent the precursor pool or the 15N enrichment of free 
glycine from the muscle homogenate. The rate of muscle protein synthesis 
in grams per day was calculated assuming that muscle mass is 29 .3%  of 
body weight and that 172g/kg of muscle is protein (ICRP, 1975).
Data is presented as the mean value and standard deviation.
5 .3  Results
The clinical features of the subjects are shown in Table 5.1. The 
subjects were all female, weight stable and had albumin concentrations in 
the normal range (36-44g/l). The body mass index (Weight/(Height2)) of 
subjects is shown in Table 5.1.
Individual rates of whole body protein turnover, whole body protein 
synthesis, urinary nitrogen excretion and resting energy expenditure are 
presented in Table 5.2. The mean rates of whole body protein turnover and 
synthesis measured using [15N]glycine were 3 .5  and 3.1gP /kg /d  
respectively. In contrast, the mean rates of whole body protein turnover 
and synthesis measured using [13C]leucine were 3 .8  and 3.5gP/kg/d 
respectively. Mean urinary nitrogen excretion was 4.2gN/d and resting 
energy expenditure 1757kcals/d.
Tissue protein synthesis rates are shown in Tables 5.3 and 5.4. The 
sample from subject 4  was lost during sample preparation (Table 5.4). It 
must be emphasised, with reference to the liver, that in the prolonged 
constant infusion protocol the rates of synthesis measured are 
predominantly of fixed hepatic proteins. This is due to labelled amino acid 
which is incorporated into synthesised liver export proteins being rapidly
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removed from the liver. When the isotopic enrichment of plasma free 
glycine was taken to represent the enrichment in the precursor pool (for 
protein synthesis) the mean values for the liver and muscle protein 
fractional synthetic rates were 8.1 and 2.3% /d respectively. In contrast, 
when the isotopic enrichments of free glycine derived from the liver and 
muscle homogenates, were taken to represent the precursor pool 
enrichment these rates increased to 10.9 and 2 .8% /d. The mean rates of 
liver and muscle protein synthesis expressed in grams of protein were 
calculated to be 21 .9  and 96.4gP/kg/d respectively. These rates were 
calculated using the enrichment of free glycine in the tissue homogenate 
and assumed that liver weight was 2%  of total body weight and that 146g 
in each kg of liver was protein (Geigy Scientific Tables). Similarly, it was 
assumed, in this group of females, that muscle weight was 29 .3%  of total 
body weight and that 172g in each kg of muscle was protein (ICRP 23, 
1975). When fixed liver and muscle protein synthesis was calculated as a 
proportion of whole body protein synthesis the mean values were found to 
be 11.3 and 50 .1%  respectively.
Insufficient sample was available to measure the isotopic enrichment 
of free leucine derived from the homogenate and because of this the 
measurement of [13C]leucine incorporation in the muscle biopsies was not 
carried out. However, if the isotopic enrichment of plasma free leucine is 
taken to represent the enrichment in the precursor pool for protein 
synthesis the mean value for the liver protein fractional synthetic rate was
7.1 %/d (Table 5.5). The mean rate of liver protein synthesis expressed in 
grams of protein was calculated to be 13.9gP/kg/d. This was calculated 
using the same assumptions as described above for tissue mass and 
protein content. When liver protein synthesis was calculated as a 
proportion of whole body protein synthesis the mean value was found to
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be 5 .9% . The isotope enrichment data, from which whole body and tissue 
protein fractional synthetic rates were calculated, for [15N]glycine and 
[13C]leucine are presented in Tables 5 .12  and 5 .13 respectively.
The enrichment of [15N]glycine and [13C]leucine in plasma was 
measured in samples taken 120, 60 and Omin before the start of surgery 
(Table 5.6). [15N]glycine and [13C]leucine enrichment measurements at 
these time-points were not significantly different.
The mean value for liver RNA concentration was 4.2ugRNA/mg 
protein and for muscle 0.5ugRNA/mg protein (Table 5.10).
The plasma amino acid concentrations just before the start of the 
leucine infusion and at the time of induction of anaesthesia are shown in 
Table 5 .7 . There was a significant increase in leucine (p < 0 .0 5 )  
concentration although there were no significant changes in the total or 
essential amino acids concentrations.
The free amino acid profile of the liver and skeletal muscle biopsies 
are shown in Table 5.8. The mean total amino acid concentrations were 
210 and 1 17nmol/mg wet weight respectively.
Urinary creatinine and 3-Methylhistidine excretion are shown in 
Table 5 .9 . The mean creatinine excretion in the 18hr urine collection was 
4.5mmol/l. The mean excretion of 3-Methylhistidine was 32umol/mmol 
creatinine.
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5.4 Discussion
In this study whole body protein turnover and synthesis values using 
[15N]glycine or [13C]leucine were similar to those obtained in previous 
work from this laboratory (Fearon et al.f 1988) and other published work 
(Chapter 7, Table 2). The use of an ammonia end-product alone 
underestimates whole body protein turnover compared to urea and the 
end-product average (Fern and Garlick, 1985a). However, the ammonia 
end-product has been shown to have similar discriminatory power as urea 
in comparative studies (Fearon et al.f 1988; see section 7 .2 .2 , Table 7.2). 
The whole body turnover and synthesis values measured by [15N]glycine 
and [13C]leucine did not rank with each other as reported by other workers 
(Golden and Waterlow, 1977). Nor did they rank with urinary nitrogen or 
resting energy expenditure. Furthermore, there was no significant 
correlation (section 4 .4) between urinary nitrogen excretion and measured 
resting energy expenditure although such a positive relationship has been 
suggested by Kinney (1988). All the subjects were over-weight as defined 
by the body mass index (Table 5 .1 , Owen, 1988).
One potential criticism of the use of a prolonged infusion of a 
labelled amino acid is that, because it can be incorporated into and 
released from protein over the time of the infusion, there may be recycling 
of the label and this could result in significant errors in the flux 
measurement. Schwenk and coworkers (1985) reported that when a 
[13C]leucine infusion was given to normal subjects for 4h and 24h this 
resulted in a 25%  underestimate of the leucine flux in the 24h compared to 
the 4h infusion. They attributed the difference in the flux measurement to 
the recycling of label. There was, however, no evidence of recycling over 
the 4h infusion and they concluded that it occurred after this time. 
Therefore, with respect to the duration of [13C]leucine infusion in this
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study (approximately 5h) it is likely that there was no significant recycling 
of the label. In the present study the [15N]glycine infusion lasted 
approximately 20h and therefore it is possible that significant recycling 
may have occurred. However, the shorter infusion duration of [13C]leucine 
compared to that of [15N]glycine would not necessarily result in 
proportionately less recycling since the free leucine and end-product pool 
sizes are some 5 fold smaller (see section 5.1) and therefore respond more 
rapidly to label re-entry. Furthermore, using a 20h infusion of [15N]glycine, 
there was little evidence of significant recycling, which would be 
demonstrated by a continuing positive gradient in the urinary ammonia or 
plasma glycine enrichment data (Tables 4 .2 , 4 .3 , 5.6), or indeed gross 
underestimation of rates of whole body protein turnover (see discussion 
above). Lastly, the prime to infusion ratio chosen (see 4.3) for the 
continuous infusion of [15N]glycine is unlikely to result in the precursor 
pool enrichment rising substantially above the final plateau isotopic 
enrichment in tissues given the data in the literature (Cryer et al., 1986; 
Thompson et al., 1989) and Tables 4 .2 , 4 .3 . Therefore, it would appear 
that the duration of the primed continuous infusions of [13C]leucine and 
[15N]glycine used in this study were not associated with significant label 
recycling.
It has been reported, using a continuous infusion of [13C]leucine, 
that premedication and the induction of anaesthesia results in acute 
changes in the enrichment of plasma leucine (Rennie and Maclennan, 
1985). These changes are not consistent with a steady state and may 
therefore invalidate calculation of whole body and fractional protein 
synthetic rate measurements using models which assume steady state 
kinetics. In order to establish whether such changes in plasma [15N]glycine 
and [13C]leucine enrichment were evident in the current protocol, plasma
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samples were taken 120 and 60min before, and also at the time of biopsy. 
The mean values for the 6 patients at each time point is given in Table 5.6 . 
There was no significant difference (analysis of variance, see 4 .4) in the 
plasma glycine or leucine enrichment between the time points leading up to 
the operation. This suggests that with glycine and leucine a stable plateau 
of isotopic enrichment was maintained and thus steady state kinetics could 
be used to calculate results.
Unfortunately, there was insufficient free leucine in the tissue 
homogenate for isotopic analysis by the analytical methods used. 
Nevertheless, when plasma leucine enrichment was used to calculate the 
liver protein fractional synthetic rate, the values obtained ranked 
approximately to those when plasma glycine enrichment was used (Tables 
5.3, 5.5). Therefore, with the protocol and methodology used in the 
present study and if it can be assumed that the plasma free amino acid 
enrichment is a valid estimate of the true precursor enrichment (for protein 
synthesis, see section 2.4), it would appear that either tracer is suitable for 
the measurement of whole body and tissue protein fractional synthetic 
rates. However, in this work, the precision and accuracy of [13C]leucine 
enrichment measurement was poorer than that of [15N]glycine (see section 
4.2 .5 ). Furthermore, the plasma [13C]leucine enrichment measurements 
were more variable than those of [15N]glycine (Table 5 .13 , 5 .12). With 
reference to the criteria in the introduction (see section 5.1) it would 
appear that [15N]glycine best estimates whole body, liver and skeletal 
muscle protein fractional synthetic rates. Therefore, [15N]glycine was 
chosen for the study of protein synthetic rates in weight-losing cancer 
patients described in Chapter 6.
It has been suggested that the enrichment of free glycine in tissue 
homogenate estimates better the true precursor enrichment for protein
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synthesis than that in plasma (Fern and Garlick, 1974). The large 
concentration gradient between intracellular free glycine and plasma free 
glycine concentrations (see Tables 5.7 , 5.8) may also be indicative of the 
likely source of glycine to charge t-RNA. The fractional synthetic rate for 
hepatic fixed protein was found to be 10.8% /d (Table 5.3) when estimated 
from homogenate free glycine enrichment. This was calculated to represent 
the synthesis of approximately 22g of protein per day and would therefore 
account for 11.3%  of protein synthesis in the whole body. Comparative 
data from other studies is very scarce. In one of the few reported studies 
in humans, Stein and coworkers determined the fixed hepatic protein 
fractional synthetic rate to be approximately 1 5 %/d (Stein et al, 1978a). 
How ever, the latter study was on cancer patients in which the 
incorporation of 15N into the alpha amino nitrogen of liver protein was 
measured and therefore the results are not directly comparable since the 
hepatic free alpha amino pool has a very different composition to that of 
the protein bound pool. Data on fixed hepatic protein synthesis in animals 
is also limited but it has been reported that in pigs (approximately 75kg), 
fixed liver protein synthesis is 23.3% /d, accounting for 10.0%  of the 
whole body protein synthesis rate (Garlick, Burk and Swick, 1976).
Fractional synthetic rates for total liver protein synthesis in growing 
lambs, rats and piglets have been reported to be between 70-115% /d, 
accounting for 12-15%  of whole body protein synthesis (Attaix et al.,
1988). In comparison with values for adults such higher fractional 
synthetic rates reflect the fact that these animals are generally of lower 
body weight and are growing. In contrast, there is no published data on 
total liver protein synthesis in man. However, there is data on the major 
liver export protein, albumin, which accounts for approximately 70%  of the 
protein secreted by the liver in normal man (Fleck, Colley and Myers,
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1985). Indeed, a similar protocol to that described in this work has been 
used to measure the fractional synthetic rates of liver export proteins via 
the incorporation of [15N]glycine into plasma albumin and fibrinogen 
(Gersovitz et al., 1980; Thompson et al., 1989). The albumin synthetic 
rate has been reported to be 4-6% /d of whole body protein synthesis 
(Gersovitz et al., 1980). Using these results and the data in Table 5.3 total 
liver synthesis would account for 17-20% /d in normal man. It would 
appear, therefore, that hepatic protein synthesis contributes substantially 
to the rate of protein synthesis in the whole body and may thus account 
for a significant proportion of whole body protein synthesis observed in 
disease states.
Measurement of skeletal muscle protein synthesis in human studies 
has been mainly carried out using [13C]leucine with sampling from the 
vastus laterlis muscle. Therefore, some caution must be taken in 
comparing values in the literature with those obtained in the present study 
(using [15N]glycine and sampling from the rectus abdominus muscle). What 
is clear is that the values obtained using [15N]glycine show greater 
variation and are higher than those obtained by other workers using 
[13C]leucine (Table 5.11) but are similar to those obtained by Halliday and 
McKeran (1975) using [15N]lysine (sampling vastus laterlis muscle). 
However, the values for muscle protein synthetic rates given in Table 5.11 
have assumed either the plasma or intracellular precursor isotopic 
enrichment to be the best estimate of the true precursor (see section 2.4) 
and therefore it is not surprising that the measured synthetic rates are 
quite different. The effect of using the plasma or intracellular amino acid 
enrichment for the calculation of the muscle protein fractional synthetic 
rate is considered further in section 7.4.
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It has been demonstrated in animal studies that biopsies from 
different muscle sites have different synthetic rates. For example, in the 
fully grown rat the fractional synthetic rate of the soleus and diaphragm 
muscles is approximately double that in the gastrocnemius and plantaris 
muscles (Waterlow, Garlick and Millward, 1978e). This is thought to be 
due to the fact that certain muscles such as rectus abdominus are aerobic 
in type whereas others such as vastus lateralis are anaerobic. Furthermore, 
different amino acids are likely to give the different values for muscle 
protein synthesis (Waterlow, Garlick and Millward, 1978f), presumably due 
to differences in their metabolism and the amounts in the tissue (for further 
discussion see section 7.4). Halliday and McKeran (1975) estimated that 
muscle protein synthesis accounted for approximately 53%  of whole body 
protein synthesis in fasted normal subjects. However, using [13C]leucine 
Rennie and coworkers, (1982a) estimated this value to be 43% . These 
values are similar to those in the present study where skeletal muscle 
protein synthesis was estimated to be 50%  of whole body protein 
synthesis. In contrast, Young and Munro (1978) estimated indirectly that 
muscle protein synthesis probably accounts for about 30%  of whole body 
protein turnover.
It is clear from the literature that interpretation of blood or tissue 
amino acid profiles must be carried out with a view to the method and 
conditions of sampling. In the present study the tissue biopsies were taken 
at the start of surgery (within 10 minutes of skin incision) and the plasma 
samples taken at the induction of anaesthesia. Therefore, it is not 
surprising that the amino acid profiles that were obtained from the tissues 
in this study are different from those obtained in studies involving 
non-operative biopsy procedures e.g., needle biopsy. In the baseline 
plasma samples (Table 5.7) the most significant difference in the amino
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acid profile was the low glutamine concentration (when compared to the 
normal range, Table 5.7). This may be characteristic of this group of 
patients since most of the other amino acids in the profile are depressed. 
Alternatively, it could be due to stress or the postabsorbtive state. Studies 
in the rat in the postabsorbtive state suggest that glutamine is extracted by 
the gut as a source of nitrogen and used for the synthesis of alanine which 
is then released by these tissues (Matsutka et al., 1973). The amino acid 
profile of the pre-operative plasma samples (Table 5.7) taken just prior to 
surgery was not significantly different from that of the baseline samples 
with the exception of the leucine concentration which was increased 
significantly (p < 0 .0 5 ). This confirms the observation of Rennie and 
M aclennan, (1 9 8 5 ) who attributed an increased plasma leucine 
concentration to the effect of premedication and/or anaesthesia. 
Alternatively, the increase in plasma leucine concentration may be due to 
the on-going leucine infusion. Interpretation of the tissue free amino acid 
profiles is difficult, as there are few literature values for man obtained 
under similar conditions (especially liver).
The free glutamine concentrations of the liver biopsies obtained in 
the present study were very low whereas, glutamate and histidine 
concentrations were very high when compared to the normal rat liver 
(Herbert, Coulson and Hernandez, 1966). It has been shown in rats that 
liver protein synthesis is reduced rapidly on the induction of anaesthesia by 
up to 37% . Furthermore, there is some evidence that premedication has a 
similar effect (Heys et al., 1989). However, it is not known what effect 
premedication/anaesthesia has on the free amino acid profile of the 
rat/human liver. It may be that the general prominence of glutamate 
reflects increased transamination in the liver at this time.
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The amino acid profiles of the skeletal muscle biopsies (rectus 
abdominus) in the present study are very similar to those of muscle taken 
by needle biopsy, except that alanine is markedly increased (Wernerman et 
al, 1985). However, a similar pattern has been reported by Wernerman et 
al, (1985) after a 1h infusion of stress hormones. The lack of alteration in 
the amino acid profile as a whole is in accord with the small effect of 
premedication/anaesthesia on skeletal muscle protein synthesis (Heys et 
al., 1989).
The variability of the amount of RNA per unit protein is much greater 
than previously reported (Millward et al., 1973; Jepson and Millward,
1989). The method has been used by a number of workers and gave 
reasonable precision with a normal liver biopsy (see section 3 .5 .3 ). 
Furthermore, the study samples were carefully treated prior to RNA 
analysis. Therefore, it is not clear what the source of variability was in the 
method used. However, it is clear with such variability of the data, 
interpretation must be limited.
The resting expenditure measurements and their variability observed 
in the normal subjects, in the present study, was similar to that reported 
previously for other groups of normal individuals (Fearon et al., 1988; 
Melville et al., 1990). The liver and skeletal muscle together probably 
account for the major part of protein turnover in the whole body 
(Waterlow, Garlick and Millward, 1978b) (approximately 60%  for fixed 
liver and skeletal muscle protein synthesis in this study). Furthermore, the 
minimum proportion of energy expenditure associated w ith protein 
synthesis is thought to be approximately 15-25%  of the total body heat 
production (Reeds, Wahle and Haggerty, 1982). In various disease states 
protein synthesis rates in these compartments may differ widely, the 
balance being reflected in whole body protein synthesis. It has been
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reported that the rate of whole body protein turnover derived from labelled 
amino acid kinetics is increased in cancer (Jeevanandam et al., 1984; 
Fearon et al., 1988). However, the magnitude of the change observed in 
such studies without an accompanying increase in energy expenditure has 
led some authors to question the nature of the relationship between tracer 
amino acid kinetics and actual whole body protein turnover (Clague et al., 
1982; Fearon et al., 1988). Therefore, measurement of whole body and 
tissue synthetic rates in weight-losing cancer patients might allow some 
resolution of these apparently contradictory findings. The results of such a 
study are reported in the following Chapter (6).
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Table 5.1
Characteristics of oatients studied as 'h ealthv'
individuals
Age Sex Weight Height BMI Albumin
(yrs) (kg) (cm) (g /D
Subj ect 1 70 F 74 157 30 40
2 53 F 69 157 28 40
3 74 F 60 152 26 39
4 67 F 70 152 30 43
5 58 F 58 152 25 41
6 39 F 86 155 36 41
Mean 60 70 154 29 41
S.D. 13 10 2 4 1
BMI, Body Mass Index=weight(kg)/[height(m)]2
Table 5.2
Whole body protein kinetics and resting enercrv expenditure 
in healthy subjects
[15N] glycine [13C] leucine
WBPT WBPS WBPT WBPS Urinary N REE
(gP/kg/d) (gP/kg/d) (mgN/kg/d) (kcals/kg/d)
Subject 1 3.5 3.3 3.3 3.1 35.1 18.1
2 2.9 2.4 3.7 3.3 69.5 29.4
3 5.4 5.1 3.8 3.6 51.6 29.6
4 2.9 2.6 4.7 4.5 51.4 20.4
5 2.3 2.0 4.8 4.5 46.5 29.5
6 4.0 3.4 2.4 2.2 94.1 26.2
Mean 3.5 3.1 3.8 3.5 58.0 25.5
S.D. 1.1 1.1 0.9 0.9 20.9 5.1
Whole Body Protein Turnover: WBPT, Whole Body Protein
Synthesis: WBPS, Grams protein per kilogram per day:
gP/kg/d, Daily urinary nitrogen excretion derived from 18 h
collection taken prior to surgery: Urinary N. Resting
energy expenditure: REE, kilocalories per day: kcals/d.
Table 5.2a
Resting energy expenditure and respiratory quotient in 
healthy subjects
VC02 VO 2 RQ REE
(1/min) (1/min) (kcal/d)
Subj ect 1 0.152 0.195 0.78 1336
2 0.246 0.293 0.84 2035
3 0.206 0.258 0.80 1775
4 0.168 0.207 0.81 1429
5 0.199 0.249 0.80 1714
6 0.275 0.324 0.85 2255
Mean 0.208 0.254 0.81 1757
S.D. 0.046 0.049 0.03 350
VC02, carbon dioxide production; V02 , oxygen consumption;
RQ, respiratory quotient; REE, resting energy expenditure; 
REE (kcal/d) = (3 . 9V02+1. 1VC02) X1440 
RQ= VC02/V02
Table 5.3
Liver orotein svnthetic rates in healthv subiects measured
usincr r 15N1crlvcine
HFSR(LHP) HFSR(PP) HPS(LHP) HPS(LHP)/WBPS
(%/d) (%/d) (gP/d) (%)
Subject 1 10.9 6.8 23.5 9.9
2 10.5 10.4 21.1 12.7
3 10.8 7.7 18.9 6.2
4 11.1 8.3 22.6 12.9
5 11.1 8.5 18.8 17.1
6 10.6 6.4 26.6 9.1
Mean 10.8 8.0 21.9 11.3
S.D. 0.3 1.4 2.9 3.8
Hepatic fractional synthetic rate (HFSR) was calculated 
using either the 15N enrichment of plasma free glycine to 
represent the precursor pool (PP) or the 15N enrichment of 
free glycine from the liver homogenate (LHP). The rate of 
hepatic protein synthesis in grams per day (HPS) was 
calculated assuming that liver mass is 2% of body weight 
and that 146g/kg of liver is protein (Geigy Scientific 
Tables). Hepatic protein synthesis is expressed as a 
percentage of whole body protein synthesis (HPS(LHP)/WBPS).
Table 5.3a
Wet weiahts of liver and skeletal muscle bioosies taken
from healthv subiects
Liver Muscle
(mg) (mg)
Subj ect 1 859 591
2 425 220
3 557 541
4 375 769
5 482 803
6 215 726
Mean 486 608
S.D. 216 216
Liver, wedge liver biopsy; Muscle, rectus abdominus biopsy.
Table 5.4
Muscle protein synthetic rates in healthy subjects measured 
using ri5Nlqlvcine
MFSR (MHP) 
(%/d)
MFSR(PP) 
(%/d)
MPS(MHP) 
(gP/d)
MPS (MHP) /WBPS 
(%)
Subj ect 1 1.7 1.1 63.4 25.9
2 2.9 2.4 100.8 60.8
3A 2.2 1.7 66.5 21.7*±
5 3.7 3.3 108.1 93.1
6 3.3 3.1 143.0 48.9
Mean 2.8 2.3 96.4 50.1
S.D. 0.8 0.9 32.8 28.9
Muscle fractional synthetic rate (MFSR) was calculated 
using either the 15N enrichment of plasma free glycine to 
represent the precursor pool (PP) or the 15N enrichment of 
free glycine from the muscle homogenate (MHP) . The rate of 
muscle protein synthesis in grams per day (HPS) was 
calculated assuming that muscle mass is 29.3% of body 
weight and that 172g/kg of muscle is protein (ICRP, 1975). 
Muscle protein synthesis is expressed as a percentage of 
whole body protein synthesis (MPS(MHP)/WBPS).
Table 5.5
Liver protein synthetic rates in healthy subjects measured 
using T13C1leucine
HFSR(PP) HPS(PP) HPS(PP)/WBPS
(%/d) (gP/d) (%)
Subj ect 1 6.9 14.9 6.5
2 3.4 6.9 3.0
3 8.5 14.8 6.9
4 8.6 17.6 6.0
5 10.9 18.5 7.0
6 4.3 10.8 5.7
Mean 7.1 13.9 5.9
S.D. 2.8 4.4 1.5
Hepatic fractional synthetic rate (HFSR) was calculated
using either the C enrichment of plasma free leucine to
represent the precursor pool (PP) as there was insufficient
sample to measure the isotopic enrichment of free leucine 
from the homogenate. The rate of hepatic protein synthesis 
in grams per day (HPS) was calculated assuming that liver 
mass is 2% of body weight and that 14 6g/kg of liver is 
protein (Geigy Scientific Tables). Hepatic protein 
synthesis is expressed as a percentage of whole body 
protein synthesis (HPS(PP)/WBPS).
Table 5.6
Plasma free ri5N1qlvcine and T13C1leucine enrichment of 
healthy subjects in period prior to biopsy
[15N] glycine
-120 min
Time to operation 
-60 min 0 min
Subject 1 0.3613 0.4756 0.4614
2 0.4068 0.4068 0.4311
3 0.5489 0.4809 0.5428
4 0.4713 0.4930 0.6239
5 0.4091 0.3822 0.3841
6 0.3488 0.4641 0.3895
Mean 0.4243 0.4504 0.4721
S.D. 0.0747 0.0449 0.0942
[13C] leucine
-120 min
Time to operation 
-60 min 0 min
Subj ect 1 1.2277 1.5734 1.1389
2 0.8916 1.1512 1.3739
3 1.0644 1.4160 1.4419
4 1.7906 1.0011 0.9922
5 1.3916 1.3407 1.0134
6 0.7707 1.4749 1.7186
Mean 1.1894 1.3262 1.2798
S.D. 0.3697 0.2134 0.2833
The measurement of plasma free [15N] glycine and [13C] leucine 
(atom% excess) in the immediate pre-operative period. The 
values obtained at each time point for the 6 subjects were 
not significantly different assessed by analysis of 
variance (Kruskal-Wallis).
Table 5.7
Plasma free amino acid concentrations in healthy subjects 
at 5 hours prior to and at the time of operation
NORMAL 8 BASELINE OPERATION CHANGE
MEAN S.D. MEAN S.D. MEAN S.D. (%)
ASP - nd
GLU 46 13 nd
ASN 47 9 31.3
SER 127 29 115.8
GLN 578 85 261.5
GLY 300 114 287.5
THR 154 40 114.7
HIS 83 14 100.8
CIT 35 10 40.7
3-MH - 6.2
ALA 373 87 329.0
TAU 141 57 83.5
ARG 75 24 94.5
CAR - - 0.0
ABU 22 8 26.0
TYR 61 13 52.2
VAL 209 31 199.3
MET 27 5 22.7
TRP 50 13 32.0
PHE 56 8 52.5
ILE 64 13 58.2
LEU* 122 23 111.5
ORN 54 18 51.8
LYS
TOTAL AA
183 34 169.3
2241.0
nd
nd
7.1 32.7 5.6 4.3
19.4 117.8 18.9 1.7
77.4 293.8 86.2 12.4
115.8 288.7 122.4 0.4
22.0 115.8 20.1 1.0
10.3 96.0 5.4 -4.8
7.1 38.8 7.8 -4.5
1.2 6.2 1.0 0.0
78.6 310.5 72.9 -5.6
23.0 92.2 24.2 10.4
17.9
0.0
96.0
0.0
16.6
0.0
1.6
4.9 27.5 5.4 5.8
10.0 48.7 7.6 -6.7
27.4 193.7 19.4 -2.8
4.4 24.0 5.9 5.9
7.3 29.7 3.7 -7.3
7.3 51.2 5.1 -2.5
6.9 55.0 5.4 -5.4
15.9 138.3 11.0 24.1
9.6 51.7 7.3 -0.3
26.0 170.0 21.5 0.4
340.4 2278.2 296. 6 1.7
All values in nmol/ml plasma. a, normal values for plasma 
amino acid concentrations in female subjects (Geigy 
Scientific Tables (a), nd, none detected. n=6, * p<0.05
Table 5.8
Liver and muscle free amino acid concentrations in healthy 
subi ects
LIVER MUSCLE
MEAN S.D. MEAN S.D
ASP nd nd
GLU 53.7 12.9 7.7 2.7
ASN 1.1 0.2 1.1 0.5
SER 8.2 1.2 4.8 2.2
GLN 2.6 1.2 38.8 15.7
GLY 36.0 9.1 6.9 2.7
THR 4.2 1.0 2.4 1.2
HIS 35.6 6.9 1.1 0.7
CIT 0.7 0.5 0.7 0.5
3-MH 0.0 0.0 0.0 0.0
ALA 30.8 7.6 15.6 5.9
TAU 5.7 1.5 15.8 5.6
ARG 1.8 0.7 2.4 1.5
CAR 0.0 0.0 11.0 2.4
ABU 2.4 0.7 0.4 0.2
TYR 1.6 0.5 0.6 0.2
VAL 2.8 0.7 1.4 0.5
MET 11.8 2.4 0.0 0.0
TRP 0.0 0.0 0.0 0.0
PHE 1.7 0.5 0.5 0.2
ILE 1.3 0.2 0.6 0.2
LEU 4.1 1.0 1.5 0.5
ORN 1.9 0.7 0.8 1.0
LYS 2.3 0.5 3.2 1.5
TOTAL AA 210.2 40.4 117.1 44.6
All values in nmol/mg tissue wet weight. n=6. nd, none 
detected.
Table 5.9
Urinary creatinine and 3-methvlhistidine excretion in 
healthy subjects
Muscle 3-MeH
Creatinine*
(mmol/vol)
Mass
(kg)
Protein
(gp)
(umol/mmol
creatinine)
Subj ect 1 3.4 10.2 1.7 39
2 5.4 16.3 2.8 20
3 3.5 10.5 1.8 43
4 3.6 10.8 1.9 31
5 2.7 8.1 1.4 33
6 8.5 25.6 4.4 27
Mean 4.5 13.6 2.3 32
S.D. 2.1 6.5 1.1 8
18h urine collection. Whole body muscle mass was 
calculated on the basis that excretion of lg urinary 
creatinine (in 24h) is derived from 20kg muscle (Greystone, 
1968) and protein assumed to constitute 172gP/kg muscle 
mass (ICRP, 1975).
Table 5.10
Liver and Muscle RNA concentration in healthy subjects
Liver Muscle Liver/Muscle 
(ug/mg Protein)
Subject 1 6.6 0.8 8.2
2 3.8 0.4 9.5
3 7.6 - -
4 1.6 0.1 16.0
5 2.2 0.3 7.3
6 3.4 0.7 4.9
Mean 4.2 0.5 9.2
S.D. 2.4 0.3 4.1
Table 5.11
Comparison of rates of skeletal muscle protein synthesis in 
normal subjects as determined bv different investigators
F.S.R. (%/d)
Author (ref) Isotope Mean S.E.M Comments
Halliday (a) [15N] lys 3.8 0.4 Sarcoplasmic
1.4 0.3 Myofibrillar
Rennie (b) [”C]leu 2.4 0.4
Halliday (c) [«C]leu 1.1 0.1
Garlick (d) [*C]leu 1.9 0.1 Flooding dose
Shaw (e) C *C]leu 2.4 0.4
This work [ N]gly 2.8 0.3
(a) Halliday et al., 1975 (b) Rennie et al., 1982 (c)
Halliday et al., 1989 (d) Garlick et al., 1989 (e) Shaw et 
al., 1991.
Whole body and tissue protein synthetic rate measurements in normal subjects using 
[15N]glycine
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6
Age 70 53 74 67 58 39
Sex F F F F F F
Weight (kg) 74 69 60 70 58 86
[15N] glycine (g/24h) 0.1 0.1 0.1 0.1 0.1 0.1
Nitrogen excreted (g/18h) 1.86 3.53 2.47 2.76 2.16 5.71
Glycine-Tissue (h) 20.3 21.5 20.3 20 20.6 21
End-product (urine ammonia)
Pre-infusion (AP) 0.36079 0.36203 0.36835 0.37027 0.36365 0.36506
Plateau (AP) 0.40815 0.42327 0.40577 0.42992 0.45637 0.40021
WBPT (gP/kg/day) 3.5 2.9 5.4 2.9 2.3 4
WBPS (gP/kg/day) 3.3 2.4 5.1 2.6 2 3.4
Plasma free glycine
Pre-infusion (AP) 0.3537 0.37056 0.3774 0.37647 0.37875 0.36914
-2h (APE) 0.36133 0.40685 0.54895 0.47133 0.40906 0.34881
-1h (APE) 0.47559 0.40685 0.48088 0.49301 0.3822 0.46413
Oh (APE) 0.46137 0.43115 0.54277 0.62391 0.38409 0.3895
Plateau (APE) 0.46848 0.419 0.51182 0.55846 0.38314 0.42681
Homogenate free glycine
Skeletal muscle (APE) 0.30799 0.35358 0.39427 * 0.34294 0.40033
Liver (APE) 0.29199 0.41658 0.36761 0.4183 0.29296 0.26008
Hydrolysate glycine
Skeletal muscle (APE) 0.0045 0.00905 0.00731 * 0.01104 0.01173
Liver (APE) 0.0271 0.0394 0.0337 0.03888 0.0281 0.02423
Fractional Synthetic Rate-homogenate free precursor 
Skeletal muscle (%/day) 1.7 2.9 2.2 * 3.7 3.3
Liver (%/day) 10.9 10.5 10.8 11.1 11.1 10.6
Fractional Synthetic Rate-plasma precursor 
Skeletal muscle (%/day) 1.1 2.4 1.7 * 3.3 3.1
Liver (%/day) 6.8 10.4 7.7 8.3 8.5 6.4
AP atom%, APE atom% excess, Glycine-Tissue (h) duration of glycine infusion prior to 
biopsy, * sample lost to analysis
Table 5.13
Whole body and tissue protein synthetic rate measurements in normal subjects using
[15C]leucine
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6
Age 70 53 74 67 58 39
Sex F F F F F F
Weight (kg) 74 69 60 70 58 86
[13C]leucine (mg/h) 65 65 65 65 65 65
Leucine-Tissue (h) 4.8 5.3 5.2 5 5.2 5.8
End-product (breath C02)
Breath C02-pre-infusion (AP) 1.1291 1.1203 1.121 1.1282 1.1212 1.1191
Plateau (APE) 0.0184 0.0144 0.0172 0.0141 0.0243 0.0154
VC02 (ml/min) 152 475 206 168 199 275
WBPT (gP/kg/day) 3.3 3.7 3.8 4.7 4.8 2.4
WBPS (gP/kg/day) 3.1 3.3 3.6 4.5 4.5 2.2
Plasma free leucine
Pre-infusion (AP) 1.0935 1.12518 1.11514 1.11537 1.1118 1.11495
-2h (APE) 1.22767 0.89161 1.06438 1.79058 1.39159 0.77074
-1h (APE) 1.57345 1.15119 1.41604 1.00112 1.34068 1.47494
Oh (APE) 1.1389 1.3739 1.44187 0.9922 1.01343 1.71863
Plateau (APE) 1.35617 1.26254 1.42895 0.99666 1.17705 1.59678
Hydrolysate leucine
Liver (APE) 0.01888 0.00932 0.02615 0.0179 0.02763 0.0166
Fractional Synthetic Rate-plasma precursor 
Liver (%/day) 6.9 3.4 8.5 8.6 10.9 4.3
AP atom%, APE atom% excess, Glycine-Tissue (h) duration of glycine infusion prior to 
biopsy, * sample lost to analysis
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CHAPTER 6: THE SIMULTANEOUS MEASUREMENT OF WHOLE BODY. 
FIXED  LIVER A N D  M USCLE PROTEIN S Y N T H E T IC  RATES IN 
WEIGHT-LOSING CANCER PATIENTS USING M5N1GLYCINE
6.1 Introduction
As discussed in Chapter 1 the majority of cancer patients with 
progressive disease lose weight, and a proportion become emaciated to the 
extent that they appear to die primarily from cachexia (Warren, 1932; 
Inagaki, Rodriguez and Bodey, 1974). The mechanisms which underlie this 
complex syndrome of nutritional and metabolic upset are poorly 
understood (Caiman, 1982; Fearon and Carter, 1988). One observation 
which has repeatedly been made is that a proportion of cancer patients 
with weight loss appear to have inappropriately elevated rates of whole 
body protein turnover (Jeevanandam et al., 1984; Eden et al., 1984; 
Inculet et al., 1987; Fearon et al., 1988). Such increased protein turnover 
might compromise the normal adaptation to semi-starvation and contribute 
to the accelerated weight loss of the cachectic cancer patient (Eden et al., 
1984). However, it is not known which tissues in the body contribute to 
this elevated protein flux.
The muscle and liver are thought to be the key organs in the 
regulation of amino acid metabolism and together represent more than 
40%  of body protein mass in adult man. In addition, studies in animals 
have suggested that these organs may account for more than 50%  of 
protein turnover in the whole body (Waterlow, Garlick and Millward, 
1978). Various studies of body composition and organ volumes in 
cachectic cancer patients have suggested that muscle mass is markedly 
reduced whereas the liver mass tends to be preserved (Preston et al., 
1987) or even increased (Heymsfield and McManus, 1985). Clearly the
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mass of protein of an organ is determined by the balance between 
synthesis and degradation. If the preserved or even increased hepatic mass 
of cancer patients were principally the result of enhanced protein synthesis 
(rather than reduced degradation) then this could mean that the liver was 
one of the main sites for the apparent increase in whole body protein 
synthesis.
Rates of protein synthesis measured in the tissues of tumour bearing 
animals or man have shown a great variety of change. In tumour-bearing 
rats Norton and coworkers (1981) reported liver protein fractional 
synthesis rates, measured by [15N]glycine infusion, to be increased 
whereas, fractional synthetic rates in skeletal muscle were decreased. 
Pain, Randall and Garlick, (1984) reported similar results in tumour-bearing 
mice with rates of protein synthesis increased in liver and decreased in 
skeletal muscle. However in a different mouse model, Emery, Lovell and 
Rennie, (1984b) reported reduced protein fractional synthetic rates in both 
liver and muscle. Comparative studies in man are few but, Lundholm and 
coworkers (1978) have reported that hepatic protein synthesis measured 
in-vitro with [14C]leucine is increased whereas skeletal muscle protein 
synthesis in vitro is reduced (Lundholm et al., 1976). A marked reduction 
in skeletal muscle protein synthesis in cachectic lung cancer patients has 
also been observed by Emery and coworkers (1984a) in-vivo using 
[13C]leucine. Such contradictory results may underly methodological 
problems or may reflect a heterogenous response to malignancy in both 
animals and man.
With particular reference to hepatic metabolism this may be 
considered in terms of export and fixed protein components. The majority 
of cancer patients with advanced disease and weight loss will have an 
acute phase protein response. These proteins are considered to be of vital
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importance to allow recovery following acute injury and to this end it has 
been suggested that the body will give priority to the synthesis and export 
of these proteins by the liver. In contrast to hepatic export proteins, little is 
known about the rate of fixed hepatic protein synthesis. This component 
of hepatic protein synthesis may be of equal or greater functional 
importance when compared to the export component yet there has only 
been one direct measurement of non-export hepatic protein synthesis in 
patients with cancer (Stein et al., 1978a). Furthermore, there has been no 
comparison of whole body, liver and muscle protein synthesis in-vivo 
between normal and weight-losing cancer patients. The aim of the present 
study was, therefore, to obtain measurements of whole body and tissue 
protein synthesis rates in weight-losing cancer patients and compare these 
with the 'normal' values already reported in Chapter 5.
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6 .2  Materials and methods
6.2.1 Subjects
Six patients with histologically proven colonic adenocarcinoma and 
hepatic metastasis who had not undergone surgery within the previous 3 
months and who had evidence of an acute phase protein response (serum 
C-reactive protein concentration >10m g/l) were entered into the study. 
The patients were weighed, wearing light night attire, on beam balance 
standing scales (Weylux 424, UK.) on the morning of the day that the 
[15]glycine infusion was commenced. Each patient was questioned 
carefully about their usual weight and weight loss. This method relied on 
each patient's subjective impression of their usual body weight and such 
recall will have a degree of error. However, it has been reported that it is 
more reliable to estimate weight loss by using the patient's recalled well 
weight than by using published tables (Morgan, Hill and Burkinshaw, 
1980). These patients had been admitted to undergo insertion of an 
implantable injection system for administration of chemotherapy via the 
hepatic artery. All individuals were of a performance status 2 or better, 
defined as 'Ambulatory and capable of all self care but unable to carry out 
any work; up and about more than 50%  of waking hours' (WHO 
performance status, 1979) and were clinically judged to be free of other 
metabolic or endocrine disorders. None were pyrexial, had clinical or 
radiological evidence of infection, were receiving steroids, or severely 
anaemic. All patients had a normal serum urea and creatinine concentration 
and although some patients with hepatic metastasis had abnormal liver 
function tests, none were clinically jaundiced (serum bilirubin <35um ol/l).
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The study was approved by the local ethical committee. All patients 
were informed of the purpose and procedure of the study and all gave 
written informed consent.
6 .2 .2  Experimental design, analytical methods and calculations
These were the same as described in chapters 3 ,4  and 5 except that 
only [15N]glycine was used as a tracer to measure whole body, fixed liver 
and skeletal muscle protein synthesis. The wet weight of the tissues 
biopsied is given in Table 6.3a.
6 .3  Results
The clinical features of the subjects are shown in Table 6 .1 . In 
contrast to the normal subjects (reported in Chapter 5) the cancer patients 
had lost on average 10%  of their pre-illness stable weight and this had 
occurred over a mean period of four months. The mean serum albumin 
concentration of the cancer patients was 34g/l, below the normal range 
(36-44g /l) and significantly lower than that of the controls (Chapter 
5 ,Table 5.1, p < 0 .0 5 ). The mean body mass index for the cancer patients 
was 24, within the normal range (20-25) and significantly lower than that 
of the control group (Table 5.1, p < 0 .0 5 ) who were in the overweight 
range (25-30, Owen, 1988).
Individual rates of whole body protein turnover, whole body protein 
synthesis, urinary nitrogen excretion and resting energy expenditure are 
presented in Table 6.2. The mean value for whole body protein turnover 
and synthesis measured using [15N]glycine was 5 .9  and 5.3gP/kg/d  
respectively which was significantly greater than that of the controls (3.5 
and 3.1gp/kg/d, p < 0 .0 1 ). Mean rates of whole body protein breakdown 
exceeded those of whole body protein synthesis by 0.6gP/kg/d in cancer
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patients and by 0.4gP/kg/d in the controls. This greater protein loss in the 
cancer patients was not reflected in statistically higher rates of urinary 
nitrogen excretion in the cancer patients than in the controls (89 .6  _±. 22.0  
v 58 .0  _+ 8.5mgN/kg/d).
The mean resting energy expenditure in the cancer patients was 
27.1kcals/kg/d which was not significantly different from that of the 
controls (25.5kcals/kg/d :Chapter 5, Table 5.2).
Tissue protein synthesis rates are shown in Table 6.3 and 6.4. The 
sample from subject 4  was lost during sample preparation (Table 6.4). 
When the isotopic enrichment of plasma free glycine was taken to 
represent the enrichment in the precursor pool for protein synthesis the 
mean values for the liver and muscle protein fractional synthetic rates were 
5.6  and 2.9% /d respectively. In contrast, when the isotopic enrichment of 
free glycine derived from the liver and muscle homogenate was taken to 
represent the precursor pool enrichment these rates increased to 7 .6  and 
5.4% /d respectively. It was proposed in Chapter 5 that the homogenate 
free glycine is more likely to represent the true precursor for protein 
synthesis. The muscle fractional synthetic rate was 93%  higher (p <  0.05) 
and the non-export hepatic fractional synthetic rate was 37%  (p < 0 .0 1 )  
lower in the cancer patients than in the controls. The mean rates of liver 
and muscle protein synthesis expressed in grams of protein were 
calculated to be 14.5 and 201gP/kg/d respectively. These rates were 
calculated using the enrichment of free glycine in the tissue homogenate 
and assumed that liver weight was 2%  of total body weight and that 146g 
in each kg of liver was protein (Geigy Scientific Tables). Similarly, it was 
assumed, that muscle weight was 29 .3%  of total body weight in females 
and 40%  in males and that 172g in each kg of muscle was protein (ICRP 
23). When liver and muscle protein synthesis was calculated as a
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proportion of whole body protein synthesis the mean values were found to 
be 4 .6  and 62 .9%  respectively. The isotope enrichment data, from which 
the whole body and tissue protein fractional synthetic rates were 
calculated, for [15N]glycine are presented in Table 6.10.
T h e  m e a n  v a l u e  f o r  l i v e r  R N A  c o n c e n t r a t i o n  w a s  
1.2ugRNA/mgProtein and muscle was 2.4ugRNA/mgProtein (Table 6.9). 
There was no significant difference between the cancer group and the 
controls (Table 5.10), although there was much greater variation in the 
results of the cancer group especially in muscle. Therefore, the results are 
of uncertain value (see section 3 .5 .3 , 5.4).
The intracellular amino acid profile of liver and skeletal muscle are 
shown in Tables 6.5 and 6.6. The mean total amino acid concentrations 
were 187.8 and 88.5nmol/mg wet weight respectively. In the comparison 
with the control group there were significant reductions in asparagine, 
histidine, citrulline and alanine concentrations (p < 0 .0 5 ) in the liver tissue. 
In the muscle tissue there was a trend towards a reduction in the 
concentration of most amino acids but this trend did not reach statistical 
significance. In certain patients it was possible to biopsy the liver tumour. 
The amino acid profile for the tumour samples (ie. liver tumour) is distinct 
from that of liver or muscle (Table 6.7). The most notable feature is the 
proportion of total amino acids made up by the essential amino acids. In 
normal muscle (8%), cancer muscle (8% ), normal liver (13% ), cancer liver 
(19% ) and tumour (25% ). This is principally due to a decrease in the tissue 
concentration of the non-essential amino acids in the cancer patients 
compared with the control group.
Urinary creatinine and 3-Methylhistidine excretion are shown in 
Table 6.8. The mean creatinine excretion in the 18hr urine collection was 
5.4mmol/l and 3-MeH was 27umol/mmol creatinine.
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6.4 Discussion
In this study we have examined a homogeneous group of patients 
with hepatic metastasis from colon cancer. The patients, therefore, had 
similar tumour type and burden. In order to avoid any confounding 
metabolic factors associated with severe cachexia or malnutrition, patients 
were studied when on average they had lost 10%  of their pre-illness 
weight (Table 6.1).
This study demonstrates that patients with hepatic metastasis 
secondary to colon cancer have rates of whole body protein synthesis 
which are 70%  greater than those observed in non-cancer controls 
(Chapter 5, Table 5.2). These results are consistent with previous findings 
(Fearon et al., 1988) and agree with those of other investigators who have 
observed increased whole body protein synthesis in patients with  
advanced malignancy (Eden et al., 1984; Jeevanadam et al., 1984). 
Furthermore, despite a significant increase in whole body protein turnover 
there was no increase in resting energy expenditure in the cancer group 
compared to the controls (Chapter 5, Table 5.2). This observation has 
been made previously in cancer patients with (Fearon et al., 1988) and 
without weight loss (Melville et al., 1990) and is discussed further in 
Chapter 7.
In contrast to the whole body measurements, non-export hepatic 
protein synthesis in cancer patients was reduced by approximately 30%  
compared to controls, irrespective of whether plasma or liver homogenate 
free [15N]glycine enrichment was taken to represent the true precursor 
enrichment (Table 6.3 and Chapter 5, Table 5.3). This reduction in liver 
protein synthesis in the cancer group is supported by the reduction in 
mean liver RNA (by about 70% ) and is associated with a trend towards 
reduced tissue free amino acid concentrations (11%) in the cancer group
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(Tables 6 .9  and 6.5) (Chapter 5, Table 5 .10 , p = ns). This clearly excludes 
accelerated synthesis of structural hepatic proteins as a factor which might 
contribute to the increased protein synthesis in the whole body. 
Furthermore, these results suggest that any increase in hepatic protein 
mass associated with malignancy (Heymsfield and McManus, 1985) is 
likely to be the outcome of decreased protein degradation rather than 
increased synthesis.
These observations represent only the second in vivo measurements 
of hepatic non-export protein synthesis in cancer patients and because of 
the limitations of the first study (Stein et al., 1978) discussed above (see 
section 5.4) it is not possible to compare the findings. With reference to 
various animal models our findings are consistent with those of Emery and 
coworkers (1984b) who demonstrated a reduction in protein synthesis in 
the liver of thymectomised mice bearing the XK1 tumour. This is an 
important model of human cancer cachexia since the XK1 tumour is human 
in origin and induces weight loss when tumour mass is similar to that at 
which weight loss occurs in man (ie. < 5 %  total body weight Stein, 
1982a). In contrast, Norton et al, (1981) reported increased liver protein 
synthesis in rats bearing a methylcholanthrene induced sarcoma. However, 
the fractional synthetic rate was calculated from 15N enrichment of the 
amino nitrogen in the tissue free homogenate and Kjeldahl digest of the 
protein bound fraction. Also, there was no weight-loss in the cancer group 
that they studied. Pain and coworkers (1984) reported increased total 
hepatic protein synthesis in mice bearing a rodent ascites tumour. 
However, in this model the tumour mass accounted for 60%  of total body 
weight and the situation cannot be compared with that in man. Lundholm 
and coworkers (1978) reported an increased incorporation rate of amino 
acids into hepatic proteins in sarcoma-bearing mice as well as in liver
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tissue from cancer patients. However, the latter study involved using 
isolated tissue samples incubated in vitro and the results obtained may not 
be physiologically meaningful. Moreover, the mouse in vivo studies 
performed by Lundholm and coworkers were limited to measurements of 
incorporation of radioactively labelled amino acids into protein, without 
consideration of the precursor pool specific activity, so that the absolute 
rates of protein synthesis could not be calculated.
In the present study, it is clear from the liver and muscle biopsies 
that there was a decrease in the concentration of the non-essential amino 
acids (principally alanine) in the cancer group. The reduction in alanine 
concentration was statistically significant for liver (p < 0 .0 5 ) but not for 
muscle (p = 0 .17). It is possible that the decrease in alanine concentration 
in these tissues reflects an increased demand for alanine as a glucose 
precursor (Felig et al., 1969). There have been repeated clinical and 
experimental observations of abnormal carbohydrate metabolism in cancer 
patients (Kern and Norton, 1988). More specifically, a decrease in 
peripheral glucose disposal (Lundholm et al., 1978) and an increase in 
basal hepatic glucose production (Shaw and Wolfe, 1986) have been 
reported in cancer patients. These reports are consistent with increased 
alanine utilisation in liver and muscle and may explain the reduction in 
tissue alanine concentration in the cancer group.
In the present study there was a mean increase of 26%  or 93%  in 
skeletal muscle protein synthesis rates when compared with the controls 
depending on whether plasma or muscle homogenate free [15N]glycine 
enrichment was taken to represent the true precursor enrichment (Table
6.4  and Chapter 5, Table 5.4). In contrast, several investigators have 
reported reduced rates of protein synthesis in the skeletal muscle of 
humans (Lundholm et al., 1976; Emery et al., 1984a) and animals (Norton
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et al., 1981; Emery, Lovell and Rennie, 1984b) with cancer cachexia. 
However, all of these studies used leucine as a tracer with the exception 
of Norton et al, (1981) who used glycine but measured the incorporation 
of 15N into the amino nitrogen of muscle protein, and therefore the results 
of the latter study are not directly comparable with that of the present. 
Furthermore, the subjects studied by other investigators were severely 
cachectic and presumably had severe muscle wasting. In contrast, the 
cancer patients examined in the present study had sustained only 10%  
weight loss and appeared to have a normal muscle mass when calculated 
from urinary creatinine excretion (with the exception of subject 2, Table 
6.8). This is in accord with the normal body mass index measured (Table 
6.1) and body composition studies which suggest that 10% documented 
weight loss in cancer patients is associated with a small reduction in lean 
body mass (more than half of lean body mass is skeletal muscle) of 
approximately 5%  (Cohn et al., 1981; Shizgal, 1985).
When the mean increase in skeletal muscle protein synthesis rate 
(93% ) is taken with a mean reduction in non-export hepatic protein 
synthesis rate of 37%  and compared with an mean increase of 71%  in 
whole body protein synthesis rate, it appears that the increase in skeletal 
muscle protein synthesis is sufficient to account for the increase in whole 
body protein synthesis (see Table 7.3). An increase in skeletal muscle 
protein synthesis would be unlikely in the presence of the marked 
reduction in intracellular amino acid concentration which was observed 
(Table 6 .6 ). In addition, there was no increase in skeletal muscle 
breakdown as measured by 3-Methylhistidine excretion (Table 6 .8  and 
Chapter 5, Table 5.9) (Young and Munro, 1978; Ballard and Thomas, 
1983; Rennie and Millward, 1983; Long et al., 1988). An increase in 
muscle protein synthesis without an accompanying increase in muscle
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protein breakdown would result in increased muscle mass which is clearly 
not the case in patients with weight-loss.
Such findings suggest that perhaps the incorporation of [15N]glycine 
may not give a good estimate muscle protein synthesis in cancer patients. 
Furthermore, the exact relationship between kinetic parameters measured 
by tracer amino acid infusion and body protein kinetics remains unclear. 
The fact that that the 70%  increase in whole body protein synthesis was 
not accompanied by an increase in resting energy expenditure suggests 
there may be a breakdown in the relationship of glycine flux to whole body 
and skeletal muscle protein synthesis in cancer patients. Possible 
mechanisms whereby this could occur are discussed in Chapter 7.
152
Table 6.1
Characteristics of cancer patients
Age
(yrs)
Sex Weight Height 
(kg) (cm)
BMI Weight
loss(%)
Albumin
(g /i)
Subj ect 1 54 M 63 168 22 19 34
2 78 F 52 157 21 15 24
3 59 M 67 175 22 7 39
4 42 M 77 170 27 8 35
5 68 M 72 168 26 6 39
6 62 M 65 165 24 7 31
Mean 61 66 167 24 10 34
S.D. 12 9 6 2 5 6
BMI, Body Mass Index=weight(kg)/[height(m)]2
Table 6.2
Whole body protein kinetics and resting energy expenditure 
in weight-losing cancer patients.
[15N] glycine
WBPT WBPS Urinary N REE
(gP/kg/d) (mgN/kg/d) (kcals/kg/d)
Subj ect 1 5.4 5.0 58.7 29.4
2 7.4 7.3 26.9 24.8
3 3.5 2.8 125.3 24.3
4 5.6 5.0 97.4 31.3
5 5.6 5.3 55.5 25.5
6 7.6 6.5 173.8 27.0
Mean 5.9 5.3 89.6 27.1
S.D. 1.5 1.5 53.8 2.8
Whole Body Protein Turnover: WBPT, Whole Body Protein
Synthesis: WBPS, Grams protein per kilogram per day:
gP/kg/d, Daily urinary nitrogen excretion derived from 18 h 
collection taken prior to surgery: Urinary N.
Table 6.2a
Resting energy expenditure and respiratory quotient of 
weight-losing cancer patients
VC02 V02 RQ REE
(1/min) (1/min) (kcal/d)
Subject 1 0.221 0.267 0.83 1850
2 0.156 0.186 0.84 1291
3 0.192 0.236 0.81 1630
4 0.281 0.350 0.80 2411
5 0.233 0.262 0.89 1840
6 0.203 0.256 0.79 1759
Mean 0.214 0.260 0.83 1797
S.D. 0.042 0.053 0.04 365
VC02, carbon dioxide production; V02, oxygen consumption;
RQ, respiratory quotient; REE, resting energy expenditure; 
REE (kcal/d) = (3 . 9V02+1.1VC02) X1440 
RQ= VC02/V02
Table 6.3
Liver protein synthetic rates in weight-losing cancer 
patients measured using riSNIclvcine
HFSR(LHP) HFSR(PP) HPS(LHP) HPS(LHP)/WBPS
(%/d) (%/d) (gP/d) (%)
Subj ect 1 7.8 6.2 14.3 4.5
2 9.5 6.7 14.4 3.8
3 8.0 4.6 15.6 8.3
4 9.8 8.8 22.0 5.7
5 6.2 3.4 13.0 3.4
6 4.0 3.6 7.6 1.8
Mean 7.6 5.6 14.5 4.6
S.D. 2.2 2.1 4.6 2.2
Hepatic fractional synthetic rate (HFSR) was calculated
using either the 15N enrichment of plasma free glycine to
represent the precursor pool (PP) or the 15N enrichment of
free glycine from the liver homogenate (LHP). The rate of
hepatic protein synthesis in grams per day (HPS) was 
calculated assuming that liver mass is 2% of body weight 
and that 146g/kg of liver is protein (Geigy Scientific 
Tables). Hepatic protein synthesis is expressed as a 
percentage of whole body protein synthesis (HPS(LHP)/WBPS).
Table 6.3a
Wet weights of liver and skeletal muscle biopsies taken 
from weight-losing cancer patients
Liver
(mg)
Muscle
(mg)
Subj ect 1 226 708
2 246 414
3 590 791
4 412 342
5 415 975
6 615 411
Mean 417 607
S.D. 164 255
Liver, wedge liver biopsy; Muscle, rectus abdominus biopsy.
Table 6.4
Muscle protein synthetic rates in weight-losing cancer 
patients measured using riSNlglvcine
MFSR(MHP) MFSR(PP) MPS(MHP) MPS(MHP)/WBPS
(%/d) (%/d) (gp/d) (%)
Subject 1 3.9 2.3 169 54
2 5.9 2.0 155 41
3 6.5 3.0
4
5 6.1 3.4 322 84
6 4.7 3.2 210 50
Mean 5.4 2.8 214 57
S.D. 1.1 0.6 76 19
Muscle fractional synthetic rate (MFSR) was calculated 
using either the 15N enrichment of plasma free glycine to 
represent the precursor pool (PP) or the 15N enrichment of 
free glycine from the muscle homogenate (MHP) . The rate of 
muscle protein synthesis in grams per day (MPS) was 
calculated assuming that muscle mass is 29.3% (females) and 
40% (males) of body weight and that 172g/kg of muscle is 
protein (IRCP, 1975). Muscle protein synthesis is expressed 
as a percentage of whole body protein synthesis 
(MPS (MHP)/WBPS) .
Table 6.5
Liver free amino acid concentrations in normal subjects
compared with those of weight-losing cancer patients
CONTROL CANCER
LIVER LIVER
(nmol/mg) (nmol/mg)
MEAN S.D. MEAN S.D. % CHANGE
ASP nd nd nd
GLU 53.7 12.9 51.6 12.0 -3.8
ASN 1.1 0.2 2.1 0.7 87.2*
SER 8.2 1.2 8.8 1.9 7.0
GLN 2.6 1.2 5.6 4.7 113.4
GLY 36.0 9.1 30.4 9.1 -15.6
THR 4.2 1.0 4.1 1.2 -0.9
HIS 35.6 6.9 19.7 12.2 -44.6*
CIT 0.7 0.5 0.1 0.2 -91.3*
3-MH 0.0 0.0 0.0 0.0
ALA 30.8 7.6 19.5 7.8 -36.6*
TAU 5.7 1.5 5.8 2.4 2.3
ARG 1.8 0.7 1.4 0.7 -22.3
CAR 0.0 0.0 0.0 0.0
ABU 2.4 0.7 2.7 1.0 10.7
TYR 1.6 0.5 1.8 0.5 11.1
VAL 2.8 0.7 3.0 1.0 4.8
MET 11.8 2.4 17.0 6.6 44.8
TRP 0.0 0.0 0.2 0.5
PHE 1.7 0.5 1.8 0.7 4.5
ILE 1.3 0.2 1.4 0.5 6.1
LEU 4.1 1.0 3.5 1.0 -13.1
ORN 1.9 0.7 3.0 1.5 58.1
LYS 2.3 0.5 4.3 1.7 86.2
TOTAL AA 210.2 40.4 187.8 46.3 -10.7
n=6, * p<0.05. nd, none detected.
Table 6.6
Muscle free amino acid concentrations in normal subjects
compared with those of weight-losing cancer patients
CONTROL CANCER
MUSCLE MUSCLE
(nmol/mg) (nmol/mg)
MEAN S.D. MEAN S.D. % CHANGE
ASP nd nd
GLU 7.7 2.7 8.7 2.9 12.9
ASN 1.1 0.5 1.1 0.5 -0.1
SER 4.8 2.2 3.2 0.2 -33.6
GLN 38.8 15.7 31.2 5.6 -19.6
GLY 6.9 2.7 4.7 1.0 -32.1
THR 2.4 1.2 1.8 0.5 -26.9
HIS 1.1 0.7 0.2 0.5 -82.5
CIT 0.7 0.5 0.3 0.2 -57.8
3-MH 0.0 0.0 0.0 0.0
ALA 15.6 5.9 10.9 2.5 -30.5
TAU 15.8 5.6 12.4 3.7 -21.5
ARG 2.4 1.5 1.7 0.7 -30.4
CAR 11.0 2.4 6.8 3.9 -38.0
ABU 0.4 0.2 0.3 0.2 -26.3
TYR 0.6 0.2 0.3 0.2 -41.1
VAL 1.4 0.5 1.0 0.2 -29.4
MET 0.0 0.0 0.3 0.2
TRP 0.0 0.0 0.1 0.2
PHE 0.5 0.2 0.3 0.2 -23.7
ILE 0.6 0.2 0.3 0.2 -46.4
LEU 1.5 0.5 0.7 0.5 -49.0
ORN 0.8 1.0 0.0 0.0 -100.0
LYS 3.2 1.5 2.3 1.0 -28.4
TOTAL AA 117.1 44.6 88.5 16.4 -24.4
n=6. nd, none detected.
Table 6.7
Tumour free amino acid concentrations in weight-losing
cancer patients
CANCER PATIENTS 
TUMOUR 
(nmol/mg)
MEAN S.D
ASP nd
GLU 30.9 26.6
ASN 1.1 0.6
SER 5.3 2.4
GLN 0.1 0.2
GLY 15.2 8.4
THR 2.9 1.2
HIS 2.4 2.8
CIT 0.4 0.4
3-MH 0.0 0.0
ALA 15.4 11.8
TAU 15.7 6.0
ARG 1.0 0.6
CAR 0.0 0.0
ABU 0.9 0.8
TYR 1.6 1.0
VAL 3.0 2.0
MET 14.0 10.2
TRP 0.0 0.0
PHE 1.6 1.2
ILE 1.6 1.2
LEU 3.5 2.4
ORN 1.2 1.4
LYS 3.4 1.6
TOTAL AA 121.2 79.0
n=4. nd, none detected.
Table 6.8
Urinary creatinine and 3-methvlhistidine excretion in 
weiaht-losina cancer patients.
Muscle 3-methylhistidine
Creatinine*
(mmol/vol)
Mass
(kg)
Protein
(gp)
(umol/mmol
creatinine)
Subject 1 3.4 10.2 1.7 33
2 0.9 2.7 0.5 20
3 6.9 20.8 3.6 55
4 7.7 23.2 4.0 16
5 5.2 15.7 2.7 19
6 10.7 32.2 5.5 21
Mean 5.8 17.5 3.0 27
S.D. 3.4 10.3 1.8 15
18h urine collection. Whole body muscle mass was 
calculated on the basis that excretion of lg urinary 
creatinine (in 24h) is derived from 20kg muscle (Greystone, 
1968) and protein assumed to constitute 172gP/kg muscle 
mass (ICRP, 1975) .
Table 6.9
Liver and muscle RNA concentrations in weight-losing cancer 
patients.
Liver Muscle Liver/Muscle 
(ug/mg Protein)
Subj ect 1 
2
0.4
11.7
0.08 5.0
3
4
0.2
3.5
2.5 0.08
5 0.3 6.7 0.04
6 1.2 0.2 6.0
Mean 2.9 2.4 2.8
S.D. 4.5 3.1 3.2
Table 6.10
Whole body and tissue protein synthetic rate measurements in weight-losing cancer 
patients using [15N]glycine
Age
Sex
Ueight (kg)
[15N]glycine (g/24h) 
Nitrogen excreted (g/18h) 
Glycine-Tissue (h)
Subject 1 
54
H
63
0.1
2.78
21
Subject 2 Subject 3 Subject 4 
78 59 42 
F M M 
52 67 77 
0.1 0.1 0.1 
1.05 6.27 5.59 
23.3 19.6 21.3
Subject 5 
68
M
72
0.1
3.02
20.7
Subject 6 
62
M
65
0.1
8.5
23.5
End-product (urine ammonia) 
Pre-infusion (AP) 0.36449 
Plateau (AP) 0.40014 
WBPT (gP/kg/day) 5.4 
WBPS (gP/kg/day) 5
0.36551
0.39696
7.4
7.3
0.36934
0.42075
3.5
2.8
0.36581
0.39423
5.6
5
0.36464
0.39473
5.6
5.3
0.36551
0.39002
7.6
6.5
Plasma free glycine 
Pre-infusion (AP) 
Plateau (APE)
0.36912
0.25939
0.36817
0.80213
0.37002
0.50285
0.36711
0.19446
0.36942
0.39482
0.36835
0.39504
Homogenate free glycine 
Skeletal muscle (APE) 
Liver (APE)
0.15458
0.20732
0.26862
0.57148
0.24763
0.29013
*
0.17501
0.2066
0.21715
0.26999
0.35159
Hydrolysate glycine 
Skeletal muscle (APE) 
Liver (APE)
0.00511
0.01407
0.01556
0.0528
0.01291
0.01902
*
0.01528
0.01157
0.01154
0.01228
0.01371
Fractional Synthetic Rate-homogenate free precursor 
Skeletal muscle (%/day) 3.9 5.9 6.1 
Liver (%/day) 7.8 9.5 8
*
9.8
6.5
6.2
4.7
4
Fractional Synthetic Rate-plasma precursor 
Skeletal muscle (%/day) 2.3 2 
Liver (%/day) 6.2 6.7
3
4.6
*
8.8
3.4
3.4
3.2
3.6
AP atom%, APE atom% excess, Glycine-Tissue (h) duration of glycine infusion prior to 
biopsy, * sample lost to analysis
CHAPTER 7: GENERAL DISCUSSION OF CLINICAL STUDIES
7.1 Introduction
It has been reported that in cancer patients with and without 
weight-loss there is an increase in whole body amino acid flux (Table 7.2). 
Within the assumptions of the two pool model for protein metabolism 
(Picou and Taylor-Roberts, 1969), this would suggest a significant increase 
in whole body protein turnover. Nevertheless, the organs or tissues that 
bring about this increase in protein turnover are unknown. Several 
investigators have proposed that the liver might be one of the principal 
organs to contribute to increased protein turnover in the cancer host (Kern 
and Norton, 1988). However, in an attempt to discover the site of such 
increased protein synthesis it has been demonstrated in this thesis that at 
least in the liver of patients with advanced colon cancer and weight-loss, 
non-export protein synthesis is reduced by 30% . It has been proposed that 
more than 50%  of protein synthesis in the liver is contributed by 
non-export protein components (Waterlow, Garlick and Millward, 1978g). 
Thus, if the liver were to account for the major part of the apparent 
increase in protein synthesis in cancer patients then this would imply that 
hepatic export protein synthesis was increased some four fold. However, 
in a chronic wasting state it would seem unlikely that liver export protein 
synthesis could increase to such an extent.
The fractional synthetic rate of skeletal muscle protein has been 
reported to be 18-25%  of the rate at which this process occurs in the 
liver, depending on which mammal is studied (rat 25% , pig 18% ; 
Waterlow, Garlick and Millward, 1978b). Moreover, several studies have 
suggested that protein synthesis in this tissue is markedly decreased in the 
cachectic cancer host (Emery et al., 1984a; Lundholm et al., 1976).
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However, from studies presented in this thesis it would appear that protein 
synthesis in the skeletal muscle of the cancer host may be markedly 
increased (Chapter 6) and might, therefore account for the greater part of 
the increase in whole body protein metabolism. In view  of these 
contradictory results it is the aim of this Chapter to examine critically the 
nature of both the accelerated whole body tracer flux and increased 
glycine incorporation into the skeletal muscle of the cancer patients 
included in the present study.
7 .2  Whole body protein synthesis
7.2.1 Comparison with other published work
From the studies detailed in Chapters 5 and 6 there was on average 
a 69%  increase in whole body protein turnover and a 71%  increase in 
whole body protein synthesis in the cancer patients compared to the 
controls. These findings are in agreement with a number of studies in the 
literature where whole body protein turnover has been measured using 
[15N]glycine in cancer patients with reference to a control group in the 
post absorptive state (Table 7.2). It is clear from other studies (Table 7.2) 
that the measurements in normal subjects can vary considerably, ranging 
from 1.9 to 3.9gP/kg/d depending on the controls, type of tracer used and, 
with [15N]glycine, the end-product used (see section 2.3). Furthermore, in 
cancer patients the variation is large despite attem pts to study 
homogeneous groups. However, there is good agreement in the results of 
different studies when the same isotopically labelled tracer has been used. 
Inculet et al. (1987) and Melville et al. (1990) using [13C]leucine reported 
an increase in whole body protein turnover of 15% and 19%  respectively 
when weight stable cancer patients were compared with weight-stable
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controls. With [15N]glycine more substantial increases have been reported 
w h en w eig h t-lo s in g  cancer patien ts  have been com pared w ith  
weight-stable controls (Norton, Stein and Brennan, 1981; Kien and 
Camitta, 1983; Ward et al., 1985; Fearon et al., 1988; see Table 7.2). In 
contrast, Jeevanandam and coworkers (1984) and Fearon and colleagues 
(1988) using [15N]glycine reported smaller increases (see Table 7.2) in 
whole body protein turnover when weight-losing controls were compared 
with weight-losing cancer patients.
Whatever the final magnitude of the change, if whole body protein 
synthesis rather than simple tracer flux were increased substantially then 
the energy cost of this might be expected to give rise to an increase in 
host resting energy expenditure. However, in the present study (Chapters 
5 and 6) and those in the literature, in which simultaneous measurements 
of energy expenditure have been made, no relationship has been 
demonstrated between resting energy expenditure and the increase in 
whole body protein turnover (Fearon et al., 1988; Melville et al., 1990).
It is of further interest that when whole body protein synthesis has 
been measured in cancer patients in the fed state rather than in the fasted 
state, several investigators have failed to demonstrate a significant 
difference when compared with controls (Emery et al., 1984a; Glass, Fern 
and Garlick, 1983). The contradictory results obtained by Emery and 
coworkers (1984a) might be explained by the heterogeneous tumour type 
of the group studied since they had extensive disease and documented 
weight loss (as had the group in the present study). However, the 
contradictory results obtained by Glass and coworkers (1983) were 
unlikely to be due to different tumour type since a homogenous group 
were studied. These patients differed in that the stage of disease (Dukes 
A, C) was not as advanced as those in the present study (Dukes D), and
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approximately half of the group studied by Glass and coworkers had 
suffered weight loss. Alternatively, the data from these two studies (Emery 
et al., 1984a; Glass, Fern and Garlick, 1983) may simply indicate that the 
rate of protein turnover responds to feeding by a smaller amount in cancer 
patients than normal individuals. However, in the light of work carried out 
in cancer patients showing a normal response to feeding (Kern and Norton,
1988) this appears unlikely. Furthermore, Melville et al. (1990) reported 
that weight-stable cancer patients had a similar protein turnover response 
to feeding as controls. Therefore, it would appear that the extent of the 
increase in whole body protein turnover associated with cancer may be 
reduced in the fed state. The differences between cancer patients in the 
fed and fasted state may also reflect the limitations of the amino acid 
kinetic model which has been used to obtain values for whole body protein 
turnover and synthesis.
7 .2 .2  Limitations of the model
[15N]glycine has been used extensively as a tracer for measuring 
whole body protein synthesis rates in health and disease. There have been 
a number of studies by different groups which have supported the use of 
[15N]glycine for turnover studies (Picou and Taylor-Roberts, 1969; Golden 
and Waterlow, 1977; Stein et al., 1980). Stein and coworkers (1980) 
validated the use of [15N]glycine for whole body protein synthesis 
measurements by obtaining similar results using two different methods. 
They compared, in rats, the indirect method of Picou and Taylor-Roberts 
(1969), which involves measuring urinary [15N]urea enrichment at plateau, 
with the direct method of Garlick, Millward and James (1973) using the 
homogenised whole rat to determine 15N tissue incorporation. Although 
this approach can be criticised for not giving accurate ('absolute correct')
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tissue protein fractional synthetic rates (see section 2.5) nevertheless the 
assumptions about the distribution of the 15N label in both methods are 
essentially the same and therefore allow a meaningful comparison.
The concept of a single value to represent the sum of all rates of 
protein synthesis in the individual tissues remains an abstract concept 
dependent on the assumptions of the kinetic model used to derive such a 
value. Although [15N]glycine has been the subject of more investigations 
than any other isotopically labelled amino acid, all the validation  
experiments have been done on healthy, non-stressed animals or subjects 
(Golden and Waterlow, 1977; Waterlow and Jackson, 1981; Waterlow, 
Golden and Garlick, 1978; Stein et al., 1976b; Stein et al., 1980; Stein et 
al., 1982b; Taruvinga, Jackson and Golden, 1979). Although it is likely 
that measured rates in the normal range (2-4gP/kg/day) are reasonable 
estimates of whole body protein turnover, the same does not necessarily 
hold for protein turnover rates derived from single amino acid kinetic 
studies in patients with disease states.
Studies of metabolically stressed subjects have documented elevated 
(up to two fold) turnover rates in trauma, burns, sepsis and cancer 
cachexia (Birkahn et al., 1981; Kien et al., 1978; Long et al., 1977; 
Jeevanandam et al., 1984). However, it must be stressed that such 
changes are derived from the flux of a single amino acid and a simple 
model of protein metabolism. It is only when a model of human protein 
metabolism is applied, such as that described by Picou-Taylor Roberts 
(1969), that a synthesis rate can be estimated. This model describes 
protein metabolism in terms of two interrelated pools; a protein pool and 
an amino acid pool. This highly simplified model seems to apply well in 
normal and moderately stressed states, but if nitrogen kinetics in the body 
are greatly disturbed, as is likely in patients that are metabolically stressed
157
(i.e displaying an acute phase protein response), then most of the 
assumptions of the model are called into question. One of the fundamental 
assumptions of the model is that there is a single amino acid pool within 
the body. Therefore, the existence of more than one amino acid pool, 
resulting in the labelled amino acid being at different enrichments in each 
pool (precursor compartmentation) is incompatible with the model.
There is some evidence, (following examination of 15N enrichment in 
nitrogenous end-products), which supports compartmentation of amino 
acids at the site of end-product formation in normal (Fern, Garlick and 
Waterlow, 1985) and metabolically stressed patients (Stein et al., 1983; 
Taggart et al., 1991). James et al., (1976) reported on theoretical grounds 
that [15N]glycine may overestimate the contribution of the liver. Animal 
experiments have also shown compartmentation of glycine-nitrogen 
metabolism when the amino acid intake is restricted (Stein et al., 1976a). 
Further evidence comes from the work of Taruvinga, Jackson and Golden, 
(1979) who reported that, when [15N]-labelled branched chain amino acids 
were used for whole body protein synthesis measurements, spuriously high 
rates were found.
In the studies carried out in Chapters 5 and 6 the increase in whole 
body protein turnover was due to the reduced urinary ammonia enrichment 
in the cancer group indicating that there was less transfer of [15N] from 
the administered glycine to the urinary ammonia precursor pool. It may be 
that if there is compartmentation of the amino acid pools in this group that 
the urinary ammonia becomes disproportionately derived from a relatively 
unenriched pool (possibly peripheral tissue). Previous studies have, 
however, confirmed an elevated rate of tracer flux whether urea or 
ammonia is used as the end-product of nitrogen metabolism (Fearon et al.,
1988). Although there appears to be a greater increase in the rate of tracer
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flux when ammonia compared with urea is used as an end-product of 
nitrogen metabolism (see section 2.3 , Table 7.2).
Another assumption of this simplified model of protein metabolism is 
that the particular labelled amino acid is involved in the synthesis of a 
mixture of proteins which does not change in the disease state. However, 
there is evidence that this is not the case with glycine in the metabolically 
stressed individual (Grimble, 1990). For example, the metabolically 
interrelated amino acids (glycine, serine and methionine) occur in high 
concentrations in many of the proteins synthesised in increased amounts 
as part of the inflammatory response (Grimble, 1990; Table 7.8). The 
incorporation of label associated with these amino acids may elevate the 
whole body protein synthesis estimate using [15N]glycine (Matthews et al., 
1981b). An increase in the fractional synthetic rate of fibrinogen (one of 
the proteins synthesised in increased amounts during inflammation) in 
patients with gastrointestinal cancer (26% /d) compared with normal 
subjects (15% /d) has been reported (Stein et al., 1978b; Stein et al., 
1978a). Using [15N]glycine to measure simultaneously whole body protein 
and fibrinogen synthesis rates Stein and coworkers (1990) have reported 
that the reduction in whole body protein synthesis rates of AIDS patients 
was accompanied by a reduction in fibrinogen synthesis compared with 
controls. Other proteins may also be of importance such as collagen. 
Indeed, when [15N]glycine was used as a tracer for the determination of 
whole body protein turnover in small preterm babies, very high protein 
synthesis rates were measured (Plath et al., 1985). This was attributed to 
a high synthesis rate of structural protein which (because of the 
composition of collagen: 33%  of amino acid residues being glycine) was 
removing a large amount of glycine from the blood and bringing about the 
apparent high protein synthesis rates.
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The metabolism of amino acids is generally interpretated in the light 
of the metabolism of protein. However, glycine acts as a precursor for the 
synthesis of a variety of physiological important compounds which include 
nucleic acids, porphyrins, hippurate and creatine. The most important, 
quantitatively, is creatine which can account, depending on diet and 
nutritional status, for approximately 5% of glycine flux (Reeds, 1981; 
Neuberger, 1981). Since the sole breakdown product of creatine is 
creatinine and the conversion of creatine and creatine phosphate to 
creatinine is non-enzymic and therefore relatively constant, then the 
urinary creatinine excretion gives an indirect measure of body creatine 
content. In these studies, urinary creatinine excretion was similar in both 
the control and cancer groups (Tables 5.9, 6.8) and therefore there is little 
evidence of markedly altered creatine synthesis.
In summary, from the work presented in this thesis and that in the 
literature it is clear that the presence of a tumour brings about an increase 
in whole body glycine flux. However, it is also clear that several 
assumptions of the model may not allow one to equate such increased 
glycine flux to an equivalent increase in whole body protein turnover in the 
weight-losing cancer patient.
7 .3  Liver protein synthesis
There has been some controversy whether total liver protein 
synthesis, measured by labelled amino acids, is increased (Lundholm et al., 
1978) or decreased (Emery, Lovell and Rennie, 1984) in cancer cachexia. 
Recently, Shaw and coworkers (1991), using [14C]leucine and assuming 
that the specific activity of plasma free leucine represents the true 
precursor activity for protein synthesis, reported that the fractional 
synthetic rates for total liver protein synthesis was approximately 29% /d in
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a group of weight-losing cancer patients (mean weight loss, 18% ). 
Furthermore, they derived a value for total liver protein fractional synthetic 
rate (from the albumin synthetic rate) of approximately 21 %/d for patients 
with no cancer and concluded that liver protein synthesis was significantly 
higher in the weight-losing cancer patients than in the non-cancer weight 
stable patients (Shaw et al., 1991). However, the multiple assumptions 
involved in reaching such a conclusion bring its validity into doubt.
The nutritional status of the patient or animal is a complicating 
factor in such measurements. In 1959 Munro and Clark measured the RNA 
content in hepatoma and host liver in rats fed a 25%  protein diet compared 
with animals fed an isocaloric, protein free diet (Munro and Clark, 1959). 
They reported a decrease in RNA content of host liver in rats ingesting the 
protein free diet suggesting that total liver protein synthesis was 
decreased. Ota et al., (1977) measured liver protein content and found 
similar results in Buffalo rats with Morris hepatomas. In contrast, another 
study of tumour-bearing rats given different intravenous feeds showed that 
those on low protein or low calorie diets had increased liver protein 
synthesis but, those on a standard protein and calorie diet had no change 
in liver protein synthesis (Oram-Smith et al., 1977). Therefore, within the 
limits of extrapolating tissue RNA and protein contents to actual rates of 
protein synthesis it is clear that the nutritional status of the animal, and 
presumably man, may be an important factor in determining whether liver 
protein synthesis is increased or decreased in cancer. The patients studied 
in the present thesis had no protein and minimal calorie intake for nearly 
36h prior to the measurement being made. However, it is not clear from 
the above studies whether this would have significantly altered the 
synthetic rate of non-export liver protein.
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The effect of increasing tumour burden on host liver energy status 
has been studied using P-31 nuclear magnetic resonance spectroscopy in 
rats inoculated w ith a non-metastastic m ethylcholanthrene-induced  
sarcoma (Schneeberger et al., 1989). This study demonstrated that 
increasing tumour burden results in early, ongoing, depletion of energy 
stores as reflected by increasing [Pi]/[ATP] ratio in the liver. It is unlikely 
that increased liver protein synthesis could be maintained against such a 
background of reduced energy stores.
In summary, it would appear that the finding of reduced non-export 
liver protein synthesis in patients with cancer cachexia (characterised by 
decreased nutrient intake) is in accord with the majority of published work. 
The question of whether hepatic export protein synthesis rates are 
changed remains unresolved.
7 .4  Muscle protein synthesis
It has been reported that the fractional synthetic rate in skeletal 
muscle protein is reduced in weight-losing cancer patients compared with 
normal subjects (Lundholm et al., 1976; Emery et al., 1984a). This finding 
has been supported by work in some animal models of cancer cachexia 
(Norton et al., 1981; Emery, lovell and Rennie, 1984b) but not in others 
(Plumb et al., 1991). It has recently been reported by Shaw and coworkers 
(1991) that muscle protein fractional synthetic rates are increased in 
weight-losing cancer patients compared with weight-stable non-cancer 
patients. Therefore, there is some support for the apparent increased 
muscle protein synthetic rates reported in the present study.
In order to compare the present study with other reports of muscle 
protein synthesis rates in normal subjects and weight-losing cancer 
patients it is necessary to consider details of the various methodologies
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that may effect the measured rate. The values for muscle protein fractional 
synthetic rates based on different tracer amino acids and precursors, in a 
number of studies are presented (if shown in the manuscript) in Table 7.9. 
With reference to the muscle protein fractional synthetic rate in normal 
subjects (see Table 7.9), it is clear that there is considerable variation in 
the rates reported. This variation may firstly be due to which substrate 
enrichment is taken to best represent that of aminoacyl-tRNA (for 
discussion see section 2.4), e.g., plasma alpha-ketoisocaproate (indicative 
of intracellular leucine enrichment; Halliday et al., 1988) or plasma leucine 
(Shaw et al., 1991). Further variation may depend upon whether a flooding 
dose (Garlick et al., 1989) or continuous infusion (Halliday et al., 1988) 
protocol is used to measure the protein fractional synthetic rate (Table
7.9). However, such differences in measured muscle protein fractional 
synthetic rate with the tw o methods may be due to choice of 
alpha-ketoisocaproate rather than muscle free leucine as the precursor for 
muscle protein synthesis in the continuous infusion protocol (as discussed 
by McNurlan and coworkers (1991)). McNurlan and coworkers (1991) refer 
to the study of Bennett and coworkers (1989) in which muscle protein 
synthesis rates are 2.3% /d when measured using muscle free leucine as 
precursor compared with 1.1 %/d using plasma leucine and 1.3% /d using 
plasma alpha-ketoisocaproate. Therefore, using a continous infusion, 
depending on which precursor for protein synthesis is measured (for 
discussion see section 2.4), apparent muscle protein fractional synthetic 
rate may vary by as much as 100% . Finally, the fraction of the muscle 
biopsy that is hydrolysed for the determination of the incorporated amino 
acid enrichment (Halliday and McKeran, 1975) may also contribute to 
differences in the measured fractional synthetic rate (Table 7.9). That is,
163
the muscle preparation methods carried out on the muscle sample prior to 
hydrolysis can selectively alter the protein composition (thus the amino 
acid composition) of the sample (Forsberg et al., 1991). Measurements of 
muscle protein fractional synthetic rates in man have been carried out by 
measuring the incorporation of the labelled amino acid into different 
fractions of muscle tissue (Table 7.9). The fraction of muscle most 
commonly used in such studies is the alkali-soluble protein which is the 
cellular protein without the collagen protein of the muscle. In normal 
muscle, alkali-soluble protein has been reported to constitute 70%  of the 
weight of the fat free solids and is only slightly reduced with age (Forsberg 
et al., 1991). However, it is not clear whether the proportion of 
alkali-soluble protein to the weight of fat free solids, in skeletal muscle, is 
further reduced in weight-losing cancer patients (Preston et al., 1987). 
Furthermore, it is not clear whether the muscle fraction used would alter 
the measured labelled leucine incorporation since collagen has little if any 
leucine residues. In contrast, the presence or absence of collagen from the 
muscle sample hydrolysed is likely to affect the enrichment of incorporated 
glycine since collagen is glycine-rich (33%  of amino acid residues, see 
section 7 .4 .2 ). Therefore, in certain circumstances, the chosen tracer 
amino acid can potentially affect the measured fractional synthetic rate.
In summary, from the above discussion it is clear that a number of 
factors can affect the measured muscle protein fractional synthetic rate. 
However, it is not clear what the relative importance of each of these 
factors is in reported studies (Table 7.9) or in the present studies. The two 
reported studies (Emery et al., 1984a; Shaw et al., 1991) that have 
attem pted to measure muscle protein fractional synthetic rates in 
weight-losing cancer patients, in vivo, report high values for their control 
group compared with normal subjects. Therefore, it would appear that the
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value of these studies is in the comparative data obtained. The present 
study of muscle protein fractional synthetic rates in normal subjects has 
also yielded high values and probably should also be considered in this 
way.
There have only been two previous studies which have specifically 
attempted to compare in vivo muscle protein synthesis of normal subjects 
and weight-losing cancer patients. One has reported an increase in muscle 
protein fractional synthetic rate in cancer patients (Shaw et al., 1991) and 
the other a decrease (Emery et al.# 1984). However, these studies differed 
in the plasma precursor used and the muscle fraction analysed for the 
enrichment of the bound amino acid. With reference to the factors 
discussed above which appear to affect the the measured fractional 
synthetic rate, the data presented in this thesis are more comparable with 
that of Shaw and coworkers (1991) and give a similar value for the muscle 
protein fractional synthetic rate in normal subjects (Table 7 .9 ) .  
Furthermore, the study of Shaw and coworkers (1991) reports an increase 
in the muscle protein fractional synthetic rate in weight-losing cancer 
patients (94% ) which is in agreement with values obtained in the present 
studies (plasma glycine, 26% , homogenate free glycine, 93% , see Table
7.9). Finally, although different tracers were used, the increase in 
muscle protein synthesis is of sufficient magnitude to account for much of 
the apparent increase in whole body protein synthesis seen by both Shaw  
and coworkers (1991) and in the present study. Shaw and coworkers 
(1991) state "Because muscle is the largest protein reservoir in the body, it 
would take only a small increase in muscle protein synthesis to alter 
significantly whole body protein synthesis. In addition, the correlation 
between the fractional synthetic rate of protein in muscle and the rate of 
whole body protein synthesis supports this concept." However, in the
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present study there was no correlation between the muscle protein 
fractional synthetic rate and the whole body protein synthesis rate when 
the values from both normal subjects and weight-losing cancer patients 
were considered. Furthermore, the measured protein synthetic rates are 
not consistent w ith the age, activity or nutritional status of the 
weight-losing cancer patients studied (Table 6.4). Also, in contrast to the 
conclusions of Shaw and coworkers (1991), there was no increase in 
skeletal muscle breakdown as measured by 3-methylhistidine excretion 
(Tables 5.9, 6 .8). An increase in muscle protein synthesis without an 
accompanying increase in muscle protein breakdown would result in 
increased muscle mass. Since neither skeletal muscle mass (measured by 
c re a t in in e  e x c re t io n )  nor m uscle  b re a k d o w n  (m ea s u re d  by 
3-methylhistidine excretion; Tables 5.9, 6.8) was increased this was 
clearly not the case in the patients studied in the present thesis.
The present work obviously does not preclude the possibility that 
important alterations in protein metabolism, sufficient to increase whole 
body protein synthesis occur in tissues other than muscle and liver. 
However, with specific reference to the increased incorporation of 
[15N]glycine in the muscle of cancer patients, in the present studies, it is 
conceivable that certain glycine-rich proteins were present resulting in 
biased estimates of protein synthesis. When considering which protein or 
proteins might be involved in this process, there are several findings which 
should be considered. Firstly, that the fixed hepatic protein rates measured 
in the normal group are in accordance with those which might be 
expected, and that the synthesis rates were not increased in the cancer 
group, means it is unlikely that there was a systematic error (the presence 
of free [15N]glycine) in the measurement of [15N]glycine incorporation into 
liver and muscle tissues. Secondly, in order to increase whole body protein
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kinetics the synthesis rate of the specific protein or proteins must be 
quantitatively significant. It follows that if such a protein or proteins were 
glycine-rich then this would proportionally enhance its effect on whole 
body and tissue specific synthesis rates measured by tracer glycine 
incorporation.
There are a limited number of glycine-rich proteins that could be 
involved in such a process. However, in patients with cancer cachexia the 
acute phase proteins (eg. fibrinogen, 10% glycine) and collagen (33%  
glycine) are of particular interest. The mechanism by which each protein 
could increase the [15N]glycine content of the biopsy would be different. 
Fibrinogen, since it is synthesised by the liver and exported, could increase 
the [15N]glycine enrichment of muscle tissue by contamination. Collagen, 
on the other hand, is synthesised in the muscle and therefore the increase 
in the [15N]glycine enrichment would be a 'true' indicator of glycine 
incorporation into the biopsy sample but not an accurate indicator of 
skeletal muscle protein synthesis and may give misleading estimates of 
myofibrillar protein synthesis rates.
7.4.1 Increased muscle protein synthesis: Effect of acute phase protein 
synthesis
The subjects in the cancer group all had evidence of an acute phase 
protein response (ie. increased C-reactive protein, Table 7.1) and it is 
possible that the postulated proteins/protein which may have contaminated 
the muscle biopsy could have come from this group of hepatic export 
proteins. Of the proteins exported by the liver as part of the acute phase 
protein response, by far the most important quantitatively is fibrinogen 
(Table 7.8). Fibrinogen has a fundamental role in the clotting process since 
under attack by thrombin it undergoes a transformation into the long
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thread-like polymer fibrin, the primary ingredient of a blood clot. The 
association between systemic activation of the clotting system and 
malignant disease has been recognised for more than a century (Sack, 
Levin and Bell, 1977; Dvorak, 1987). Patients with many types of 
malignancy, especially in their advanced stages, exhibit a diverse spectrum 
of coagulopathies that may include thrombophlebitis, haemorrhage, 
embolism and disseminated intravascular coagulation. As many as 98%  of 
cancer patients (including those with colorectal cancer) may exhibit some 
type of clotting abnormality (Sun et al., 1979). Several authors have 
reported increased plasma fibrinogen concentrations in cancer patients 
(Sack, Levin and Bell, 1977) and the synthetic rate of fibrinogen is also 
increased (Stein et al., 1978a). Fibrinogen, in the normal individual, has the 
shortest half-life (approximately 85h; Stein et al., 1978b; Thompson et al.,
1989) of the major plasma proteins. This occurs not only because 
fibrinogen is consumed in any clotting process, but also because the 
parent molecule seems to be particularly vulnerable to breakdown by 
proteolytic enzymes other than thrombin. Moreover, the degradation 
products resulting from such proteolysis may be involved in the stimulation 
of fibrinogen biosynthesis. Fibrinogen is not normally found outwith the 
vascular compartment because of its large molecular size (341 ,000daltons) 
but, in neoplastic disease fibrin is deposited both in solid tumours and 
normal tissues (Brown et al., 1988).
The mechanism by which fibrin is deposited in tissues has been 
investigated to some extent. Many tumours have been found to secrete a 
factor (vascular permeability factor) which increases blood vessel 
permeability such that the microvasculature about tumours becomes 
hyperpermeable to fibrinogen (Dvorak, 1986) and other plasma proteins 
(Fleck et al., 1985; Senger et al., 1983). This process also occurs in
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normal tissues, but to a lesser extent. Extravasated fibrinogen is converted 
rapidly to fibrin by means of procoagulants associated with tumour and 
perhaps with other tissues (Dvorak et al., 1985). This increased volume of 
distribution together with increased fibrinogen concentration in the plasma 
suggests there may be a substantial increase in synthesis of this 
glycine-rich protein.
In the current studies (Chapters 5 and 6) fibrinogen would not have 
been removed from the muscle samples by the acid/alcohol wash as part 
of the sample preparation procedure since much lower concentrations of 
neutral pH alcohol would be required to ensure solubilisation (about 9%  
ethanol). Furthermore, fibrin or fibrinogen degradative products formed 
from fibrinogen would not have been removed from the muscle. The 
formation of fibrin and together with the insoluble nature of such material 
in the tumour and normal tissues of the cancer host (eg. muscle) has been 
shown by Brown and coworkers (1988). These investigators demonstrated 
clearly the influx of 125l-labelled fibrinogen into the tumour and normal 
tissues of tumour-bearing mice. The influx into the muscle was 
approximately one third that of the flux into the transplanted carcinoma. 
Given the larger mass of muscle in man it is concievable that this 
mechanism of fibrinogen deposition represents a significant removal and 
trapping of free glycine of cancer patients with an acute phase response. 
Confirmatory evidence for this mechanism would require demonstration of 
fibrin deposits in the muscle of the cancer group and demonstration of a 
significantly increased fibrinogen synthetic rate. However, from the 
literature such evidence is inconclusive. This lack of evidence could be due 
to the fact that methods to identify fibrin are complicated and technically 
difficult. The methodology to assess fibrin deposition or fibrinogen 
synthetic rates were not developed in the present study, however,
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increased fibrinolysis was demonstrated in the cancer group when 
compared to the control group (Table 7.1).
If we assume that total liver protein synthesis can account for 
approximately 20%  of whole body protein synthesis (Waterlow, Garlick 
and Millward, 1978d; Shaw et al., 1991) and that half of total liver protein 
synthesis is export protein synthesis then this would account for 
approximately 22gP/d in the control group and 35gP/d in the cancer group 
(Table 7.3). Therefore, from the above calculation, even if all liver export 
protein was fibrinogen, it could not explain the entire increase in 
[15N]glycine muscle incorporation of the cancer group (Table 7 .3 ). 
Nevertheless, fibrin/fibrinogen deposition in normal tissues (see above) 
such as muscle may contribute to the increased [15N]glycine enrichment in 
the muscle of the cancer group.
An increase in the fractional synthetic rate of fibrinogen in cancer 
patients has been reported. It has been reported to be 1 5 %/d in normal 
subjects (Stein et al., 1978a) and 26% /d in cancer patients (Stein et al., 
1978b). However, the degree of inflammatory response in the cancer 
patients is not clear from the report by Stein and coworkers (1978b) and 
it is conceivable that the cancer patients in our study (Chapter 6), with a 
significant elaboration of acute phase proteins (Table 7.1), had an even 
greater increase in fibrinogen turnover. It has been reported that in burns 
patients fibrinogen synthesis can be increased to 85% /d (Thompson et al.,
1989) and if this were the case in the patients in the present study this 
suggests that fibrinogen could indeed be responsible for some of the 
increased [15N]glycine enrichment of the skeletal muscle biopsies in the 
cancer group.
In summary, fibrinogen synthesis is likely to have been increased in 
the cancer group and could potentially, through contamination, be
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responsible for a significant proportion of the apparent increase in skeletal 
muscle protein synthesis (i.e. [15N]glycine enrichment).
7 .4 .2  Increased muscle protein synthesis: Effect of collagen synthesis
Another protein which might contribute to an apparent increase in 
muscle protein synthesis would be collagen. It is the most abundant 
protein in mammals, accounting for approximately a quarter of total body 
protein. It is present in nearly all organs and serves to hold cells together in 
discrete units. In the mouse for example, collagen represents 20%  of total 
protein (of which 40%  is in the skin, and 50%  in the bone and muscle; 
W aterlow, Garlick and Millward, 1978h). The proportion of glycine 
residues in collagen is approximately 33%  which is unusually high for a 
protein (e.g glycine content of haemoglobin is 5%  (Stryer, 1988). 
Therefore, collagen accounts for approximately half of the body's bound 
glycine.
Collagen is synthesised in fibroblasts on the membrane-bound 
ribosomes of the rough endoplasmic reticulum and is a secreted protein. In 
common with most export proteins collagen is synthesised as a precursor 
molecule, procollagen, some 15-30%  larger than collagen. The formation 
of the collagen fibre is analogous to the formation of fibrin fibres. Indeed, 
fibrin is replaced by collagen when a clot becomes organised.
Collagen accounts for 8.75gP/kg of 'normal' muscle (Geigy Scientific 
Tables) and therefore, there is 154g muscle collagen/70kg adult ( assuming 
17.6kg muscle/70kg adult). Since glycine constitutes 33%  of the amino 
acid residues of collagen then using glycine incorporation to measure 
muscle protein synthesis (where the protein was collagen) would give a 
value of 847gP (that is 5.5 times the mixed protein value). Thus, to 
account for the increase in protein turnover in skeletal muscle measured by
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glycine flux (125gP/d), assuming no compositional change, then the 
fractional synthetic rate of collagen in muscle would have to be 
approximately 14%/d. Total collagen synthesis in the body is thought to be 
about 1% /d (Waterlow, Garlick and Millward, 1978h) but there is likely to 
be a difference between bone, which accounts for up to 50%  of body 
collagen, and tissue collagen. The part played by tissue collagen is likely to 
be quantitatively important since in malnutrition the amount of collagen in 
the body is relatively increased, and that of cellular protein decreased. This 
has been shown in the pig, cockerel (Dickerson and McCance, 1964) and 
man (Picou, Halliday and Garrow, 1966). Therefore, collagen does not 
share in the general depletion of body protein. Animal experiments have 
shown that the amount of collagen is more stable in some tissues than 
others. In rats, cockerels, and pigs on a low protein diet the collagen 
content of muscle was found to be increased; the muscle mass was 
greatly reduced, but the absolute amount of collagen in an individual 
muscle was the same as in animals on a normal diet (Mendes and 
Waterlow, 1958; Dickerson and McCance, 1964). On a low protein diet it 
has been shown, with photomicrographs, that muscle tissue shrinks inside 
its collagen scaffolding, (Montgomery, 1962). This shrinking or atrophy of 
skeletal muscle fibres has also been demonstrated, using quantitative 
histological and histochemical techniques, in weight-losing cancer patients 
(Lindboe and Torvik, 1982)
The turnover of collagen is thought to be necessary for structural 
modifications of the body which accompany growth or any condition 
which alters body structure. In adult man about half of the total collagen is 
present in bone and therefore in the normal subject hydroxyproline 
excretion is considered to be a reflection of bone collagen turnover (Dull 
and Henneman, 1963; Guzzo and Kivirikko, 1967). However, attempts to
172
use hydroxyproline as a marker for bone disease have met with mixed 
success. It appears that unless there is significant bone breakdown, in the 
absence of any other pathology, hydroxyproline excretion data is of limited 
value. Increased hydroxyproline excretion is found in most cancer patients 
with or without bone metastases. Without bone metastases the urinary 
hydroxyproline concentration increases 2-3 times, with bone metastases it 
increases 4 -10  times that of the normal subject (Guzzo et al., 1969). 
Therefore, in the cancer patients examined in this study who had no 
evidence of bone metastases, measurement of urinary hydroxyproline 
might give an indication of increased collagen turnover. From the results 
(Table 7.5) this would appear not to be the case since there was no 
increase in the urinary hydroxyproline excretion when compared with the 
control group.
Nevertheless, the presence of collagen in the muscle fraction 
analysed for [15N]glycine enrichment may contribute to higher muscle 
protein fractional synthetic rates in the control group compared to other 
studies (see section 7.4). It is of interest that 3 subjects in the cancer 
group had detectable serum concentrations of tumour necrosis factor (see 
Table 7.4). Tumour necrosis factor is known to play a major role in tissue 
inflammation and remodelling by stimulating production of tissue 
collagenases (Evans, Argiles and Williamson, 1989; Vlassara et al., 1988). 
Therefore, it is possible that, in the cancer group, increased muscle 
collagen synthesis may contribute to the apparently increased muscle 
protein fractional synthetic rate.
7 .4 .3  Increased muscle protein synthesis: summary
In summary, to explain the majority of increased [15N]glycine 
incorporation into the muscle of the cancer patient it is proposed that the
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amounts of glycine-rich proteins, such as fibrinogen, in muscle is 
increased. Collagen, as a major glycine-rich structural protein, was also 
considered likely to be involved in such a proposed mechanism since the 
relative amount of muscle collagen may increase as the cachexia develops 
in the cancer patient. However, in the present study (Chapters 5 and 6) 
there was little evidence of changes in the muscle metabolism of the 
cancer patients (no significant difference in urinary creatinine or 
hydroxyproline excretion) to support the involvement of collagen in the 
above process.
7 .5  A pparently  elevated w hole body protein synthesis rates in 
weight-losing cancer patients: A hypothesis
Very lame and imperfect theories are sufficient to suggest useful 
experiments which serve to correct those theories and give birth to others 
more perfect. These, then, occasion further experiments which bring us 
still nearer to the truth; and in this method of approximation we must be 
content to proceed, and we ought to think ourselves happy if, in this slow 
method, we make any real progress.
Joseph Priestly
(quoted by Waterlow, Garlick and Millward, 1978)
As has been discussed already (Chapter 2) the calculation of protein 
synthesis from glycine flux requires a model of protein metabolism which is 
based on a number of assumptions. The concept of a single pool of 
nitrogen in the body is perhaps the most fundamental assumption of the 
'end-product' methods that have been used for measuring the rate of 
whole body protein metabolism in man. It is assumed that the metabolically 
active nitrogen (and tracer 15N) in the body is contained in a single
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homogenous pool into which nitrogen from the diet and from protein 
breakdown enters, and from which nitrogen is removed for the synthesis 
of proteins and excretory products. This concept, first proposed by 
Springson and Rittenberg (1949), therefore assumes that there is uniform 
distribution of nitrogen throughout the body and that there is unrestricted 
metabolic exchange between the free amino acids of this pool. In reality, 
the situation may be much more complex with more than one free amino 
nitrogen pool, that is, compartmentation of the precursor pool for protein 
synthesis. This has been demonstrated in rats (Fern and Garlick, 1976) and 
proposed to occur in normal man (Fern et al., 1985a, 1985b) when using 
[14C] and [15N]glycine respectively. Nevertheless, the idea of a single 
precursor pool for protein synthesis has been widely accepted in practice, 
and has remained a central feature of many subsequent models and studies 
of whole-body nitrogen metabolism in man and in animals. This acceptance 
stems mainly from an absence of workable alternative models and appears 
to give reasonable comparative results in normal man (Garlick and Fern, 
1985).
A hypothesis for the aetiology of the compartmentation of amino 
acid metabolism has been put forward by Stein and coworkers (1983). He 
proposes that the normal response to metabolic stress (alterations in 
substrate metabolism resulting from injury, infection, cancer) is an increase 
in protein turnover which imposes additional demands on the liver. If the 
liver's 'metabolic capacity' is exceeded, it no longer has the capacity to 
supply substrates, process waste products and interconvert metabolites 
which have been partially metabolised by one tissue and are necessary for 
normal peripheral metabolism. The impairment of liver function will thus 
affect amino acid metabolism as there will no longer be unimpeded transfer 
and exchange between the various tissue pools of amino acids. Therefore,
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under these circumstances, the single amino acid pool of the model may 
not be valid and the measurement of whole body protein turnover could be 
biased. In Chapter 6, it was demonstrated that structural hepatic protein 
synthesis in the cancer group was reduced significantly and may therefore 
further compromise the ability of these patients to deal with the metabolic 
stress of cancer. Stein's evidence to link impaired liver function with the 
lack of validity of the current model was simply that there was a good 
correlation between elevated whole body protein synthesis and abnormal 
liver function tests in the metabolically stressed patient.
Further evidence of the relationship between the degree of metabolic 
stress (in patients w ith cancer) and whole body protein turnover 
measurements has been demonstrated by a number of workers using 
[15N]glycine (Stein et al., 1983; Fearon et al., 1990). In particular, 
Carmichael and coworkers (1980) using [14C]leucine reported a correlation 
between tumour burden as defined by tumour mass/anatomical staging and 
whole body protein synthesis rates. These findings have been confirmed 
using [15N]glycine (Fearon et al., 1988; Fearon et al., 1990). Furthermore, 
it has been shown that the degree to which protein turnover is elevated 
relates to the ultimate duration of survival of patients with colorectal 
cancer (Fearon et al., 1990).
Thus, it would appear that irrespective of whether leucine or glycine 
is used to measure whole body protein turnover there is a relationship 
between whole body protein turnover and the degree of metabolic stress 
imposed by cancer. However, such studies certainly do not establish a 
cause and effect relationship (as proposed by Stein and coworkers, 1983) 
between metabolic stress causing liver dysfunction and the observed 
changes in tracer amino acid flux.
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W ith reference to that discussed previously (see 7 .4 .1 ) , an 
alternative hypothesis, which I propose to account for the apparently 
elevated whole body protein turnover rates of cancer patients, would be 
that the measurement is influenced by an inflammatory response and the 
subsequent enhanced turnover of fibrinogen and other glycine-rich proteins 
(see section 7 .4 .1 , 7 .4 .2 , 7.6) results in a significant proportion of the 
total glycine pool being diverted for their synthesis. Such enhanced 
fibrinogen synthesis would result in [15N]glycine being removed and not 
being returned to the circulation during the course of the experiment. This 
hypothesis would also explain why measurements (using [15N]glycine) 
made on patients who were fed (Glass, Fern and Garlick, 1983) showed no 
significant increase in whole body protein turnover, since the glycine pool 
would have been expanded and the body would be more able to supply the 
demand for glycine. Therefore, glycine flux would be less biased towards 
the synthesis of glycine-rich proteins (Grimble, 1990). Furthermore, the 
increased synthesis of these glycine-rich proteins as part of the 
inflammatory response in cancer patients may explain why the increase in 
whole body protein turnover measured in similar control and cancer groups 
is greater with [15N]glycine (Fearon et al., 1988) compared with that 
obtained with [13C]leucine (Inculet et al., 1987; Melville et al., 1989; see 
Table 7.2).
7 .6  The mediators of increased fibrinogen synthesis in weight-losing 
cancer patients
In the previous sections of this Chapter it has been proposed that 
the increase in skeletal muscle protein synthesis, measured using 
[15N]glycine, in the cancer patients might be explained by the presence of 
glycine-rich proteins, in particular, fibrinogen and perhaps by the increased
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synthesis of collagen in the muscle (although there was no evidence for 
the latter process in the cancer group). Furthermore, it would appear that 
increased glycine-rich protein synthesis in the cancer group may have a 
significant influence on the body glycine pool, possibly introducing a bias 
in the whole body protein synthesis value estimated using [15N]glycine. 
However, is not clear what the metabolic basis of such increased 
glycine-rich protein synthesis might be.
Increased fibrinogen synthesis might be part of a generalised 
inflammatory response in the cancer patients (as documented by an 
increased plasma concentration of C-reactive protein (Table 7.1) (Pepys 
and Baltz, 1983)). This is in accord with other published work which 
suggests that the majority of cancer patients with progressive disease will 
develop such a inflammatory response elaborating acute phase proteins 
(Raynes and Cooper, 1983; Cooper and Stone, 1979; Fearon and Carter, 
1988). The question which next arises is what might be the mediators of 
such an acute phase response? From the literature there appear to be two  
main mediators of increased fibrinogen synthesis, namely cortisol and 
interleukin-6. The role of these factors in cancer patients' metabolic 
abnormalities will be discussed in the following section.
7.6.1 The influence of cortisol and lnterleukin-6 on fibrinogen synthesis
It is well established that increasing glucocorticoid (cortisol) 
concentration in blood results in increased fibrinogen synthesis (Waterlow, 
Garlick and Millward, 1978g). Furthermore, there is mounting evidence 
that, as part of the general inflammatory response, the cytokine 
interleukin-6 is a primary mediator of the increase in synthesis of acute 
phase proteins, including fibrinogen, (Heinrich, Castell and Andus, 1990). 
Other cytokines such as interleukin-1 and tumour necrosis factor alpha also
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stimulate fibroblasts, endothelial cells and keratinocytes to synthesise 
in terleuk in -6  and thus am plify its biological e ffec ts . M oreover, 
interleukin-6, interleukin-1 and tumour necrosis factor alpha have been 
shown to stimulate the release of adrenocorticotrophic hormone from 
pituitary cells, leading to an increased secretion of glucocorticoids 
including cortisol. The glucocorticoids can increase the stimulatory effect 
of cytokines on the synthesis of acute phase proteins by hepatocytes and 
also inhibit the synthesis of the monokines. With particular reference to 
fibrinogen, interleukin-6 is the only cytokine that has been shown to 
increase synthesis in man (Heinrich, Castell and Andus, 1990). 
Furthermore, it has been demonstrated that in vitro in the rat hepatoma cell 
line recombinant human interleukin-6 can produce a six fold increase in 
fibrinogen mRNA (Andus et al., 1988).
Therefore, in the present study both cortisol and interleukin-6 were 
measured on the basal serum and plasma samples of the cancer patients 
and controls (see protocol Chapter 5). From the results (Table 7.6) it can 
be seen that there was a significant increase in both the cortisol and 
interleukin-6 concentrations in the cancer group compared with the 
controls. This was in the presence of low insulin concentrations (many of 
the metabolic effects of cortisol are dependent on insulin concentration 
being low at the same time; Johnston et al., 1982) and normal glucose 
concentrations, with the exception of subject 5 in the cancer group (Table 
7 .7 ). A similar elevated cortisokinsulin ratio has been reported in 
weight-losing cancer patients by Selberg and coworkers (1990). Thus, 
with the established effects of interleukin-6 and cortisol, the raised 
concentrations of these mediators could have been responsible for the 
elevated fibrinogen synthesis. Furthermore, in the present study there was 
a statistically significant correlation between the interleukin-6 and
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fibrinogen concentrations (r2 = 58 .5% , p = 0 .0 1 , n = 10) but, not with 
cortisol and fibrinogen (r2 = 11% , p = 0 .291 , n = 12). However, when the 
concentration of cortisol was multiplied by that of interleukin-6 and the 
resultant product correlated with that of fibrinogen the relationship became 
even more significant (r2 = 66% , p =  0 .004 , n = 10). In addition, the most 
significant correlation was between the product of cortisol multiplied by 
interleukin-6 and fibrin degradative product values (r2 = 82 .8 , p < 0 .001, 
n = 10). In summary, these data are consistent with increased fibrinogen 
turnover, as part of the acute phase protein response, mediated by cortisol 
and interleukin-6.
7 .6 .2  Comparison with other work
Clague and coworkers (1982) have previously described an increase 
in whole body [14C)leucine flux associated with increased incorporation of 
[14C]leucine into plasma proteins. In patients with colorectal cancer there 
was an increase in the percentage of the total dose administered that was 
incorporated into plasma proteins with increasing advancement of cancer. 
The mean percentages were; Duke's A, 6 .7% ; Duke's B, 8 .3% ; Duke's C, 
9.4% , Dukes D, 11.8% . In these calculations the authors assumed that the 
distribution of these proteins was confined to the plasma volume. 
However, with reference to the more advanced cases of colorectal cancer, 
the volume of distribution is likely to be much greater (discussed in 7.4.1) 
and therefore the percentage of the total dose incorporated into the plasma 
proteins is likely to be substantially underestimated in the advanced cancer 
patients. Clague and coworkers (1982) also reported a statistically 
significant correlation between the percentage increase in plasma cortisol 
levels postoperatively and the increase in the percentage incorporation of 
[14C]leucine into plasma proteins (r = 0 .84 , p < 0 .0 1 ) in a group of patients
180
undergoing elective cholecystectomy. In order to find out which of the 
plasma proteins were responsible for this increase, the plasma was 
fractionated by gel filtration and the eluted fractions counted. The 
radioactivity was then plotted against the eluted fraction for each plasma 
sample to assess the distribution of counts throughout the various plasma 
proteins. Examples, were given of the different profiles, but no attempt 
was made to adjust the [14Cjleucine activity to the amino acid composition 
of the protein. That is, different proteins contain different amounts of 
leucine (% of amino acid residues), for example, albumin is 8 .9%  leucine 
whereas fibrinogen is 6 .3% . In contrast the amino acid composition of 
human albumin is 3%  glycine and fibrinogen is 9 .9%  (Grimble, 1990 ; 
Cartwright and Kekwick, 1970).
If this were done then the the radioactivity profile would then give 
some idea of the relative amounts of protein that were being synthesised. 
Taking the example of albumin and fibrinogen it would appear that 
relatively more fibrinogen was being synthesised (29% ). Another point of 
interest from these plasma protein incorporation profiles was that of a 
unknown peak of activity with a molecular weight less than albumin 
(66,000daltons). Clague and coworkers (1982) do not suggest what this 
protein might be. From the results presented in this Chapter, one 
suggestion for this protein fraction would be fibrinogen/fibrin degradative 
products which is the term covering the peptide fragments with molecular 
w eights ranging from approxim ately 1 0 ,0 0 0 -5 0 ,OOOdaltons. The 
concentration of degradation products from cross linked fibrin were 
measured and found to be increased in the cancer group in the present 
study (Table 7.1).
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7.7 Summary
The alteration in protein synthesis in weight-losing cancer patients 
may be biased towards the increased synthesis of glycine-rich proteins, 
probably as part of the inflammatory response to the tumour. Thus, with 
reference to the model for the calculation of whole body protein synthesis, 
the assumption that similar mixes of protein are being synthesised in the 
cancer and control subjects is possibly invalid resulting in an overestimate 
of whole body protein synthesis when [15N]glycine is used. Furthermore, 
the deposition of glycine-rich structural proteins such as fibrinogen and/or 
increased collagen synthesis in muscle tissue might account for increased 
glycine enrichment of skeletal muscle independent of any alteration in the 
synthesis of cellular proteins in the tissue itself. However, confirmation of 
this hypothesis will require a demonstration of increased fibrinogen 
synthesis and/or fibrin deposition and/or collagen synthesis in the tissues 
of patients with cancer and altered protein kinetics.
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Table 7.1
Changes in plasma protein concentrations in normal subjects
and weiaht-losinq cancer patients
C-reactive Fibrinogen Albumin FDP
protein (mg/1) (g/1) (g/D (ug/l)
Control 1 10 3.3 40 207
2 10 2.5 40 141
3 6 4.5 39 388
4 10 4.1 43 184
5 8 3.0 41 126
6 8 4.2 41 243
Mean 9 3.6 41 215
S.D. 2 0.8 1 95
Cancer 1 120 6.7 34 1363
2 41 4.6 24 394
3 11 5.5 39 523
4 115 6.8 35 1310
5 52 5.5 39 201
6 108 4.9 31 1092
Mean 75* 5.7** 34** 814*
S.D. 46 0.9 6 502
FDP, fibrin degradative products, * p<0.05, ** P<0.01
Table 7.2
Comparison of whole body protein turnover in normal 
subjects and cancer patients as determined bv different 
investigators
Protein turnover (g protein/kg/d)
weight- weight- weight- weight- 
stable losing stable losing 
Author (ref) Tracer controls patients
Heber (a) [ *C]lys 1.9 3.2(68)
Inculet (b) t!*C] leu 3.9 4.5(15)
Jeevanandam (c) [ =N]glyx 2.4 3.2(33)
Norton (d) [ *N]glyy 2.9 5.0(72)
Kien (e) [ =N]glyy 3.5 5.5(57)
Ward (f) [ *N]glyz 2.9 2.7(-7) 3.9(34)
Fearon (g) [ *N]glyz 3.1 4.6(48) 4.6(48) 4.9(58)
Fearon (g) [ *N]gly>' 2.2 3.5(59) 3.6(64) 4.0(82)
Melville (h) [ *C]leu 3.1 3.7(19)
This work [ N]giyy 3.5 5.9(69)
Mean value (% increase from control)
(a) Heber et al., 1982 (b) Inculet et al., 1987 (c)
Jeevanandam et al., 1984 (d) Norton, Stein and Brennan,
1981 (e) Kien and Camitta, 1983 (f) Ward et al., 1985 (g) 
Fearon et al., 1988 (h) Melville et al., 1989. 
x end-product average, y ammonia end-product, z urea 
end-product (see section 2.3).
Table 7.3
Whole body, liver and skeletal muscle protein synthesis in
normal subjects and weight-losing cancer patients
Protein synthesis (gP/d)
WBPSa MPSb LPSa LPS+MPS /WBPSb
(%)
Control 217(31) 96(15) 22(1) 61(14)
Cancer 345(35)* 214(76)* 15(2)** 67(10)
All values, Mean(SEM), in grams Protein/day, a n=6, b n=4, 
*p<0. 05, **p<0.01
Table 7.4
Rates of protein synthesis and potential mediators in
normal subjects and weight-losing cancer patients
TNFa
(pg/mi)
Hydroxyproline 
/Creatinine
MPS WBPS 
(gP/kg/d)
Control 1 <12 0.085 0.9 3.3
2 <12 0.032 1.4 2.4
3 <12 0.076 1.1 5.1
4 <12 0.130 2.6
5 <12 0.059 1.8 2.0
6 <12 0.018 1.7 3.4
Mean 0.066 1.4 3.1
S.D. 0.040 0.4 1.1
Cancer 1 15 0.091 2.7 5.0
2 22 0 .1 1 1 3.0 7.3
3 <12 0.035 2.6 2.8
4 <12 0.018 5.0
5 <12 0.095 4.2 5.3
6 15 0.034 3.2 6.5
Mean 0.064 3.1* 5.3*
S.D. 0.039 0.6 1.5
a Method described in Fearon et al., 1991, TNF tumour 
necrosis factor, MPS, muscle protein synthesis? WBPS, whole 
body protein synthesis? * p<0.05, ** P<0.01
Table 7.5
Urinary hvdroxvproline excretion in normal subjects and
weicrht-losincr cancer natients
Hydroxyproline Creatinine 
(mmol/vol) (mmol/vol)
Hydroxyproline 
/Creatinine
Control 1 0.290 3.4 0.085
2 0.172 5.4 0.032
3 0.266 3.5 0.076
4 0.468 3.6 0.130
5 0.161 2.7 0.059
6 0.155 8.5 0.018
Mean 0.252 4.5 0.066
S.D. 0.120 2.1 0.040
Cancer 1 0.312 3.4 0.091
2 0.100 0.9 0.111
3 0.247 6.9 0.035
4 0.139 7.7 0.018
5 0.498 5.2 0.095
6 0.372 10.7 0.034
Mean 0.278 5.8 0.064
S.D. 0.149 3.4 0.039
Hydroxyproline/Creatinine reference range 0.003-0.033
Table 7.6
Rates of protein synthesis and potential mediators in
normal subjects and weight-losing cancer patients
Cortisol 11-6 CRP Fibrinogen MPS WBPS
(nmol/1) (u/ml) (mg/1) (g /i) (gP/kg/d)
Control 1 324 16 10 3.3 0.9 3.3
2 542 10 10 2.5 1.4 2.4
3 164 <10 6 4.5 1.1 5.1
4 201 <10 10 4.1 2.6
5 192 14 8 3.0 1.8 2.0
6 307 13 8 4.2 1.7 3.4
Mean 288 9 3.6 1.4 3.1
S.D. 140 2 0.8 0.4 1.1
Cancer 1 399 330 120 6.7 2.7 5.0
2 452 96 41 4.6 3.0 7.3
3 230 26 11 5.5 2.6 2.8
4 608 170 115 6.8 5.0
5 575 70 52 5.5 4.2 5.3
6 543 118 108 4.9 3.2 6.5
Mean 468* 135 75* 5.7** 3.1* 5.3*
S.D. 140 107 46 0.9 0.6 1.5
MPS, muscle protein synthesis; WBPS, whole body protein 
synthesis? * p<0.05, ** P<0.01
Table 7.7
Fasting plasma insulin and glucose concentrations in normal
subjects and weight-losing cancer patients
Insulin Glucose
(m u /l) (mmol/1)
Control 1 18.1 5.4
2 12.6 4.4
3 9.1 4.8
4 13.4 4.6
5 <3.0 4.7
6 <3.0 4.5
Mean 4.7
S.D. 0.4
Cancer 1 <3.0 3.5
2 <3.0 5.9
3 10.8 4.5
4 17.7 6.7
5 48.0 10.8
6 <3.0 4.6
Mean 6.0
S.E.M. 2.6
Table 7.8
The acute phase plasma proteins in man
Mol.wt 
(d)
Concn Carb.cont.
(g/i) (%)
Glycine Serine 
(% aa residues)
Fibrinogen 341,000 3.0 2.5 10 8
Haptoglobin 99,000 2.0 19.3 7 5
Alpha-1-
Antitrypsin 54,000 2.0 12.4 5 5
Alpha-1-
Acid glycoprotein 44,000 1.0 41.4 4 4
Haemopexin 57,000 0.8 22.6 - -
Caeruloplasmin 130,000 0.2 8.0 7 6
C-reactive protein 105,000 <0.01 0 8 10
Serum Amyloid A 12,000 <0.001 0 12 9
Mol.wt= Molecular weight, (d) = daltons, Concn= Normal 
plasma concentration, Carb.cont.= Carbohydrate content, % 
aa residues= % of amino acid residues. From Fleck, Colley 
and Myers, 1985; Grimble, 1990; Cartwright and Kekwick, 
1971.
Table 7.9
Comparison of skeletal muscle protein synthesis in vivo in
normal subjects and cancer patients as determined bv
different investigators
Protein FSR (%/d)
weight- weight- muscle
Precursor stable losing fraction
Author (ref) used subj ects patients
Halliday (a) plasma lys 3.8(0.4) sarcoplas
Rennie (b)
1.4 (0.3) myofibril
plasma KIC 2.4(0.4) ASP
Halliday (c) plasma KIC 1.1(0.1) ASP
Emery (d) plasma KIC 4.8(0.5) 0.7(0.2) ASP
Garlick (e) plasma KIC 1.9(0.1) ASP
Shaw (f) plasma leu 2.4(0.4) 4.6(0.9) FFS
This work plasma gly 2.3(0.4) 2.9(0.2) solids
homog gly 2.8(0.3) 5.4(0.5) solids
Mean value (SEM)
(a) Halliday and Mckeran, 1975 (b) Rennie et al., 1982 (c) 
Halliday et al., 1988 (d) Emery et al., 1984a (e) Garlick 
et al., 1989 (f) Shaw et al., 1991.
lys, free lysine? KIC, free alphaketoisocaproate; leu, free 
leucine; gly, free glycine; homog, homogenate. 
sarcoplas, sarcoplasmic; myofibril, myofibrillar; ASP, 
alkali-soluble protein; FFS, fat-free solids.
CHAPTER 8: CONCLUSION
8.1 Introduction
In chapter 1 the aims of this thesis were defined as follows;
1. To develop methods whereby whole body and tissue protein fractional 
synthetic rates could be measured using a single mass spectrometer.
2. To establish a clinical protocol to measure simultaneously resting energy 
expenditure and whole body, fixed hepatic and skeletal muscle protein 
synthesis in man.
3. To use this protocol to compare the protein and energy metabolism in 
normal subjects with those in weight-losing cancer patients.
8 .2  Aim 1
There have been several attempts over the years to establish a 
single methodology for the determination of the product and precursor pool 
specific activity/enrichment. One reason for this is that the potential for 
systematic analytical errors introduced by the use of different methods is 
minimised and thus the precision and accuracy of data derived from such 
studies may be increased. Attempts to use Gas Chromatography-Mass 
Spectrometry to measure both free and bound amino acid isotopic 
enrichment have required the use of a non-tracer dose of the labelled 
amino acid which may invalidate the synthetic rate measurements (see 
Chapter 2). Horber and coworkers (1989) have described the separation of 
labelled leucine from plasma and hydrolysed tissues, prior to the  
measurement of specific radioactivity, using an isocratic high performance 
liquid chromatographic system. They reported that fractional protein 
synthetic rates in a variety of tissues could be determined with better
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accuracy and precision, and that the analysis time was similar to that 
required using conventional radioactive isotope methodology. However, the 
use of radioactive isotopes for tracer studies in man is largely precluded on 
ethical grounds. Halliday and McKeran (1975) used liquid chromatography 
for the separation of the stable isotope labelled amino acid lysine from 
plasma and tissue hydrolysate samples prior to measurement by Isotope 
Ratio Mass Spectrometry. However, the method was slow and required 
large amounts of plasma for isotopic analysis. Considering the first aim it 
has been demonstrated in this thesis that Isotope Ratio Mass Spectrometry 
in the form of Continuous Flow-lsotope Ratio Mass Spectrometry can be 
used in conjunction with high performance liquid chromatography to 
measure the isotopic enrichment of both plasma/tissue free and protein 
bound glycine using a tracer dose of the amino acid (Chapter 4 .2 -4 .6 ). 
Therefore Continuous Flow-lsotope Ratio Mass Spectrometry together with 
high performance liquid chromatography offers an alternative to the 
conventional instrumentation (Gas Chromatography-Mass Spectrometry 
and Isotope Ratio Mass Spectrometry) for stable isotope tracer work and 
does not introduce the complication of cross calibrating different mass 
spectrometers. The work presented in this thesis is only the second report 
of liquid chromatography in conjunction with isotope ratio mass 
spectrometry being used to measure fractional protein synthetic rates in 
man. Furthermore, it appears from the literature that it is the first to report 
the use of a volatile buffer, with consequent advantages in sample 
preparation, in the separation of amino acids in tracer studies.
8 .3  Aim 2
In normal individuals, measurement of whole body and tissue 
specific amino acid kinetics was achieved with the use of [15N]glycine but
not [13C]leucine (Chapter 5). The use of leucine was restricted by the 
limitations of the instrumentation used for measuring tissue homogenate 
free [13C]leucine enrichment. In the control subjects the clinical protocol 
gave similar resting energy expenditure and whole body protein turnover 
values to other studies and a plasma plateau of [15N]glycine enrichment 
was established over the time of the infusion. With reference to data in the 
literature it would appear that the values obtained for non-export liver 
protein synthesis in the control group were reasonable, being only the 
second report in man. However, values for muscle protein synthesis were 
above published values measuring [13C]leucine incorporation in alkali 
soluble protein, but in accord with values recently published measuring 
[14C]leucine incorporation in fat free solids (Table 7.9).
8 .4  Aim 3
Whole body and tissue specific rates of protein synthesis were 
measured in a group of weight-losing cancer using the same [15N]glycine 
protocol as that used for the controls (see Aim 2). Whole body amino acid 
kinetics were found to be grossly elevated but this was not associated 
with an increase in resting energy expenditure (Chapter 6). Labelled glycine 
incorporation into hepatic fixed protein was significantly reduced whilst 
tracer incorporation into skeletal muscle appeared to be significantly 
increased (Chapter 6). However, critical assessment of these results 
appears to draw attention to the limitations of extrapolating the kinetics of 
a single labelled amino acid to the rate of synthesis of protein either in 
individual tissues or in the whole body (Chapter 7). In particular, from the 
work presented in this thesis and the work of Emery and coworkers 
(1984a) and Shaw and coworkers (1991), it would appear that depending 
on the tracer amino acid used, muscle protein synthesis may be either
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increased or decreased in the cancer host. One reason for such a 
divergence in the apparent protein synthesis rates might be that there is an 
alteration in the pattern of proteins synthesised/or found in the muscle of 
cancer patients. This would result in amino acids being incorporated into 
proteins at different rates from that in normal subjects. This may explain 
why the documented increase in whole body protein synthesis in cancer 
patients appears to be greater when [15N]glycine is used compared with 
[13C]leucine (Table 7.2). Therefore, in order to obtain values which more 
truely reflect protein synthesis in the whole body and different tissues in 
weight-losing cancer patients it would seem necessary to use more than 
one labelled amino acid and integrate the kinetic data with that obtained 
from the conventional nitrogen balance technique (Bier, Matthews and 
Young, 1985). Indeed, this approach has been used in small infants and 
gives lower and more plausible results than with a single tracer (Heine, 
1988). The protein synthetic rate of the tissue could then be calculated by 
adjusting the individual amino acid flux measurements to the amino acid 
composition of the tissue protein and then averaging the corrected amino 
acid flux rates.
Thus, despite the fact that at least ten studies over the last decade 
have shown that whole body "protein turnover" is increased in cancer 
patients (with and without weight-loss) (Table 7.2) such results should be 
treated with caution since these measurements have been made using 
single amino acid tracers and there has been no concomitant increase in 
resting energy expenditure. With regard to measurement of muscle protein 
synthesis, it is possible that in weight-losing cancer patients the protein 
composition (and therefore the amino acid uptake) of muscle changes 
markedly and this must be considered when interpretating tracer 
incorporation data. It must be noted, however, that despite uncertainty
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about the true significance of the altered tracer kinetics documented in the 
present study, these results emphasise the markedly altered metabolism of 
the weight-losing cancer host (Figure 8.1).
How such changes in host protein metabolism are mediated remains 
an open question. It is still not clear whether such abnormalities are 
induced by a factor or factors produced by the tumour itself or by the host 
in response to the tumour. Nevertheless, in the present study, hepatic 
fixed protein synthesis was shown to be decreased (Table 6.3) whilst the 
plasma concentration of at least two acute phase hepatic export proteins 
was increased (fibrinogen and C-reactive protein, Table 7 .1 ). This 
reprioritization of hepatic protein synthesis (Sganga et al., 1985) was 
associated with significant elevation of serum cortisol and interleukin-6 
concentrations (Table 7.6). Both these factors are known to influence 
hepatic acute phase protein production and may well have been 
responsible for at least some of the changes in hepatic protein metabolism. 
Furthermore, if as suggested (Chapter 7 .4 .1) increased production of 
glycine-rich hepatic export proteins such as fibrinogen may bias whole 
body and tissue specific protein kinetics measured by [15N]glycine then 
cortisol and interleukin-6 may also influence, albeit indirectly, some of the 
extra-hepatic changes in cancer patients' protein metabolism. Further 
studies will be required to define the altered protein metabolism and 
mediators of such changes in cancer patients. However, it is to be hoped 
that by elucidating the mechanisms of weight loss in cancer, better 
methods of supporting and improving the nutritional and metabolic status 
of such patients will result.
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Figure 8.1 Protein synthesis and metabolites in weight-losing cancer 
patients. The mean value in the cancer group was normalised to the 
mean value in the control group (100%). * p<0.05, ** p<0.01.
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